<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1549-4918" xmlns="http://purl.org/rss/1.0/"><title>STEM CELLS</title><description> Wiley Online Library : STEM CELLS</description><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2F%28ISSN%291549-4918</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Copyright © 2013 by AlphaMed Press</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1066-5099</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1549-4918</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">May 2013</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">31</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">5</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">829</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1031</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/stem.v31.5/asset/cover.gif?v=1&amp;s=1100898402dc183d8ea7ae4fdc23d04f4be19bc9"/><items><rdf:Seq><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1419"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1413"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1400"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1417"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1421"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1423"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1415"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1416"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1424"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1384"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1418"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1420"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1426"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1414"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1411"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1410"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1409"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1408"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1407"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1406"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1405"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1395"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1397"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1404"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1402"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1403"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1401"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1399"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1398"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1396"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1394"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1379"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1378"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1388"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1386"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1385"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1383"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1382"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1391"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1387"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1389"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1390"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1393"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1392"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1380"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1377"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1376"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1375"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1374"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1373"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1368"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1370"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1371"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1372"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1369"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1367"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1366"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1365"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1364"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1363"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1362"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1361"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1360"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1359"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1358"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1357"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1356"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1353"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1354"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1352"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1349"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1355"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1350"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1348"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1344"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1331"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1340"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1342"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1317"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1322"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1345"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1323"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1324"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1330"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1332"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1334"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1335"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1339"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1341"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1338"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1343"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1351"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1308"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1347"/><rdf:li rdf:resource="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1346"/></rdf:Seq></items></channel><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1419" xmlns="http://purl.org/rss/1.0/"><title>Kit receptor gain-of-function in hematopoiesis enhances stem cell self-renewal and promotes progenitor cell expansion</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1419</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Kit receptor gain-of-function in hematopoiesis enhances stem cell self-renewal and promotes progenitor cell expansion</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shayu Deshpande, Benedikt Bosbach, Yasemin Yozgat, Christopher Y. Park, Malcolm A.S. Moore, Peter Besmer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-16T20:40:12.323067-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1419</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1419</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1419</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The KIT receptor tyrosine kinase has important roles in hematopoiesis. We have recently produced a mouse model for imatinib resistant gastrointestinal stromal tumor (GIST) carrying the Kit<sup>V558Δ</sup> and Kit<sup>T669I</sup> (human KIT<sup>T670I</sup>) mutations found in imatinib-resistant GIST. The Kit<sup>V558Δ;T669I/+</sup> mice developed microcytic erythrocytosis with an increase in erythroid progenitor numbers, a phenotype previously seen only in mouse models of polycythemia vera (PV) with alterations in Epo or Jak2. Significantly, the increased hematocrit observed in Kit<sup>V558Δ;T669I/+</sup> mice normalized upon splenectomy. In accordance with increased erythroid progenitors, myeloerythroid progenitor numbers were also elevated in the Kit<sup>V558Δ;T669I/+</sup> mice. Hematopoietic stem cell (HSC) numbers in the bone marrow (BM) of Kit<sup>V558Δ;T669I/+</sup> mice were unchanged in comparison to wild-type mice. However, increased HSC numbers were observed in fetal livers and the spleen and peripheral blood of adult Kit<sup>V558Δ;T669I/+</sup> mice. Importantly, HSC from Kit<sup>V558Δ;T669I/+</sup> BM had a competitive advantage over wild-type HSC. In response to 5-fluorouracil treatment elevated numbers of dividing Lin<sup>-</sup>Sca<sup>+</sup> cells were found in the Kit<sup>V558Δ;T669I/+</sup> BM compared to wild-type. Our study demonstrates that signaling from the Kit<sup>V558Δ;T669I/+</sup> receptor has important consequences in hematopoiesis enhancing HSC self-renewal and resulting in increased erythropoiesis.</p></div>
]]></content:encoded><description>

The KIT receptor tyrosine kinase has important roles in hematopoiesis. We have recently produced a mouse model for imatinib resistant gastrointestinal stromal tumor (GIST) carrying the KitV558Δ and KitT669I (human KITT670I) mutations found in imatinib-resistant GIST. The KitV558Δ;T669I/+ mice developed microcytic erythrocytosis with an increase in erythroid progenitor numbers, a phenotype previously seen only in mouse models of polycythemia vera (PV) with alterations in Epo or Jak2. Significantly, the increased hematocrit observed in KitV558Δ;T669I/+ mice normalized upon splenectomy. In accordance with increased erythroid progenitors, myeloerythroid progenitor numbers were also elevated in the KitV558Δ;T669I/+ mice. Hematopoietic stem cell (HSC) numbers in the bone marrow (BM) of KitV558Δ;T669I/+ mice were unchanged in comparison to wild-type mice. However, increased HSC numbers were observed in fetal livers and the spleen and peripheral blood of adult KitV558Δ;T669I/+ mice. Importantly, HSC from KitV558Δ;T669I/+ BM had a competitive advantage over wild-type HSC. In response to 5-fluorouracil treatment elevated numbers of dividing Lin-Sca+ cells were found in the KitV558Δ;T669I/+ BM compared to wild-type. Our study demonstrates that signaling from the KitV558Δ;T669I/+ receptor has important consequences in hematopoiesis enhancing HSC self-renewal and resulting in increased erythropoiesis.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1413" xmlns="http://purl.org/rss/1.0/"><title>Very Small Embryonic-Like Stem Cells from the Murine Bone Marrow Differentiate into Epithelial Cells of the Lung</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1413</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Very Small Embryonic-Like Stem Cells from the Murine Bone Marrow Differentiate into Epithelial Cells of the Lung</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susannah H. Kassmer, Huiyan Jin, Ping-Xia Zhang, Emanuela M. Bruscia, Kartoosh Heydari, Joo-Hyeon Lee, Carla F. Kim, Diane S. Krause</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-16T20:39:15.741471-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1413</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1413</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1413</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The view that adult stem cells are lineage restricted has been challenged by numerous reports of bone marrow (BM) derived cells giving rise to epithelial cells. Previously, we demonstrated that non-hematopoietic bone marrow cells are the primary source of BM derived lung epithelial cells. Here we tested the hypothesis that very small embryonic like cells (VSELs) are responsible for this engraftment. We directly compared the level of BM derived epithelial cells after transplantation of VSELs, hematopoietic stem/progenitor cells, or other nonhematopoietic cells. VSELs clearly had the highest rate of forming epithelial cells in the lung. By transplanting VSELs from donor mice expressing H2B-GFP under a type 2 pneumocyte specific promoter, we demonstrate that this engraftment occurs by differentiation and not fusion. This is the first report of VSELs differentiating into an endodermal lineage <em>in vivo</em>, thereby potentially crossing germ layer lineages. Our data suggest that Oct4+ VSELs in the adult BM exhibit broad differentiation potential.</p></div>
]]></content:encoded><description>

The view that adult stem cells are lineage restricted has been challenged by numerous reports of bone marrow (BM) derived cells giving rise to epithelial cells. Previously, we demonstrated that non-hematopoietic bone marrow cells are the primary source of BM derived lung epithelial cells. Here we tested the hypothesis that very small embryonic like cells (VSELs) are responsible for this engraftment. We directly compared the level of BM derived epithelial cells after transplantation of VSELs, hematopoietic stem/progenitor cells, or other nonhematopoietic cells. VSELs clearly had the highest rate of forming epithelial cells in the lung. By transplanting VSELs from donor mice expressing H2B-GFP under a type 2 pneumocyte specific promoter, we demonstrate that this engraftment occurs by differentiation and not fusion. This is the first report of VSELs differentiating into an endodermal lineage in vivo, thereby potentially crossing germ layer lineages. Our data suggest that Oct4+ VSELs in the adult BM exhibit broad differentiation potential.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1400" xmlns="http://purl.org/rss/1.0/"><title>Two Negative Feedback Loops Place Mesenchymal Stem/Stromal Cells (MSCs) at the Center of Early Regulators of Inflammation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1400</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Two Negative Feedback Loops Place Mesenchymal Stem/Stromal Cells (MSCs) at the Center of Early Regulators of Inflammation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Darwin J. Prockop</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-16T20:38:28.860314-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1400</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1400</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1400</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Stem Cell Technology: Epigenetics, Genomics, Proteomics and Metabonomics</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Recent data demonstrated that MSCs can be activated by pro-inflammatory signals to introduce two negative feedback loops into the generic pathway of inflammation. In one loop, the activated MSCs secrete PGE2 that drives resident macrophages with an M1 pro-inflammatory phenotype toward an M2 anti-inflammatory phenotype. In the second loop, the activated MSCs secrete TSG-6 that interacts with CD44 on resident macrophages to decrease TLR2/NFκ-B signaling and thereby decrease the secretion of pro-inflammatory mediators of inflammation. The PGE2 and TSG-6 negative feedback loops allow MSCs to serve as regulators of the very early phases of inflammation. These and many related observations suggest that the MSC-like cells found in most tissues may be part of the pantheon of cells that protect us from foreign invaders, tissue injury and aging.</p></div>
]]></content:encoded><description>

Recent data demonstrated that MSCs can be activated by pro-inflammatory signals to introduce two negative feedback loops into the generic pathway of inflammation. In one loop, the activated MSCs secrete PGE2 that drives resident macrophages with an M1 pro-inflammatory phenotype toward an M2 anti-inflammatory phenotype. In the second loop, the activated MSCs secrete TSG-6 that interacts with CD44 on resident macrophages to decrease TLR2/NFκ-B signaling and thereby decrease the secretion of pro-inflammatory mediators of inflammation. The PGE2 and TSG-6 negative feedback loops allow MSCs to serve as regulators of the very early phases of inflammation. These and many related observations suggest that the MSC-like cells found in most tissues may be part of the pantheon of cells that protect us from foreign invaders, tissue injury and aging.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1417" xmlns="http://purl.org/rss/1.0/"><title>Polycomb Determines Responses to Smad2/3 Signaling in Embryonic Stem Cell Differentiation and in Reprogramming</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1417</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Polycomb Determines Responses to Smad2/3 Signaling in Embryonic Stem Cell Differentiation and in Reprogramming</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Oslash;yvind Dahle, Michael R. Kuehn</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-10T08:28:07.639253-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1417</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1417</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1417</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Integration of extrinsic signals, epigenetic regulators and intrinsic transcription factors establishes pluripotent stem cell identity. Interplay between these components also underlies the capacity of stem cells to undergo differentiation, and of differentiated cells to reestablish the pluripotent state in direct reprogramming. Polycomb repressive complexes are epigenetic regulators that play key roles in stem cell identity and in differentiated cell fates. Smad2 and Smad3 (Smad2/3), the intracellular mediators of the Nodal/Activin/Transforming growth factor (TGF)β cell-cell signaling pathway also are implicated in stem cell pluripotency and in differentiation. Here we show that Polycomb imposes responses to Smad2/3 mediated signaling to selectively regulate expression of the master pluripotency factor Oct4 during initiation of differentiation, but not in the self-renewing pluripotent ground state. During reprogramming back to the ground state, we find that the enhancement of reprogramming efficiency stemming from blocking Nodal/Activin/TGFβ signaling also depends on Polycomb. These context dependent responses to Smad2/3 imposed by Polycomb action provide a mechanism for selective gene regulation that can reconcile the apparently conflicting roles of this signaling pathway in pluripotency, differentiation and reprogramming.</p></div>
]]></content:encoded><description>

Integration of extrinsic signals, epigenetic regulators and intrinsic transcription factors establishes pluripotent stem cell identity. Interplay between these components also underlies the capacity of stem cells to undergo differentiation, and of differentiated cells to reestablish the pluripotent state in direct reprogramming. Polycomb repressive complexes are epigenetic regulators that play key roles in stem cell identity and in differentiated cell fates. Smad2 and Smad3 (Smad2/3), the intracellular mediators of the Nodal/Activin/Transforming growth factor (TGF)β cell-cell signaling pathway also are implicated in stem cell pluripotency and in differentiation. Here we show that Polycomb imposes responses to Smad2/3 mediated signaling to selectively regulate expression of the master pluripotency factor Oct4 during initiation of differentiation, but not in the self-renewing pluripotent ground state. During reprogramming back to the ground state, we find that the enhancement of reprogramming efficiency stemming from blocking Nodal/Activin/TGFβ signaling also depends on Polycomb. These context dependent responses to Smad2/3 imposed by Polycomb action provide a mechanism for selective gene regulation that can reconcile the apparently conflicting roles of this signaling pathway in pluripotency, differentiation and reprogramming.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1421" xmlns="http://purl.org/rss/1.0/"><title>B Cell Progenitors and Precursors Change their Microenvironment in Fetal Liver During Early Development</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1421</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">B Cell Progenitors and Precursors Change their Microenvironment in Fetal Liver During Early Development</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Motokazu Tsuneto, Koji Tokoyoda, Ekaterina Kajikhina, Anja E. Hauser, Takahiro Hara, Shizue Tani-ichi, Koichi Ikuta, Fritz Melchers</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-10T08:27:45.027686-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1421</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1421</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1421</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The microenvironments, in which B-lymphocytes develop in fetal liver, are largely still unknown. Among the non-hematopoietic cells we have identified and FACS-separated two subpopulations, CD45<sup>-</sup>TER119<sup>-</sup>VCAM-1<sup>+</sup> cells that are either CD105<sup>high</sup>LYVE-1<sup>high</sup> or CD105<sup>low</sup>ALCAM<sup>high</sup>. Immunohistochemical analyses find three of four c-Kit<sup>+</sup>IL-7Rα<sup>+</sup>B220<sup>low</sup>CD19<sup>-</sup>SLC<sup>-</sup> B-progenitors in contact with vascular endothelial-type LYVE-1<sup>high</sup> cells on embryonic day 13.5. One day later c-Kit<sup>+</sup>IL-7Rα<sup>+</sup> cells develop to CD19<sup>- and +</sup>, SLC-expressing, DHJH-rearranged pre/pro and pro/preB-I cells. Less than 10% are still in contact with LYVE-1<sup>high</sup> cells, but half of them are now in contact with mesenchymally-derived ALCAM<sup>high</sup> liver cells. All of these ALCAM<sup>high</sup> cells, but not the LYVE-1<sup>high</sup> cells produce IL-7 and CXCL12, while both produce CXCL10. Progenitors and pro/preB-I cells are chemo-attracted <em>in vitro</em> towards CXCL10 and 12, suggesting that lymphoid progenitors with Ig gene loci in germline configuration enter the developing fetal liver at E13.5 from vascular endothelium, attracted by CXCL10, and then migrate within a day to an ALCAM<sup>high</sup> liver cell-microenvironment, differentiating to DHJH-rearranging, surrogate light chain-expressing pre/proB and pro/preB-I cells, attracted by CXCL10 and 12. Between E15.5 and E16.5 preB-I cells expand 10 fold in continued contact with ALCAM<sup>high</sup> cells, and begin VH- to DHJH-rearrangements in further differentiated c-Kit<sup>-</sup>IL-7Rα<sup>-</sup> preBII cells.</p></div>
]]></content:encoded><description>

The microenvironments, in which B-lymphocytes develop in fetal liver, are largely still unknown. Among the non-hematopoietic cells we have identified and FACS-separated two subpopulations, CD45-TER119-VCAM-1+ cells that are either CD105highLYVE-1high or CD105lowALCAMhigh. Immunohistochemical analyses find three of four c-Kit+IL-7Rα+B220lowCD19-SLC- B-progenitors in contact with vascular endothelial-type LYVE-1high cells on embryonic day 13.5. One day later c-Kit+IL-7Rα+ cells develop to CD19- and +, SLC-expressing, DHJH-rearranged pre/pro and pro/preB-I cells. Less than 10% are still in contact with LYVE-1high cells, but half of them are now in contact with mesenchymally-derived ALCAMhigh liver cells. All of these ALCAMhigh cells, but not the LYVE-1high cells produce IL-7 and CXCL12, while both produce CXCL10. Progenitors and pro/preB-I cells are chemo-attracted in vitro towards CXCL10 and 12, suggesting that lymphoid progenitors with Ig gene loci in germline configuration enter the developing fetal liver at E13.5 from vascular endothelium, attracted by CXCL10, and then migrate within a day to an ALCAMhigh liver cell-microenvironment, differentiating to DHJH-rearranging, surrogate light chain-expressing pre/proB and pro/preB-I cells, attracted by CXCL10 and 12. Between E15.5 and E16.5 preB-I cells expand 10 fold in continued contact with ALCAMhigh cells, and begin VH- to DHJH-rearrangements in further differentiated c-Kit-IL-7Rα- preBII cells.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1423" xmlns="http://purl.org/rss/1.0/"><title>Fetal Deficiency of Lin28 Programs Life-Long Aberrations in Growth and Glucose Metabolism</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1423</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Fetal Deficiency of Lin28 Programs Life-Long Aberrations in Growth and Glucose Metabolism</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gen Shinoda, Ng Shyh-Chang, T. Yvanka de Soysa, Hao Zhu, Marc T. Seligson, Samar P. Shah, Nora Abo-Sido, Akiko Yabuuchi, John P. Hagan, Richard I. Gregory, John M. Asara, Lewis C. Cantley, Eric G. Moss, George Q. Daley</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-10T08:27:06.376118-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1423</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1423</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1423</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Stem Cell Technology: Epigenetics, Genomics, Proteomics and Metabonomics</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>LIN28A/B are RNA binding proteins implicated by genetic association studies in human growth and glucose metabolism. Mice with ectopic over-expression of <em>Lin28a</em> have shown related phenotypes. Here we describe the first comprehensive analysis of the physiologic consequences of <em>Lin28a</em> and <em>Lin28b</em> deficiency in knockout (KO) mice. <em>Lin28a/b</em>-deficiency led to dwarfism starting at different ages, and compound gene deletions showed a cumulative dosage effect on organismal growth. Conditional gene deletion at specific developmental stages revealed that fetal but neither neonatal nor adult deficiency resulted in growth defects and aberrations in glucose metabolism. Tissue-specific KO mice implicated skeletal muscle-deficiency in the abnormal programming of adult growth and metabolism. The effects of <em>Lin28b</em> KO can be rescued by <em>Tsc1</em> haplo-insufficiency in skeletal muscles. Our data implicate fetal expression of <em>Lin28a/b</em> in the regulation of life-long effects on metabolism and growth, and demonstrate that fetal <em>Lin28b</em> acts at least in part via mTORC1 signaling.</p></div>
]]></content:encoded><description>

LIN28A/B are RNA binding proteins implicated by genetic association studies in human growth and glucose metabolism. Mice with ectopic over-expression of Lin28a have shown related phenotypes. Here we describe the first comprehensive analysis of the physiologic consequences of Lin28a and Lin28b deficiency in knockout (KO) mice. Lin28a/b-deficiency led to dwarfism starting at different ages, and compound gene deletions showed a cumulative dosage effect on organismal growth. Conditional gene deletion at specific developmental stages revealed that fetal but neither neonatal nor adult deficiency resulted in growth defects and aberrations in glucose metabolism. Tissue-specific KO mice implicated skeletal muscle-deficiency in the abnormal programming of adult growth and metabolism. The effects of Lin28b KO can be rescued by Tsc1 haplo-insufficiency in skeletal muscles. Our data implicate fetal expression of Lin28a/b in the regulation of life-long effects on metabolism and growth, and demonstrate that fetal Lin28b acts at least in part via mTORC1 signaling.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1415" xmlns="http://purl.org/rss/1.0/"><title>Improved Cell Therapy Protocol for Parkinson's Disease Based on Differentiation Efficiency and Safety of Hesc-, Hipsc and Non-Human Primate Ipsc-Derived DA Neurons</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1415</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Improved Cell Therapy Protocol for Parkinson's Disease Based on Differentiation Efficiency and Safety of Hesc-, Hipsc and Non-Human Primate Ipsc-Derived DA Neurons</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sundberg Maria, Bogetofte Helle, Lawson Tristan, Smith Gaynor, Astradsson Arnar, Moore Michele, Osborn Teresia, Cooper Oliver, Spealman Roger, Hallett Penelope, Isacson Ole</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-10T08:26:44.159195-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1415</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1415</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1415</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regenerative Medicine</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The main motor symptoms of Parkinson's disease are due to the loss of dopaminergic (DA) neurons in the ventral midbrain (VM). For the future treatment of Parkinson's disease with cell transplantation it is important to develop efficient differentiation methods for production of human iPSCs and hESCs-derived midbrain-type DA neurons. Here we describe an efficient differentiation and sorting strategy for DA-neurons from both human ES/iPS cells and non-human primate iPSCs. The use of non-human primate iPSCs for neuronal differentiation and autologous transplantation is important for pre-clinical evaluation of safety and efficacy of stem cell-derived DA neurons. The aim of this study was to improve the safety of human- and non-human primate-iPSC (PiPSC)-derived DA neurons. According to our results, NCAM<sup>+</sup>/CD29<sup>low</sup> sorting enriched VM DA-neurons from pluripotent stem cell-derived neural cell populations. NCAM<sup>+</sup>/CD29<sup>low</sup> DA-neurons were positive for FOXA2/TH and EN1/TH and this cell population had increased expression levels of <em>FOXA2, LMX1A, TH, GIRK2, PITX3, EN1, NURR1</em> mRNA compared to unsorted neural cell populations. PiPSC-derived NCAM<sup>+</sup>/CD29<sup>low</sup> DA-neurons were able to restore motor function of 6-OHDA lesioned rats 16 weeks after transplantation. The transplanted sorted cells also integrated in the rodent brain tissue, with robust TH+/hNCAM+ neuritic innervation of the host striatum. One year after autologous transplantation, the primate iPSC-derived neural cells survived in the striatum of one primate without any immunosuppression. These neural cell grafts contained FOXA2/TH-positive neurons in the graft site. This is an important proof of concept for the feasibility and safety of iPSC-derived cell transplantation therapies in the future.</p></div>
]]></content:encoded><description>

The main motor symptoms of Parkinson's disease are due to the loss of dopaminergic (DA) neurons in the ventral midbrain (VM). For the future treatment of Parkinson's disease with cell transplantation it is important to develop efficient differentiation methods for production of human iPSCs and hESCs-derived midbrain-type DA neurons. Here we describe an efficient differentiation and sorting strategy for DA-neurons from both human ES/iPS cells and non-human primate iPSCs. The use of non-human primate iPSCs for neuronal differentiation and autologous transplantation is important for pre-clinical evaluation of safety and efficacy of stem cell-derived DA neurons. The aim of this study was to improve the safety of human- and non-human primate-iPSC (PiPSC)-derived DA neurons. According to our results, NCAM+/CD29low sorting enriched VM DA-neurons from pluripotent stem cell-derived neural cell populations. NCAM+/CD29low DA-neurons were positive for FOXA2/TH and EN1/TH and this cell population had increased expression levels of FOXA2, LMX1A, TH, GIRK2, PITX3, EN1, NURR1 mRNA compared to unsorted neural cell populations. PiPSC-derived NCAM+/CD29low DA-neurons were able to restore motor function of 6-OHDA lesioned rats 16 weeks after transplantation. The transplanted sorted cells also integrated in the rodent brain tissue, with robust TH+/hNCAM+ neuritic innervation of the host striatum. One year after autologous transplantation, the primate iPSC-derived neural cells survived in the striatum of one primate without any immunosuppression. These neural cell grafts contained FOXA2/TH-positive neurons in the graft site. This is an important proof of concept for the feasibility and safety of iPSC-derived cell transplantation therapies in the future.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1416" xmlns="http://purl.org/rss/1.0/"><title>Abi3bp is a Multifunctional Autocrine/Paracrine Factor that Regulates Mesenchymal Stem Cell Biology</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1416</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Abi3bp is a Multifunctional Autocrine/Paracrine Factor that Regulates Mesenchymal Stem Cell Biology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Conrad P Hodgkinson, Vinogran Naidoo, Karl G Patti, Jose A Gomez, Jeffrey Schmeckpeper, Zhiping Zhang, Bryce Davis, Richard E Pratt, Maria Mirotsou, Victor J Dzau</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-10T08:26:03.255959-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1416</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1416</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1416</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Mesenchymal stem cells (MSCs) transplanted into injured myocardium promote repair through paracrine mechanisms. We have previously shown that MSCs overexpressing AKT1 (Akt-MSCs) exhibit enhanced properties for cardiac repair. In this study, we investigated the relevance of Abi3bp towards MSC biology. Abi3bp formed extracellular deposits with expression controlled by Akt1 and ubiquitin-mediated degradation. Abi3bp knockdown/knockout stabilized focal adhesions and promoted stress-fiber formation. Furthermore, MSCs from Abi3bp knockout mice displayed severe deficiencies in osteogenic and adipogenic differentiation. Knockout or stable knockdown of Abi3bp increased MSC and Akt-MSC proliferation, promoting S-phase entry via cyclin-d1, ERK1/2 and Src. Upon Abi3bp binding to integrin-β1 Src associated with paxillin which inhibited proliferation. In vivo, Abi3bp knockout increased MSC number and proliferation in bone marrow, lung, and liver. In summary, we have identified a novel extracellular matrix protein necessary for the switch from proliferation to differentiation in MSCs.</p></div>
]]></content:encoded><description>

Mesenchymal stem cells (MSCs) transplanted into injured myocardium promote repair through paracrine mechanisms. We have previously shown that MSCs overexpressing AKT1 (Akt-MSCs) exhibit enhanced properties for cardiac repair. In this study, we investigated the relevance of Abi3bp towards MSC biology. Abi3bp formed extracellular deposits with expression controlled by Akt1 and ubiquitin-mediated degradation. Abi3bp knockdown/knockout stabilized focal adhesions and promoted stress-fiber formation. Furthermore, MSCs from Abi3bp knockout mice displayed severe deficiencies in osteogenic and adipogenic differentiation. Knockout or stable knockdown of Abi3bp increased MSC and Akt-MSC proliferation, promoting S-phase entry via cyclin-d1, ERK1/2 and Src. Upon Abi3bp binding to integrin-β1 Src associated with paxillin which inhibited proliferation. In vivo, Abi3bp knockout increased MSC number and proliferation in bone marrow, lung, and liver. In summary, we have identified a novel extracellular matrix protein necessary for the switch from proliferation to differentiation in MSCs.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1424" xmlns="http://purl.org/rss/1.0/"><title>Multi-Potential Differentiation of Human Urine-Derived Stem Cells: Potential for Therapeutic Applications in Urology</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1424</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Multi-Potential Differentiation of Human Urine-Derived Stem Cells: Potential for Therapeutic Applications in Urology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shantaram Bharadwaj, Guihua Liu, Yingai Shi, Rongpei Wu, Bin Yang, Tongchuan He, Yuxin Fan, Xinyan Lu, Xiaobo Zhou, Hong Liu, Anthony Atala, Jan Rohozinski, Yuanyuan Zhang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-10T08:21:21.350703-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1424</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1424</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1424</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>We sought to biologically characterize and identify a subpopulation of urine-derived stem cells (USCs) with the capacity for multipotent differentiation. We demonstrated that single USCs can expand to a large population with 60-70 population doublings. Nine of 15 individual USC clones expressed detectable levels of telomerase and have long telomeres. These cells expressed pericyte and mesenchymal stem cell markers. Upon induction with appropriate media <em>in vitro</em>, USCs differentiated into bladder-associated cell types, including functional urothelial and smooth muscle cell lineages. When the differentiated USCs were seeded onto a scaffold and subcutaneously implanted into nude mice, multilayered tissue-like structures formed consisting of urothelium and smooth muscle. Additionally, USCs were able to differentiate into endothelial, osteogenic, chondrogenic, adipogenic, skeletal myogenic and neurogenic lineages, but did not form teratomas during the 1-month study despite telomerase activity. USCs may be useful in cell-based therapies and tissue engineering applications, including urogenital reconstruction.</p></div>
]]></content:encoded><description>

We sought to biologically characterize and identify a subpopulation of urine-derived stem cells (USCs) with the capacity for multipotent differentiation. We demonstrated that single USCs can expand to a large population with 60-70 population doublings. Nine of 15 individual USC clones expressed detectable levels of telomerase and have long telomeres. These cells expressed pericyte and mesenchymal stem cell markers. Upon induction with appropriate media in vitro, USCs differentiated into bladder-associated cell types, including functional urothelial and smooth muscle cell lineages. When the differentiated USCs were seeded onto a scaffold and subcutaneously implanted into nude mice, multilayered tissue-like structures formed consisting of urothelium and smooth muscle. Additionally, USCs were able to differentiate into endothelial, osteogenic, chondrogenic, adipogenic, skeletal myogenic and neurogenic lineages, but did not form teratomas during the 1-month study despite telomerase activity. USCs may be useful in cell-based therapies and tissue engineering applications, including urogenital reconstruction.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1384" xmlns="http://purl.org/rss/1.0/"><title>Pursuing Self-Renewal and Pluripotency with the Stem Cell Factor Nanog</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1384</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pursuing Self-Renewal and Pluripotency with the Stem Cell Factor Nanog</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arven Saunders, Francesco Faiola, Jianlong Wang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-07T06:30:45.622798-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1384</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1384</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1384</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Pluripotent embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) hold great promise for future use in tissue replacement therapies due to their ability to self-renew indefinitely and to differentiate into all adult cell types. Harnessing this therapeutic potential efficiently requires a much deeper understanding of the molecular processes at work within the pluripotency network. The transcription factors Nanog, Oct4, and Sox2 reside at the core of this network, where they interact and regulate their own expression as well as that of numerous other pluripotency factors. Of these core factors, Nanog is critical for blocking the differentiation of pluripotent cells, and more importantly, for establishing the pluripotent ground state during somatic cell reprogramming. Both mouse and human Nanog are able to form dimers <em>in vivo</em>, allowing them to preferentially interact with certain factors and perform unique functions. Recent studies have identified an evolutionary functional conservation among vertebrate Nanog orthologs from chick, zebrafish, and the axolotl salamander, adding an additional layer of complexity to Nanog function. Here we present a detailed overview of published work focusing on Nanog structure, function, dimerization, and regulation at the genetic and post-translational levels with regard to the establishment and maintenance of pluripotency. The full spectrum of Nanog function in pluripotent stem cells and in cancer is only beginning to be revealed. We therefore use this evidence to advocate for more comprehensive analysis of Nanog in the context of disease, development, and regeneration.</p></div>
]]></content:encoded><description>

Pluripotent embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) hold great promise for future use in tissue replacement therapies due to their ability to self-renew indefinitely and to differentiate into all adult cell types. Harnessing this therapeutic potential efficiently requires a much deeper understanding of the molecular processes at work within the pluripotency network. The transcription factors Nanog, Oct4, and Sox2 reside at the core of this network, where they interact and regulate their own expression as well as that of numerous other pluripotency factors. Of these core factors, Nanog is critical for blocking the differentiation of pluripotent cells, and more importantly, for establishing the pluripotent ground state during somatic cell reprogramming. Both mouse and human Nanog are able to form dimers in vivo, allowing them to preferentially interact with certain factors and perform unique functions. Recent studies have identified an evolutionary functional conservation among vertebrate Nanog orthologs from chick, zebrafish, and the axolotl salamander, adding an additional layer of complexity to Nanog function. Here we present a detailed overview of published work focusing on Nanog structure, function, dimerization, and regulation at the genetic and post-translational levels with regard to the establishment and maintenance of pluripotency. The full spectrum of Nanog function in pluripotent stem cells and in cancer is only beginning to be revealed. We therefore use this evidence to advocate for more comprehensive analysis of Nanog in the context of disease, development, and regeneration.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1418" xmlns="http://purl.org/rss/1.0/"><title>Maintenance of Stem cell Self-renewal in Head and Neck Cancers Requires Actions of GSK3β Influenced by CD44 and RHAMM.</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1418</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Maintenance of Stem cell Self-renewal in Head and Neck Cancers Requires Actions of GSK3β Influenced by CD44 and RHAMM.</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hideo Shigeishi, Adrian Biddle, Luke Gammon, Helena Emich, Camila.O. Rodini, Emilios Gemenetzidis, Bilal Fazil, Masaru Sugiyama, Nobuyuki Kamata, Ian C. Mackenzie</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-07T06:30:15.89747-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1418</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1418</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1418</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cells sorted from head and neck cancers on the basis of their high expression of CD44 have high potency for tumor initiation. These cells are also involved in epithelial to mesenchymal transition (EMT) and we have previously reported that cancer stem cells (CSCs) exist as two biologically distinct phenotypes. Both phenotypes are CD44<sup>high</sup> but whereas one is also ESA<sup>high</sup> and maintains epithelial characteristics, the other is ESA<sup>low</sup>, has mesenchymal characteristics and is migratory. Examining CD44-regulated signal pathways in these cells we show that CD44, and also RHAMM, act to inhibit phosphorylation of glycogen synthase kinase 3β (GSK3β) and that such inhibition reduces the formation of both “tumour spheres” and “holoclone” colonies, functional indicators of stemness. GSK3β inhibition also reduces the expression of stem cell markers such as Oct4, Sox2 and Nanog and up-regulates expression of the differentiation markers Calgranulin B and Involucrin in the CD44<sup>high</sup>/ESA<sup>high</sup> cell fraction. Transition of CSCs out of EMT and back to the epithelial CSC phenotype is induced by GSK3β knockdown. These results indicate that GSK3β plays a central role in determining and maintaining the phenotypes and behavior of CSCs <em>in vitro</em> and are likely to be involved in controlling the growth and spread of tumours <em>in vivo</em>.</p></div>
]]></content:encoded><description>

Cells sorted from head and neck cancers on the basis of their high expression of CD44 have high potency for tumor initiation. These cells are also involved in epithelial to mesenchymal transition (EMT) and we have previously reported that cancer stem cells (CSCs) exist as two biologically distinct phenotypes. Both phenotypes are CD44high but whereas one is also ESAhigh and maintains epithelial characteristics, the other is ESAlow, has mesenchymal characteristics and is migratory. Examining CD44-regulated signal pathways in these cells we show that CD44, and also RHAMM, act to inhibit phosphorylation of glycogen synthase kinase 3β (GSK3β) and that such inhibition reduces the formation of both “tumour spheres” and “holoclone” colonies, functional indicators of stemness. GSK3β inhibition also reduces the expression of stem cell markers such as Oct4, Sox2 and Nanog and up-regulates expression of the differentiation markers Calgranulin B and Involucrin in the CD44high/ESAhigh cell fraction. Transition of CSCs out of EMT and back to the epithelial CSC phenotype is induced by GSK3β knockdown. These results indicate that GSK3β plays a central role in determining and maintaining the phenotypes and behavior of CSCs in vitro and are likely to be involved in controlling the growth and spread of tumours in vivo.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1420" xmlns="http://purl.org/rss/1.0/"><title>Function of Ezrin-Radixin-Moesin Proteins in Migration of Subventricular Zone-Derived Neuroblasts Following Traumatic Brain Injury</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1420</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Function of Ezrin-Radixin-Moesin Proteins in Migration of Subventricular Zone-Derived Neuroblasts Following Traumatic Brain Injury</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Younghye Moon, Joo Yeon Kim, Woon Ryoung Kim, Hyun Jung Kim, Min Jee Jang, Yoonkey Nam, Kyungjin Kim, Hyun Kim, Woong Sun</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-07T06:29:23.718161-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1420</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1420</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1420</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Throughout life, newly generated neuroblasts from the subventricular zone migrate toward the olfactory bulb through the rostral migratory stream. Upon brain injury, these migrating neuroblasts change their route and begin to migrate toward injured regions, which is one of the regenerative responses after brain damage. This injury-induced migration is triggered by SDF1 released from microglia near the damaged site; however, it is still unclear how these cells transduce SDF1 signals and change their direction. In this study, we found that SDF1 promotes the phosphorylation of ezrin-radixin-moesin (ERM) proteins, which are key molecules in organizing cell membrane and linking signals from the extracellular environment to the intracellular actin cytoskeleton. Blockade of ERM activation by overexpressing dominant-negative ERM (DN-ERM) efficiently perturbed the migration of neuroblasts. Considering that DN-ERM--expressing neuroblasts failed to maintain proper migratory cell morphology, it appears that ERM-dependent regulation of cell shape is required for the efficient migration of neuroblasts. These results suggest that ERM activation is an important step in the directional migration of neuroblasts in response to SDF1-CXCR4 signaling following brain injury.</p></div>
]]></content:encoded><description>

Throughout life, newly generated neuroblasts from the subventricular zone migrate toward the olfactory bulb through the rostral migratory stream. Upon brain injury, these migrating neuroblasts change their route and begin to migrate toward injured regions, which is one of the regenerative responses after brain damage. This injury-induced migration is triggered by SDF1 released from microglia near the damaged site; however, it is still unclear how these cells transduce SDF1 signals and change their direction. In this study, we found that SDF1 promotes the phosphorylation of ezrin-radixin-moesin (ERM) proteins, which are key molecules in organizing cell membrane and linking signals from the extracellular environment to the intracellular actin cytoskeleton. Blockade of ERM activation by overexpressing dominant-negative ERM (DN-ERM) efficiently perturbed the migration of neuroblasts. Considering that DN-ERM--expressing neuroblasts failed to maintain proper migratory cell morphology, it appears that ERM-dependent regulation of cell shape is required for the efficient migration of neuroblasts. These results suggest that ERM activation is an important step in the directional migration of neuroblasts in response to SDF1-CXCR4 signaling following brain injury.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1426" xmlns="http://purl.org/rss/1.0/"><title>Hes1 Desynchronizes Differentiation of Pluripotent Cells by Modulating STAT3 Activity</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1426</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hes1 Desynchronizes Differentiation of Pluripotent Cells by Modulating STAT3 Activity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xinzhi Zhou, Andrew J.H. Smith, Anna Waterhouse, Guillaume Blin, Mattias Malaguti, Chia-Yi Lin, Rodrigo Osorno, Ian Chambers, Sally Lowell</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-05-07T06:28:58.036594-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1426</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1426</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1426</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Robust development of the early embryo may benefit from mechanisms that ensure that not all pluripotent cells differentiate at exactly the same time: such mechanisms would build flexibility into the process of lineage allocation. This idea is supported by the observation that pluripotent stem cells differentiate at different rates in vitro. We use a clonal commitment assay to confirm that pluripotent cells commit to differentiate asynchronously even under uniform differentiation conditions. Stochastic variability in expression of the Notch target gene Hes1 has previously been reported to influence neural vs. mesodermal differentiation through modulation of Notch activity. Here we report that Hes1 also has an earlier role to delay exit from the pluripotent state into all lineages. The early function of Hes1 to delay differentiation can be explained by an ability of Hes1 to amplify STAT3 responsiveness in a cell-autonomous manner. Variability in Hes1 expression therefore helps to explain why STAT3 responsiveness varies between individual ES cells, and this in turn helps to explain why pluripotent cells commit to differentiate asynchronously.</p></div>
]]></content:encoded><description>

Robust development of the early embryo may benefit from mechanisms that ensure that not all pluripotent cells differentiate at exactly the same time: such mechanisms would build flexibility into the process of lineage allocation. This idea is supported by the observation that pluripotent stem cells differentiate at different rates in vitro. We use a clonal commitment assay to confirm that pluripotent cells commit to differentiate asynchronously even under uniform differentiation conditions. Stochastic variability in expression of the Notch target gene Hes1 has previously been reported to influence neural vs. mesodermal differentiation through modulation of Notch activity. Here we report that Hes1 also has an earlier role to delay exit from the pluripotent state into all lineages. The early function of Hes1 to delay differentiation can be explained by an ability of Hes1 to amplify STAT3 responsiveness in a cell-autonomous manner. Variability in Hes1 expression therefore helps to explain why STAT3 responsiveness varies between individual ES cells, and this in turn helps to explain why pluripotent cells commit to differentiate asynchronously.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1414" xmlns="http://purl.org/rss/1.0/"><title>Ex-vivo Expansion of Human Outgrowth Endothelial Cells Leads to IL-8-Mediated Replicative Senescence and Impaired Vasoreparative Function</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1414</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ex-vivo Expansion of Human Outgrowth Endothelial Cells Leads to IL-8-Mediated Replicative Senescence and Impaired Vasoreparative Function</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Reinhold J. Medina, Christina L. O'Neill, T. Michelle O'Doherty, Sarah EJ. Chambers, Jasenka Guduric-Fuchs, Jessica Neisen, David J. Waugh, David A. Simpson, Alan W. Stitt</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T03:53:49.411967-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1414</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1414</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1414</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Harnessing outgrowth endothelial cells (OECs) for vasoreparative therapy and tissue-engineering requires efficient <em>ex-vivo</em> expansion. How such expansion impacts on OEC function is largely unknown. In this study, we show that OECs become permanently cell-cycle arrested after <em>ex-vivo</em> expansion, which is associated with enlarged cell size, β-galactosidase activity, DNA damage, tumour suppressor pathway activation and significant transcriptome changes. These senescence hallmarks were coupled with low telomerase activity and telomere shortening, indicating replicative senescence. OEC senescence limited their regenerative potential by impairing vasoreparative properties in-vitro and <em>in-vivo</em>. Integrated transcriptome-proteome analysis identified inflammatory signalling pathways as major mechanistic components of the OEC senescence programme. In particular, IL8 was an important facilitator of this senescence; depletion of IL8 in OECs significantly extended <em>ex-vivo</em> lifespan, delayed replicative senescence and enhanced function. While the ability to expand OEC numbers prior to autologous or allogeneic therapy remains a useful property, their replicative senescence and associated impairment of vasorepair needs to be considered. The current study also suggests that modulation of the senescence-associated secretory phenotype (SASP) could be used to optimise OEC therapy.</p></div>
]]></content:encoded><description>

Harnessing outgrowth endothelial cells (OECs) for vasoreparative therapy and tissue-engineering requires efficient ex-vivo expansion. How such expansion impacts on OEC function is largely unknown. In this study, we show that OECs become permanently cell-cycle arrested after ex-vivo expansion, which is associated with enlarged cell size, β-galactosidase activity, DNA damage, tumour suppressor pathway activation and significant transcriptome changes. These senescence hallmarks were coupled with low telomerase activity and telomere shortening, indicating replicative senescence. OEC senescence limited their regenerative potential by impairing vasoreparative properties in-vitro and in-vivo. Integrated transcriptome-proteome analysis identified inflammatory signalling pathways as major mechanistic components of the OEC senescence programme. In particular, IL8 was an important facilitator of this senescence; depletion of IL8 in OECs significantly extended ex-vivo lifespan, delayed replicative senescence and enhanced function. While the ability to expand OEC numbers prior to autologous or allogeneic therapy remains a useful property, their replicative senescence and associated impairment of vasorepair needs to be considered. The current study also suggests that modulation of the senescence-associated secretory phenotype (SASP) could be used to optimise OEC therapy.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1411" xmlns="http://purl.org/rss/1.0/"><title>Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1411</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Role of the P2Y13 receptor in the differentiation of bone marrow stromal cells into osteoblasts and adipocytes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Galadrielle Biver, Ning Wang, Alison Gartland, Isabel Orriss, Timothy R. Arnett, Jean-Marie Boeynaems, Bernard Robaye</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T03:52:52.029517-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1411</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1411</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1411</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Accumulating evidence indicates that extracellular nucleotides, signaling through purinergic receptors, play a significant role in bone remodeling. Mesenchymal stem cells (MSC) express functional P2Y receptors whose expression level is regulated during osteoblast or adipocyte differentiation. P2Y<sub>13−</sub>deficient mice were previously shown to exhibit a decreased bone turnover associated with a reduction in the number of both osteoblasts and osteoclasts on the bone surfaces. We therefore examined whether P2Y<sub>13</sub>R activation was involved in the osteogenic differentiation of MSC. Our study demonstrated that ADP stimulation of P2Y<sub>13</sub>R<sup>+/+</sup> (but not P2Y<sub>13</sub>R<sup>−/−</sup>) adherent bone marrow stromal cells (BMSC) increased significantly the formation of alkaline phosphatase-colony forming units (CFU-ALP), as well as the expression of osteoblastic markers (Osterix, Alkaline Phosphatase, Collagen I) involved in the maturation of pre-osteoblasts into osteoblasts. The number of CFU-ALP obtained from P2Y<sub>13</sub>R<sup>−/−</sup> BMSC and the level of osteoblastic gene expression after osteogenic stimulation were strongly reduced compared to those obtained in wild-type cell cultures. In contrast, when P2Y<sub>13</sub>R<sup>−/−</sup> BMSC were incubated in an adipogenic medium, the number of adipocytes generated and the level of adipogenic gene expression (PPARγ2 and Adipsin) were higher than those obtained in P2Y<sub>13</sub>R<sup>+/+</sup> MSC. Interestingly we observed a significant increase of the number of bone marrow adipocytes in tibia of P2Y<sub>13</sub>R<sup>−/−</sup> mice. In conclusion, our findings indicate that the P2Y<sub>13</sub>R plays an important role in the balance of osteoblast and adipocyte terminal differentiation of bone marrow progenitors. Therefore, the P2Y<sub>13</sub> receptor can be considered as a new pharmacological target for the treatment of bone diseases like osteoporosis.</p></div>
]]></content:encoded><description>

Accumulating evidence indicates that extracellular nucleotides, signaling through purinergic receptors, play a significant role in bone remodeling. Mesenchymal stem cells (MSC) express functional P2Y receptors whose expression level is regulated during osteoblast or adipocyte differentiation. P2Y13−deficient mice were previously shown to exhibit a decreased bone turnover associated with a reduction in the number of both osteoblasts and osteoclasts on the bone surfaces. We therefore examined whether P2Y13R activation was involved in the osteogenic differentiation of MSC. Our study demonstrated that ADP stimulation of P2Y13R+/+ (but not P2Y13R−/−) adherent bone marrow stromal cells (BMSC) increased significantly the formation of alkaline phosphatase-colony forming units (CFU-ALP), as well as the expression of osteoblastic markers (Osterix, Alkaline Phosphatase, Collagen I) involved in the maturation of pre-osteoblasts into osteoblasts. The number of CFU-ALP obtained from P2Y13R−/− BMSC and the level of osteoblastic gene expression after osteogenic stimulation were strongly reduced compared to those obtained in wild-type cell cultures. In contrast, when P2Y13R−/− BMSC were incubated in an adipogenic medium, the number of adipocytes generated and the level of adipogenic gene expression (PPARγ2 and Adipsin) were higher than those obtained in P2Y13R+/+ MSC. Interestingly we observed a significant increase of the number of bone marrow adipocytes in tibia of P2Y13R−/− mice. In conclusion, our findings indicate that the P2Y13R plays an important role in the balance of osteoblast and adipocyte terminal differentiation of bone marrow progenitors. Therefore, the P2Y13 receptor can be considered as a new pharmacological target for the treatment of bone diseases like osteoporosis.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1410" xmlns="http://purl.org/rss/1.0/"><title>Geminin Restrains Mesendodermal Fate Acquisition of Embryonic Stem Cells and is Associated with Antagonism of Wnt Signaling and Enhanced Polycomb-Mediated Repression</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1410</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Geminin Restrains Mesendodermal Fate Acquisition of Embryonic Stem Cells and is Associated with Antagonism of Wnt Signaling and Enhanced Polycomb-Mediated Repression</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elizabeth A. Caronna, Ethan S. Patterson, Pamela M. Hummert, Kristen L. Kroll</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T03:52:30.376085-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1410</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1410</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1410</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Embryonic cells utilize both growth factor signaling and cell intrinsic transcriptional and epigenetic regulation to acquire early cell fates. Underlying mechanisms that integrate these cues are poorly understood. Here we investigated the role of Geminin, a nucleoprotein that interacts with both transcription factors and epigenetic regulatory complexes, during fate acquisition of mouse embryonic stem cells. In order to determine Geminin's role in mesendoderm formation, a process which occurs during embryonic gastrulation, we selectively over-expressed or knocked down Geminin in an <em>in vitro</em> model of differentiating mouse embryonic stem cells. We found that Geminin antagonizes mesendodermal fate acquisition, while these cells instead maintain elevated expression of genes associated with pluripotency of embryonic stem cells. During mesendodermal fate acquisition, Geminin knockdown promotes Wnt signaling, while Bmp, Fgf, and Nodal signaling are not affected. Moreover, we showed that Geminin facilitates the repression of mesendodermal genes that are regulated by the Polycomb repressor complex. Geminin directly binds several of these genes, while Geminin knockdown in mesendodermal cells reduces Polycomb repressor complex occupancy at these loci and increases trimethylation of histone H3 lysine 4, which correlates with active gene expression. Together, these results indicate that Geminin is required to restrain mesendodermal fate acquisition of early embryonic cells and that this is associated with both decreased Wnt signaling and enhanced Polycomb repressor complex retention at mesendodermal genes.</p></div>
]]></content:encoded><description>

Embryonic cells utilize both growth factor signaling and cell intrinsic transcriptional and epigenetic regulation to acquire early cell fates. Underlying mechanisms that integrate these cues are poorly understood. Here we investigated the role of Geminin, a nucleoprotein that interacts with both transcription factors and epigenetic regulatory complexes, during fate acquisition of mouse embryonic stem cells. In order to determine Geminin's role in mesendoderm formation, a process which occurs during embryonic gastrulation, we selectively over-expressed or knocked down Geminin in an in vitro model of differentiating mouse embryonic stem cells. We found that Geminin antagonizes mesendodermal fate acquisition, while these cells instead maintain elevated expression of genes associated with pluripotency of embryonic stem cells. During mesendodermal fate acquisition, Geminin knockdown promotes Wnt signaling, while Bmp, Fgf, and Nodal signaling are not affected. Moreover, we showed that Geminin facilitates the repression of mesendodermal genes that are regulated by the Polycomb repressor complex. Geminin directly binds several of these genes, while Geminin knockdown in mesendodermal cells reduces Polycomb repressor complex occupancy at these loci and increases trimethylation of histone H3 lysine 4, which correlates with active gene expression. Together, these results indicate that Geminin is required to restrain mesendodermal fate acquisition of early embryonic cells and that this is associated with both decreased Wnt signaling and enhanced Polycomb repressor complex retention at mesendodermal genes.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1409" xmlns="http://purl.org/rss/1.0/"><title>Mir-133b Promotes Neural Plasticity and Functional Recovery after Treatment of Stroke with Multipotent Mesenchymal Stromal Cells in Rats Via Transfer of Exosome-Enriched Extracellular Particles</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1409</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Mir-133b Promotes Neural Plasticity and Functional Recovery after Treatment of Stroke with Multipotent Mesenchymal Stromal Cells in Rats Via Transfer of Exosome-Enriched Extracellular Particles</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hongqi Xin, Yi Li, Zhongwu Liu, Xinli Wang, Xia Shang, Yisheng Cui, Zheng Gang Zhang, Michael Chopp</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T03:51:58.013395-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1409</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1409</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1409</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>To test, <em>in vivo</em>, the hypothesis that exosomes from multipotent mesenchymal stromal cells (MSCs) mediate microRNA 133b (miR-133b) transfer which promotes neurological recovery from stroke, we employed knock-in and knock-down technologies to up-regulate or down-regulate the miR-133b level in MSCs (miR-133b<sup>+</sup>MSCs or miR-133b<sup>−</sup>MSCs) and their corresponding exosomes, respectively. Rats were subjected to middle cerebral artery occlusion (MCAo) and were treated with naïve MSCs, miR-133b<sup>+</sup>MSCs, or miR-133b<sup>−</sup>MSC at one day after MCAo. Compared with controls, rats receiving naïve MSC treatment significantly improved functional recovery, and exhibited increased axonal plasticity and neurite remodeling in the ischemic boundary zone (IBZ) at day 14 after MCAo. The outcomes were significantly enhanced with miR-133b<sup>+</sup>MSC treatment, and were significantly decreased with miR-133b<sup>−</sup>MSC treatment, compared to naïve MSC treatment. The miR-133b level in exosomes collected from the cerebral spinal fluid was significantly increased after miR-133b<sup>+</sup>MSC treatment, and was significantly decreased after miR-133b<sup>−</sup>MSC treatment at day 14 after MCAo, compared to naïve MSC treatment. Tagging exosomes with green fluorescent protein demonstrated that exosomes-enriched extracellular particles were released from MSCs and transferred to adjacent astrocytes and neurons. The expression of selective targets for miR-133b, connective tissue growth factor and ras homolog gene family member A, were significantly decreased in the IBZ after miR-133b<sup>+</sup>MSC treatment, while their expression remained at similar elevated levels after miR-133b<sup>−</sup>MSC treatment, compared to naïve MSC treatment. Collectively, our data suggest that exosomes from MSCs mediate the miR-133b transfer to astrocytes and neurons, which regulate gene expression, subsequently benefit neurite remodeling and functional recovery after stroke.</p></div>
]]></content:encoded><description>

To test, in vivo, the hypothesis that exosomes from multipotent mesenchymal stromal cells (MSCs) mediate microRNA 133b (miR-133b) transfer which promotes neurological recovery from stroke, we employed knock-in and knock-down technologies to up-regulate or down-regulate the miR-133b level in MSCs (miR-133b+MSCs or miR-133b−MSCs) and their corresponding exosomes, respectively. Rats were subjected to middle cerebral artery occlusion (MCAo) and were treated with naïve MSCs, miR-133b+MSCs, or miR-133b−MSC at one day after MCAo. Compared with controls, rats receiving naïve MSC treatment significantly improved functional recovery, and exhibited increased axonal plasticity and neurite remodeling in the ischemic boundary zone (IBZ) at day 14 after MCAo. The outcomes were significantly enhanced with miR-133b+MSC treatment, and were significantly decreased with miR-133b−MSC treatment, compared to naïve MSC treatment. The miR-133b level in exosomes collected from the cerebral spinal fluid was significantly increased after miR-133b+MSC treatment, and was significantly decreased after miR-133b−MSC treatment at day 14 after MCAo, compared to naïve MSC treatment. Tagging exosomes with green fluorescent protein demonstrated that exosomes-enriched extracellular particles were released from MSCs and transferred to adjacent astrocytes and neurons. The expression of selective targets for miR-133b, connective tissue growth factor and ras homolog gene family member A, were significantly decreased in the IBZ after miR-133b+MSC treatment, while their expression remained at similar elevated levels after miR-133b−MSC treatment, compared to naïve MSC treatment. Collectively, our data suggest that exosomes from MSCs mediate the miR-133b transfer to astrocytes and neurons, which regulate gene expression, subsequently benefit neurite remodeling and functional recovery after stroke.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1408" xmlns="http://purl.org/rss/1.0/"><title>Astrocytic ATP release regulates the proliferation of neural stem cells in the adult hippocampus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1408</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Astrocytic ATP release regulates the proliferation of neural stem cells in the adult hippocampus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiong Cao, Liang-Ping Li, Xi-He Qin, Shu-Ji Li, Meng Zhang, Qian Wang, Hong-Hai Hu, Ying-Ying Fang, Yu-Bo Gao, Xiao-Wen Li, Li-Rong Sun, Wen-Chao Xiong, Tian-Ming Gao, Xin-Hong Zhu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T03:51:31.596947-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1408</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1408</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1408</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Astrocytes are key components of the niche for neural stem cells (NSCs) in the adult hippocampus and play a vital role in regulating NSC proliferation and differentiation. However, the exact molecular mechanisms by which astrocytes modulate NSC proliferation have not been identified. Here, we identified adenosine 5′-triphosphate (ATP) as a proliferative factor required for astrocyte-mediated proliferation of NSCs in the adult hippocampus. Our results indicate that ATP is necessary and sufficient for astrocytes to promote NSC proliferation <em>in vitro</em>. The lack of inositol 1, 4, 5-trisphosphate receptor type 2 (IP<sub>3</sub>R2) and transgenic blockage of vesicular gliotransmission induced deficient ATP release from astrocytes. This deficiency led to a dysfunction in NSC proliferation that could be rescued via the administration of exogenous ATP. Moreover, P2Y1-mediated purinergic signaling is involved in the astrocyte promotion of NSC proliferation. As adult hippocampal neurogenesis is potentially involved in major mood disorder, our results might offer mechanistic insights into this disease.</p></div>
]]></content:encoded><description>

Astrocytes are key components of the niche for neural stem cells (NSCs) in the adult hippocampus and play a vital role in regulating NSC proliferation and differentiation. However, the exact molecular mechanisms by which astrocytes modulate NSC proliferation have not been identified. Here, we identified adenosine 5′-triphosphate (ATP) as a proliferative factor required for astrocyte-mediated proliferation of NSCs in the adult hippocampus. Our results indicate that ATP is necessary and sufficient for astrocytes to promote NSC proliferation in vitro. The lack of inositol 1, 4, 5-trisphosphate receptor type 2 (IP3R2) and transgenic blockage of vesicular gliotransmission induced deficient ATP release from astrocytes. This deficiency led to a dysfunction in NSC proliferation that could be rescued via the administration of exogenous ATP. Moreover, P2Y1-mediated purinergic signaling is involved in the astrocyte promotion of NSC proliferation. As adult hippocampal neurogenesis is potentially involved in major mood disorder, our results might offer mechanistic insights into this disease.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1407" xmlns="http://purl.org/rss/1.0/"><title>CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1407</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CXC chemokine receptor 4 is essential for maintenance of renal cell carcinoma-initiating cells and predicts metastasis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maximilian Gassenmaier, Dong Chen, Alexander Buchner, Lynette Henkel, Matthias Schiemann, Brigitte Mack, Dolores J. Schendel, Wolfgang Zimmermann, Heike Pohla</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T03:50:58.588659-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1407</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1407</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1407</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In many solid tumors, cancer stem cells (CSC) represent a small cell population with tumor-initiating, self-renewal and differentiation potential, which can be identified by surface protein markers. No generally applicable markers are yet known for renal cell carcinoma (RCC). Two RCC cell lines (RCC-26, RCC-53) were found to differ widely in their capacity to form spheres in vitro and to establish tumors in mice, potentially reflecting differences in CSC content. A subpopulation expressing the CXC chemokine receptor 4 (CXCR4) was present only in the more tumorigenic cell line RCC-53. When grown as spheres, most of the RCC-53 cells were CXCR4-positive, expressed stem cell-associated transcription factor genes at elevated levels and were more resistant towards the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Sorted CXCR4-positive cells exhibited greater capacity for sphere formation and tumor growth-inducing potential in vivo than CXCR4-negative cells. Significantly, higher CXCR4 mRNA levels in primary RCC tumors from patients with localized but not disseminated disease predicted longer survival. Downregulation of CXCR4 expression by siRNA or pharmacological inhibition by AMD3100 compromised tumor sphere formation, viability of CXCR4-positive cells and increased their responsiveness towards tyrosine kinase inhibitors. In conclusion, CXCR4 identifies a subpopulation of tumor-initiating cells in RCC cell lines and plays a role in their maintenance. The relative insensitivity of such cells to tyrosine kinase inhibitors might contribute to the development of therapy resistance in RCC patients. Future therapies therefore could combine blockade of the CXCR4 signaling pathway with standard therapies for more effective treatments of metastatic RCC.</p></div>
]]></content:encoded><description>

In many solid tumors, cancer stem cells (CSC) represent a small cell population with tumor-initiating, self-renewal and differentiation potential, which can be identified by surface protein markers. No generally applicable markers are yet known for renal cell carcinoma (RCC). Two RCC cell lines (RCC-26, RCC-53) were found to differ widely in their capacity to form spheres in vitro and to establish tumors in mice, potentially reflecting differences in CSC content. A subpopulation expressing the CXC chemokine receptor 4 (CXCR4) was present only in the more tumorigenic cell line RCC-53. When grown as spheres, most of the RCC-53 cells were CXCR4-positive, expressed stem cell-associated transcription factor genes at elevated levels and were more resistant towards the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib. Sorted CXCR4-positive cells exhibited greater capacity for sphere formation and tumor growth-inducing potential in vivo than CXCR4-negative cells. Significantly, higher CXCR4 mRNA levels in primary RCC tumors from patients with localized but not disseminated disease predicted longer survival. Downregulation of CXCR4 expression by siRNA or pharmacological inhibition by AMD3100 compromised tumor sphere formation, viability of CXCR4-positive cells and increased their responsiveness towards tyrosine kinase inhibitors. In conclusion, CXCR4 identifies a subpopulation of tumor-initiating cells in RCC cell lines and plays a role in their maintenance. The relative insensitivity of such cells to tyrosine kinase inhibitors might contribute to the development of therapy resistance in RCC patients. Future therapies therefore could combine blockade of the CXCR4 signaling pathway with standard therapies for more effective treatments of metastatic RCC.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1406" xmlns="http://purl.org/rss/1.0/"><title>Impaired Cell Reprogramming in Non-Homologous End Joining Deficient Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1406</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Impaired Cell Reprogramming in Non-Homologous End Joining Deficient Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">F. Javier Molina-Estevez, M. Luz Lozano, Susana Navarro, Yaima Torres, Ivana Grabundzija, Zoltan Ivics, Enrique Samper, Juan A. Bueren, Guillermo Guenechea</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T03:49:57.828659-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1406</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1406</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1406</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Although there is an increasing interest in defining the role of DNA damage response mechanisms in cell reprogramming, the relevance of proteins participating in Non-Homologous End Joining (NHEJ), a major mechanism of DNA double strand breaks repair, in this process remains to be investigated. Herein, we present data related to the reprogramming of primary mouse embryonic fibroblasts (MEF) from severe combined immunodeficient (Scid) mice defective in DNA-PKcs: a key protein for NHEJ. Reduced numbers of induced pluripotent stem cell (iPSC) colonies were generated from Scid cells using reprogramming lentiviral vectors (LV), being the reprogramming efficiency 4 to 7 fold lower than the observed in wt cells. Moreover, these Scid iPSC-like clones were prematurely lost or differentiated spontaneously. While the Scid mutation did not reduce the proliferation rate nor the transduction efficacy of fibroblasts transduced with reprogramming LV, both the expression of SA-β-Gal and of P16/INK<sup>4a</sup> senescence markers were highly increased in Scid versus wt pMEFs during the reprogramming process, accounting for the reduced reprogramming efficacy of Scid MEFs. The use of improved Sleeping Beauty (SB) transposon/transposase systems allowed us, however, to isolate DNA-PKcs-deficient iPSCs which preserved their parental genotype and hypersensitivity to ionizing radiation. This new disease-specific iPSC model would be useful to understand the physiological consequences of the DNA-PKcs mutation during development and would help to improve current cell and gene therapy strategies for the disease.</p></div>
]]></content:encoded><description>

Although there is an increasing interest in defining the role of DNA damage response mechanisms in cell reprogramming, the relevance of proteins participating in Non-Homologous End Joining (NHEJ), a major mechanism of DNA double strand breaks repair, in this process remains to be investigated. Herein, we present data related to the reprogramming of primary mouse embryonic fibroblasts (MEF) from severe combined immunodeficient (Scid) mice defective in DNA-PKcs: a key protein for NHEJ. Reduced numbers of induced pluripotent stem cell (iPSC) colonies were generated from Scid cells using reprogramming lentiviral vectors (LV), being the reprogramming efficiency 4 to 7 fold lower than the observed in wt cells. Moreover, these Scid iPSC-like clones were prematurely lost or differentiated spontaneously. While the Scid mutation did not reduce the proliferation rate nor the transduction efficacy of fibroblasts transduced with reprogramming LV, both the expression of SA-β-Gal and of P16/INK4a senescence markers were highly increased in Scid versus wt pMEFs during the reprogramming process, accounting for the reduced reprogramming efficacy of Scid MEFs. The use of improved Sleeping Beauty (SB) transposon/transposase systems allowed us, however, to isolate DNA-PKcs-deficient iPSCs which preserved their parental genotype and hypersensitivity to ionizing radiation. This new disease-specific iPSC model would be useful to understand the physiological consequences of the DNA-PKcs mutation during development and would help to improve current cell and gene therapy strategies for the disease.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1405" xmlns="http://purl.org/rss/1.0/"><title>Zac1 regulates astroglial differentiation of neural stem cells through Socs3</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1405</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Zac1 regulates astroglial differentiation of neural stem cells through Socs3</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Udo Schmidt-Edelkraut, Anke Hoffmann, Guillaume Daniel, Dietmar Spengler</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-30T03:49:11.813548-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1405</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1405</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1405</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cell-fate decisions and differentiation of embryonic and adult neural stem cells (NSC) are tightly controlled by lineage-restricted and temporal factors that interact with cell-intrinsic programs and extracellular signals through multiple regulatory loops. Imprinted genes are important players in neurodevelopment and mental health although their molecular and cellular functions remain poorly understood. Here, we show that the paternally expressed transcriptional regulator Zac1 (zinc finger protein regulating apoptosis and cell cycle arrest) is transiently induced during astroglial and neuronal differentiation of embryonic and adult NSC lines. Thereby, Zac1 transactivates <em>Socs3</em> (suppressor of cytokine signaling 3), a potent inhibitor of pro-differentiative Jak/Stat3 signaling, in a lineage-specific manner to prevent precocious astroglial differentiation. In vivo Zac1 and Socs3 colocalize in the neocortical ventricular zone during incipient astrogliogenesis. Zac1 overexpression in primary NSCs delays astroglial differentiation whereas knock-down of Zac1 or Socs3 facilitates formation of astroglial cells. This negative feedback loop is unrelated to Zac1's cell cycle arrest function and specific to the Jak/Stat3 pathway. Hence, reinstating Jak/Stat3 signaling in the presence of increased Zac1 expression allows for timely astroglial differentiation.</p></div>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Overall we suggest that the imprinted gene <em>Zac1</em> curtails astroglial differentiation of NSCs in the developing and adult brain.</p></div>
]]></content:encoded><description>

Cell-fate decisions and differentiation of embryonic and adult neural stem cells (NSC) are tightly controlled by lineage-restricted and temporal factors that interact with cell-intrinsic programs and extracellular signals through multiple regulatory loops. Imprinted genes are important players in neurodevelopment and mental health although their molecular and cellular functions remain poorly understood. Here, we show that the paternally expressed transcriptional regulator Zac1 (zinc finger protein regulating apoptosis and cell cycle arrest) is transiently induced during astroglial and neuronal differentiation of embryonic and adult NSC lines. Thereby, Zac1 transactivates Socs3 (suppressor of cytokine signaling 3), a potent inhibitor of pro-differentiative Jak/Stat3 signaling, in a lineage-specific manner to prevent precocious astroglial differentiation. In vivo Zac1 and Socs3 colocalize in the neocortical ventricular zone during incipient astrogliogenesis. Zac1 overexpression in primary NSCs delays astroglial differentiation whereas knock-down of Zac1 or Socs3 facilitates formation of astroglial cells. This negative feedback loop is unrelated to Zac1's cell cycle arrest function and specific to the Jak/Stat3 pathway. Hence, reinstating Jak/Stat3 signaling in the presence of increased Zac1 expression allows for timely astroglial differentiation.
Overall we suggest that the imprinted gene Zac1 curtails astroglial differentiation of NSCs in the developing and adult brain.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1395" xmlns="http://purl.org/rss/1.0/"><title>Ubiquitin E3 Ligase Itch Negatively Regulates Osteoblast Differentiation from Mesenchymal Progenitor Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1395</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ubiquitin E3 Ligase Itch Negatively Regulates Osteoblast Differentiation from Mesenchymal Progenitor Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zhang Hengwei, Xing Lianping</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-19T02:09:40.387692-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1395</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1395</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1395</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Itch, a HECT family E3 ligase, affects numerous cell functions by regulating ubiquitination and proteasomal degradation of target proteins. However, the role of Itch in osteoblasts has not been investigated. We report that <em>Itch</em><sup>−/−</sup> mice have significantly increased bone volume, osteoblast numbers and bone formation rate. Using bone marrow stromal cells from <em>Itch</em><sup>−/−</sup> mice and WT littermates as bone marrow mesenchymal precursor cells (BM-MPCs), we found BM-MPCs from <em>Itch</em><sup>−/−</sup> mice have compatible numbers of cells expressing mesenchymal stem cell markers. However, <em>Itch</em><sup>−/−</sup> BM-MPCs grew faster in an <em>in vitro</em> culture, formed more CFU-F mesenchymal colonies, and exhibited increased osteoblast differentiation and decreased adipogenesis. Importantly, <em>Itch</em><sup>−/−</sup> mesenchymal colony cells formed significantly more new bone in a tibial defect of recipient mice compared with WT cells. The expression levels of JunB, an AP-1 transcription factor that positively regulate osteoblast differentiation, were significantly increased in <em>Itch</em><sup>−/−</sup> BM-MPCs when proteasome function is intact. In contrast, the amount of ubiquitinated JunB protein was markedly decreased in <em>Itch</em><sup>−/−</sup> cells when proteasome function was blocked. Over-expression of WT Itch, but not an Itch ligase-inactive mutant, rescued differentiation defects of <em>Itch</em><sup>−/−</sup> BM-MPCs. <em>Itch</em><sup>−/−</sup> BM-MPCs had a similar role in immune modulation as WT cells. Thus, Itch negatively controls osteoblast differentiation from BM-MPCs through the regulation of proteasomal degradation of positive osteoblast regulator JunB protein. Itch is a potential new target for bone anabolic drug development to treat patients with bone loss.</p></div>
]]></content:encoded><description>

Itch, a HECT family E3 ligase, affects numerous cell functions by regulating ubiquitination and proteasomal degradation of target proteins. However, the role of Itch in osteoblasts has not been investigated. We report that Itch−/− mice have significantly increased bone volume, osteoblast numbers and bone formation rate. Using bone marrow stromal cells from Itch−/− mice and WT littermates as bone marrow mesenchymal precursor cells (BM-MPCs), we found BM-MPCs from Itch−/− mice have compatible numbers of cells expressing mesenchymal stem cell markers. However, Itch−/− BM-MPCs grew faster in an in vitro culture, formed more CFU-F mesenchymal colonies, and exhibited increased osteoblast differentiation and decreased adipogenesis. Importantly, Itch−/− mesenchymal colony cells formed significantly more new bone in a tibial defect of recipient mice compared with WT cells. The expression levels of JunB, an AP-1 transcription factor that positively regulate osteoblast differentiation, were significantly increased in Itch−/− BM-MPCs when proteasome function is intact. In contrast, the amount of ubiquitinated JunB protein was markedly decreased in Itch−/− cells when proteasome function was blocked. Over-expression of WT Itch, but not an Itch ligase-inactive mutant, rescued differentiation defects of Itch−/− BM-MPCs. Itch−/− BM-MPCs had a similar role in immune modulation as WT cells. Thus, Itch negatively controls osteoblast differentiation from BM-MPCs through the regulation of proteasomal degradation of positive osteoblast regulator JunB protein. Itch is a potential new target for bone anabolic drug development to treat patients with bone loss.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1397" xmlns="http://purl.org/rss/1.0/"><title>Multipotent Stromal Cells Alleviate Inflammation, Neuropathology, and Symptoms Associated with Globoid Cell Leukodystrophy in the Twitcher Mouse</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1397</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Multipotent Stromal Cells Alleviate Inflammation, Neuropathology, and Symptoms Associated with Globoid Cell Leukodystrophy in the Twitcher Mouse</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Brittni A. Scruggs, Xiujuan Zhang, Annie C. Bowles, Peter A. Gold, Julie A. Semon, Jeanne M. Fisher-Perkins, Shijia Zhang, Ryan W. Bonvillain, Leann Myers, Su Chen Li, Allan V. Kalueff, Bruce A. Bunnell</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-19T02:09:20.30969-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1397</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1397</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1397</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regenerative Medicine</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Globoid cell leukodystrophy (GLD) is a common neurodegenerative lysosomal storage disorder caused by a deficiency in galactocerebrosidase (GALC), an enzyme that cleaves galactocerebroside during myelination. Bone marrow transplantation has shown promise when administered to late-onset GLD patients. However, the side effects (e.g., graft versus host disease), harsh conditioning regimens (e.g., myelosuppression), and variable therapeutic effects make this an unsuitable option for infantile GLD patients. We previously reported modest improvements in the twitcher mouse model of GLD after intracerebroventricular (ICV) injections of a low dose of multipotent stromal cells (MSCs). Goals of this study were to improve bone marrow-derived MSC (BMSC) therapy for GLD by increasing the cell dosage and comparing cell type (e.g., transduced v. native), treatment timing (e.g., single v. weekly), and administration route (e.g., ICV v. intraperitoneal). Neonatal twitcher mice received (1) 2x10<sup>5</sup> BMSCs by ICV injection, (2) 1x10<sup>6</sup> BMSCs by intraperitoneal (IP) injection, (3) weekly IP injections of 1x10<sup>6</sup> BMSCs, or (4) 1x10<sup>6</sup> lentiviral-transduced BMSCs overexpressing GALC (GALC-BMSC) by IP injection. All treated mice lived longer than untreated mice. However, the mice receiving peripheral MSC therapy had improved motor function (e.g., hind limb strength and rearing ability), twitching symptoms, and weight compared to both the untreated and ICV-treated mice. Inflammatory cell, globoid cell, and apoptotic cell levels in the sciatic nerves were significantly decreased as a result of the GALC-BMSC or weekly IP injections. The results of this study indicate a promising future for peripheral MSC therapy as a non-invasive, adjunct therapy for patients affected with GLD.</p></div>
]]></content:encoded><description>

Globoid cell leukodystrophy (GLD) is a common neurodegenerative lysosomal storage disorder caused by a deficiency in galactocerebrosidase (GALC), an enzyme that cleaves galactocerebroside during myelination. Bone marrow transplantation has shown promise when administered to late-onset GLD patients. However, the side effects (e.g., graft versus host disease), harsh conditioning regimens (e.g., myelosuppression), and variable therapeutic effects make this an unsuitable option for infantile GLD patients. We previously reported modest improvements in the twitcher mouse model of GLD after intracerebroventricular (ICV) injections of a low dose of multipotent stromal cells (MSCs). Goals of this study were to improve bone marrow-derived MSC (BMSC) therapy for GLD by increasing the cell dosage and comparing cell type (e.g., transduced v. native), treatment timing (e.g., single v. weekly), and administration route (e.g., ICV v. intraperitoneal). Neonatal twitcher mice received (1) 2x105 BMSCs by ICV injection, (2) 1x106 BMSCs by intraperitoneal (IP) injection, (3) weekly IP injections of 1x106 BMSCs, or (4) 1x106 lentiviral-transduced BMSCs overexpressing GALC (GALC-BMSC) by IP injection. All treated mice lived longer than untreated mice. However, the mice receiving peripheral MSC therapy had improved motor function (e.g., hind limb strength and rearing ability), twitching symptoms, and weight compared to both the untreated and ICV-treated mice. Inflammatory cell, globoid cell, and apoptotic cell levels in the sciatic nerves were significantly decreased as a result of the GALC-BMSC or weekly IP injections. The results of this study indicate a promising future for peripheral MSC therapy as a non-invasive, adjunct therapy for patients affected with GLD.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1404" xmlns="http://purl.org/rss/1.0/"><title>The Therapeutic Activities of Engrafted Neural Stem/Precursor Cells are Not Dormant in the Chronically Injured Spinal Cord</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1404</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The Therapeutic Activities of Engrafted Neural Stem/Precursor Cells are Not Dormant in the Chronically Injured Spinal Cord</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hiromi Kumamaru, Kazu Kobayakawa, Hirokazu Saiwai, Kensuke Kubota, Kazuya Yokota, Yasuyuki Ohkawa, Keiichiro Shiba, Yukihide Iwamoto, Seiji Okada</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-19T02:09:01.22216-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1404</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1404</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1404</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regenerative Medicine</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The transplantation of neural stem/precursor cells (NSPCs) is a promising therapeutic strategy for many neurodegenerative disorders including spinal cord injury (SCI) because it provides for neural replacement or trophic support. This strategy is now being extended to the treatment of chronic SCI patients. However, understanding of biological properties of chronically transplanted NSPCs and their surrounding environments is limited. Here, we performed temporal analysis of injured spinal cords and demonstrated their multiphasic cellular and molecular responses. In particular, chronically injured spinal cords were growth factor-enriched environments, whereas acutely injured spinal cords were enriched by neurotrophic and inflammatory factors. To determine how these environmental differences affect engrafted cells, NSPCs transplanted into acutely, subacutely, and chronically injured spinal cords were selectively isolated by flow-cytometry, and their whole transcriptomes were compared by RNA-sequencing. This analysis revealed that NSPCs produced many regenerative/neurotrophic molecules irrespective of transplantation timing, and these activities were prominent in chronically transplanted NSPCs. Furthermore, chronically injured spinal cords permitted engrafted NSPCs to differentiate into neurons/oligodendrocytes and provided more neurogenic environment for NSPCs than other environments. Despite these results demonstrate that transplanted NSPCs have adequate capacity in generating neurons/oligodendrocytes and producing therapeutic molecules in chronic SCI microenvironments, they did not improve locomotor function. Our results indicate that failure in chronic transplantation is not due to the lack of therapeutic activities of engrafted NSPCs, but the refractory state of chronically injured spinal cords. Environmental modulation, rather modification of transplanting cells, will be significant for successful translation of stem cell-based therapies into chronic SCI patients.</p></div>
]]></content:encoded><description>

The transplantation of neural stem/precursor cells (NSPCs) is a promising therapeutic strategy for many neurodegenerative disorders including spinal cord injury (SCI) because it provides for neural replacement or trophic support. This strategy is now being extended to the treatment of chronic SCI patients. However, understanding of biological properties of chronically transplanted NSPCs and their surrounding environments is limited. Here, we performed temporal analysis of injured spinal cords and demonstrated their multiphasic cellular and molecular responses. In particular, chronically injured spinal cords were growth factor-enriched environments, whereas acutely injured spinal cords were enriched by neurotrophic and inflammatory factors. To determine how these environmental differences affect engrafted cells, NSPCs transplanted into acutely, subacutely, and chronically injured spinal cords were selectively isolated by flow-cytometry, and their whole transcriptomes were compared by RNA-sequencing. This analysis revealed that NSPCs produced many regenerative/neurotrophic molecules irrespective of transplantation timing, and these activities were prominent in chronically transplanted NSPCs. Furthermore, chronically injured spinal cords permitted engrafted NSPCs to differentiate into neurons/oligodendrocytes and provided more neurogenic environment for NSPCs than other environments. Despite these results demonstrate that transplanted NSPCs have adequate capacity in generating neurons/oligodendrocytes and producing therapeutic molecules in chronic SCI microenvironments, they did not improve locomotor function. Our results indicate that failure in chronic transplantation is not due to the lack of therapeutic activities of engrafted NSPCs, but the refractory state of chronically injured spinal cords. Environmental modulation, rather modification of transplanting cells, will be significant for successful translation of stem cell-based therapies into chronic SCI patients.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1402" xmlns="http://purl.org/rss/1.0/"><title>A New Immuno- Dystrophin-Deficient Model, the NSG-Mdx4cv Mouse, Provides Evidence for Functional Improvement Following Allogeneic Satellite Cell Transplantation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1402</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A New Immuno- Dystrophin-Deficient Model, the NSG-Mdx4cv Mouse, Provides Evidence for Functional Improvement Following Allogeneic Satellite Cell Transplantation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert W. Arpke, Radbod Darabi, Tara L. Mader, Yu Zhang, Akira Toyama, Cara-lin Lonetree, Nardina Nash, Dawn A. Lowe, Rita C.R. Perlingeiro, Michael Kyba</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-19T02:08:24.481434-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1402</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1402</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1402</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Transplantation of a myogenic cell population into an immunodeficient recipient is an excellent way of assessing the <em>in vivo</em> muscle-generating capacity of that cell population. To facilitate both allogeneic and xenogeneic transplantations of muscle-forming cells in mice we have developed a novel immunodeficient muscular dystrophy model, the <em>NSG-mdx<sup>4Cv</sup></em> mouse. The <em>IL2Rg</em> mutation, which is linked to the <em>Dmd</em> gene on the X chromosome, simultaneously depletes NK cells and suppresses thymic lymphomas, issues that limit the utility of the <em>SCID/mdx</em> model. The <em>NSG-mdx</em><sup>4Cv</sup> mouse presents a muscular dystrophy of similar severity to the conventional <em>mdx</em> mouse. We show that this animal supports robust engraftment of both pig and dog muscle mononuclear cells. The question of whether satellite cells prospectively isolated by flow cytometry can confer a functional benefit upon transplantation has been controversial. Using allogeneic <em>Pax7-ZsGreen</em> donors and <em>NSG-mdx<sup>4Cv</sup></em> recipients, we demonstrate definitively that as few as 900 FACS-isolated satellite cells can provide functional regeneration <em>in vivo</em>, in the form of an increased mean maximal force-generation capacity in cell-transplanted muscles, compared to a sham-injected control group. These studies highlight the potency of satellite cells to improve muscle function, and the utility of the <em>NSG-mdx<sup>4Cv</sup></em> model for studies on muscle regeneration and Duchenne muscular dystrophy therapy.</p></div>
]]></content:encoded><description>

Transplantation of a myogenic cell population into an immunodeficient recipient is an excellent way of assessing the in vivo muscle-generating capacity of that cell population. To facilitate both allogeneic and xenogeneic transplantations of muscle-forming cells in mice we have developed a novel immunodeficient muscular dystrophy model, the NSG-mdx4Cv mouse. The IL2Rg mutation, which is linked to the Dmd gene on the X chromosome, simultaneously depletes NK cells and suppresses thymic lymphomas, issues that limit the utility of the SCID/mdx model. The NSG-mdx4Cv mouse presents a muscular dystrophy of similar severity to the conventional mdx mouse. We show that this animal supports robust engraftment of both pig and dog muscle mononuclear cells. The question of whether satellite cells prospectively isolated by flow cytometry can confer a functional benefit upon transplantation has been controversial. Using allogeneic Pax7-ZsGreen donors and NSG-mdx4Cv recipients, we demonstrate definitively that as few as 900 FACS-isolated satellite cells can provide functional regeneration in vivo, in the form of an increased mean maximal force-generation capacity in cell-transplanted muscles, compared to a sham-injected control group. These studies highlight the potency of satellite cells to improve muscle function, and the utility of the NSG-mdx4Cv model for studies on muscle regeneration and Duchenne muscular dystrophy therapy.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1403" xmlns="http://purl.org/rss/1.0/"><title>p130Cas Alters the Differentiation Potential of Mammary Luminal Progenitors by Deregulating C-Kit Activity</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1403</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">p130Cas Alters the Differentiation Potential of Mammary Luminal Progenitors by Deregulating C-Kit Activity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giusy Tornillo, Angela Rita Elia, Isabella Castellano, Michela Spadaro, Paola Bernabei, Brigitte Bisaro, Maria del Pilar Camacho-Leal, Alessandra Pincini, Paolo Provero, Anna Sapino, Emilia Turco, Paola Defilippi, Sara Cabodi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-17T06:23:21.047315-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1403</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1403</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1403</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>It has recently been proposed that defective differentiation of mammary luminal progenitors predisposes to basal-like breast cancer. However, the molecular and cellular mechanisms involved are still unclear. Here, we describe that the adaptor protein p130Cas is a crucial regulator of mouse mammary epithelial cell (MMEC) differentiation. By using a transgenic mouse model, we show that forced p130Cas over-expression in the luminal progenitor cell compartment results in the expansion of luminal cells, which aberrantly display basal cell features and reduced differentiation in response to lactogenic stimuli. Interestingly, MMECs over-expressing p130Cas exhibit hyperactivation of the tyrosine kinase receptor c-Kit. In addition, we demonstrate that the constitutive c-Kit activation alone mimics p130Cas over-expression whereas c-Kit downregulation is sufficient to re-establish proper differentiation of p130Cas over-expressing cells. Overall, our data indicate that high levels of p130Cas, via abnormal c-Kit activation, promote mammary luminal cell plasticity, thus providing the conditions for the development of basal-like breast cancer. Consistently, p130Cas is over-expressed in human triple negative breast cancer, further suggesting that p130Cas upregulation may be a priming event for the onset of basal-like breast cancer.</p></div>
]]></content:encoded><description>

It has recently been proposed that defective differentiation of mammary luminal progenitors predisposes to basal-like breast cancer. However, the molecular and cellular mechanisms involved are still unclear. Here, we describe that the adaptor protein p130Cas is a crucial regulator of mouse mammary epithelial cell (MMEC) differentiation. By using a transgenic mouse model, we show that forced p130Cas over-expression in the luminal progenitor cell compartment results in the expansion of luminal cells, which aberrantly display basal cell features and reduced differentiation in response to lactogenic stimuli. Interestingly, MMECs over-expressing p130Cas exhibit hyperactivation of the tyrosine kinase receptor c-Kit. In addition, we demonstrate that the constitutive c-Kit activation alone mimics p130Cas over-expression whereas c-Kit downregulation is sufficient to re-establish proper differentiation of p130Cas over-expressing cells. Overall, our data indicate that high levels of p130Cas, via abnormal c-Kit activation, promote mammary luminal cell plasticity, thus providing the conditions for the development of basal-like breast cancer. Consistently, p130Cas is over-expressed in human triple negative breast cancer, further suggesting that p130Cas upregulation may be a priming event for the onset of basal-like breast cancer.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1401" xmlns="http://purl.org/rss/1.0/"><title>FoxG1 Interacts with Bmi1 to Regulate Self-Renewal and Tumorigenicity of Medulloblastoma Stem Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1401</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">FoxG1 Interacts with Bmi1 to Regulate Self-Renewal and Tumorigenicity of Medulloblastoma Stem Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Branavan Manoranjan, Xin Wang, Robin M. Hallett, Chitra Venugopal, Stephen C. Mack, Nicole McFarlane, Sara M. Nolte, Katrin Scheinemann, Thorsteinn Gunnarsson, John A. Hassell, Michael D. Taylor, Cathy Lee, Joanna Triscott, Colleen M. Foster, Christopher Dunham, Cynthia Hawkins, Sandra E. Dunn, Sheila K. Singh</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-17T06:22:50.869161-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1401</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1401</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1401</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Brain tumors represent the leading cause of childhood cancer mortality, of which medulloblastoma (MB) is the most frequent malignant tumor. Recent studies have demonstrated the presence of several MB molecular subgroups, each distinct in terms of prognosis and predicted therapeutic response. Groups 1 and 2 are characterized by relatively good clinical outcomes and activation of the Wnt and Shh pathways, respectively. In contrast, Groups 3 and 4 (“non-Shh/Wnt MBs”) are distinguished by metastatic disease, poor patient outcome, and lack a molecular pathway phenotype. Current gene expression platforms have not detected brain tumor-initiating cell (BTIC) self-renewal genes in Group 3 and 4 MBs as BTICs typically comprise a minority of tumor cells and may therefore go undetected on bulk tumor analyses. Since increasing BTIC frequency has been associated with increasing tumor aggressiveness and poor patient outcome, we investigated the subgroup-specific gene expression profile of candidate stem cell genes within 251 primary human MBs from four non-overlapping MB transcriptional databases (Amsterdam, Memphis, Toronto, Boston) and 74 NanoString-subgrouped MBs (Vancouver). We assessed the functional relevance of two genes, <em>FoxG1</em> and <em>Bmi1</em>, which were significantly enriched in non-Shh/Wnt MBs, and showed these genes to mediate MB stem cell self-renewal and tumor initiation in mice. We also identified their transcriptional regulation through reciprocal promoter occupancy in CD15+ MB stem cells. Our work demonstrates the application of stem cell data gathered from genomic platforms to guide functional BTIC assays, which may then be used to develop novel BTIC self-renewal mechanisms amenable to therapeutic targeting.</p></div>
]]></content:encoded><description>

Brain tumors represent the leading cause of childhood cancer mortality, of which medulloblastoma (MB) is the most frequent malignant tumor. Recent studies have demonstrated the presence of several MB molecular subgroups, each distinct in terms of prognosis and predicted therapeutic response. Groups 1 and 2 are characterized by relatively good clinical outcomes and activation of the Wnt and Shh pathways, respectively. In contrast, Groups 3 and 4 (“non-Shh/Wnt MBs”) are distinguished by metastatic disease, poor patient outcome, and lack a molecular pathway phenotype. Current gene expression platforms have not detected brain tumor-initiating cell (BTIC) self-renewal genes in Group 3 and 4 MBs as BTICs typically comprise a minority of tumor cells and may therefore go undetected on bulk tumor analyses. Since increasing BTIC frequency has been associated with increasing tumor aggressiveness and poor patient outcome, we investigated the subgroup-specific gene expression profile of candidate stem cell genes within 251 primary human MBs from four non-overlapping MB transcriptional databases (Amsterdam, Memphis, Toronto, Boston) and 74 NanoString-subgrouped MBs (Vancouver). We assessed the functional relevance of two genes, FoxG1 and Bmi1, which were significantly enriched in non-Shh/Wnt MBs, and showed these genes to mediate MB stem cell self-renewal and tumor initiation in mice. We also identified their transcriptional regulation through reciprocal promoter occupancy in CD15+ MB stem cells. Our work demonstrates the application of stem cell data gathered from genomic platforms to guide functional BTIC assays, which may then be used to develop novel BTIC self-renewal mechanisms amenable to therapeutic targeting.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1399" xmlns="http://purl.org/rss/1.0/"><title>P38α MAPK Regulates Adult Muscle Stem Cell Fate By Restricting Progenitor Proliferation During Postnatal Growth And Repair</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1399</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">P38α MAPK Regulates Adult Muscle Stem Cell Fate By Restricting Progenitor Proliferation During Postnatal Growth And Repair</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrick Brien, Dhamayanthi Pugazhendhi, Samuel Woodhouse, David Oxley, Jennifer M Pell</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-17T06:22:19.426469-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1399</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1399</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1399</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Stem cell function is essential for the maintenance of adult tissue homeostasis. Controlling the balance between self-renewal and differentiation is crucial to maintain a receptive satellite cell pool capable of responding to growth and regeneration cues. The MAP kinase p38α has been implicated in the regulation of these processes but its influence in adult muscle remains unknown. Using conditional satellite cell p38α knockout mice we have demonstrated that p38α restricts excess proliferation in the postnatal growth phase while promoting timely myoblast differentiation. Differentiation was still able to occur in the p38α-null satellite cells, however, but was delayed. An absence of p38α resulted in a postnatal growth defect along with the persistence of an increased reservoir of satellite cells into adulthood. This population was still capable of responding to cardiotoxin-induced injury, resulting in complete, albeit delayed, regeneration, with further enhancement of the satellite cell population. Increased p38γ phosphorylation accompanied the absence of p38α, and inhibition of p38γ <em>ex vivo</em> substantially decreased the myogenic defect. We have employed genome-wide transcriptome analysis to characterise the changes in expression that occur between resting and regenerating muscle, and the influence p38α has on these expression profiles. This study provides novel evidence for the fundamental role of p38α in adult muscle homeostasis <em>in vivo</em>.</p></div>
]]></content:encoded><description>

Stem cell function is essential for the maintenance of adult tissue homeostasis. Controlling the balance between self-renewal and differentiation is crucial to maintain a receptive satellite cell pool capable of responding to growth and regeneration cues. The MAP kinase p38α has been implicated in the regulation of these processes but its influence in adult muscle remains unknown. Using conditional satellite cell p38α knockout mice we have demonstrated that p38α restricts excess proliferation in the postnatal growth phase while promoting timely myoblast differentiation. Differentiation was still able to occur in the p38α-null satellite cells, however, but was delayed. An absence of p38α resulted in a postnatal growth defect along with the persistence of an increased reservoir of satellite cells into adulthood. This population was still capable of responding to cardiotoxin-induced injury, resulting in complete, albeit delayed, regeneration, with further enhancement of the satellite cell population. Increased p38γ phosphorylation accompanied the absence of p38α, and inhibition of p38γ ex vivo substantially decreased the myogenic defect. We have employed genome-wide transcriptome analysis to characterise the changes in expression that occur between resting and regenerating muscle, and the influence p38α has on these expression profiles. This study provides novel evidence for the fundamental role of p38α in adult muscle homeostasis in vivo.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1398" xmlns="http://purl.org/rss/1.0/"><title>Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene-Dependent Model of CN-AML</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1398</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Entinostat Prevents Leukemia Maintenance in a Collaborating Oncogene-Dependent Model of CN-AML</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joanne M Ramsey, Laura MJ Kettyle, Daniel J Sharpe, Nuala M Mulgrew, Glenda J Dickson, Janet J Bijl, Pamela Austin, Nadine Mayotte, Sonia Cellot, Terence RJ Lappin, Shu-Dong Zhang, Ken I. Mills, Jana Krosl, Guy Sauvageau, Alexander Thompson</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-17T06:22:00.910152-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1398</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1398</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1398</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Translational And Clinical Research</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The incidence of refractory acute myeloid leukemia (AML) is on the increase due in part to an aging population that fails to respond to traditional therapies. High throughput genomic analysis promises better diagnosis, prognosis and therapeutic intervention based on improved patient stratification. Relevant pre-clinical models are urgently required to advance drug development in this area. The collaborating oncogenes, <em>HOXA9</em> and <em>MEIS1</em>, are frequently co-overexpressed in cytogenetically normal AML (CN-AML) and a conditional transplantation mouse model was developed that demonstrated oncogene-dependency and expression levels comparable to CN-AML patients. Integration of gene signatures obtained from the mouse model and a cohort of CN-AML patients using statistically significant connectivity Map (sscMap) analysis identified Entinostat as a drug with the potential to alter the leukemic condition towards the normal state. <em>Ex vivo</em> treatment of leukemic cells, but not age-matched normal bone marrow controls, with Entinostat validated the gene signature and resulted in reduced viability in liquid culture, impaired colony formation and loss of the leukemia initiating cell. Furthermore, <em>in vivo</em> treatment with Entinostat resulted in prolonged survival of leukemic mice. This study demonstrates that the HDAC inhibitor Entinostat inhibits disease maintenance and prolongs survival in a clinically relevant murine model of cytogenetically normal AML.</p></div>
]]></content:encoded><description>

The incidence of refractory acute myeloid leukemia (AML) is on the increase due in part to an aging population that fails to respond to traditional therapies. High throughput genomic analysis promises better diagnosis, prognosis and therapeutic intervention based on improved patient stratification. Relevant pre-clinical models are urgently required to advance drug development in this area. The collaborating oncogenes, HOXA9 and MEIS1, are frequently co-overexpressed in cytogenetically normal AML (CN-AML) and a conditional transplantation mouse model was developed that demonstrated oncogene-dependency and expression levels comparable to CN-AML patients. Integration of gene signatures obtained from the mouse model and a cohort of CN-AML patients using statistically significant connectivity Map (sscMap) analysis identified Entinostat as a drug with the potential to alter the leukemic condition towards the normal state. Ex vivo treatment of leukemic cells, but not age-matched normal bone marrow controls, with Entinostat validated the gene signature and resulted in reduced viability in liquid culture, impaired colony formation and loss of the leukemia initiating cell. Furthermore, in vivo treatment with Entinostat resulted in prolonged survival of leukemic mice. This study demonstrates that the HDAC inhibitor Entinostat inhibits disease maintenance and prolongs survival in a clinically relevant murine model of cytogenetically normal AML.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1396" xmlns="http://purl.org/rss/1.0/"><title>Human Placenta-Derived Mesenchymal Stem Cells Promote Hepatic Regeneration in Ccl4-Injured Rat Liver Model Via Increased Autophagic Mechanism</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1396</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Human Placenta-Derived Mesenchymal Stem Cells Promote Hepatic Regeneration in Ccl4-Injured Rat Liver Model Via Increased Autophagic Mechanism</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jieun Jung, Jong Ho Choi, Youjin Lee, Jong-Wan Park, IL-Hoan Oh, Seong-Gyu Hwang, Kwang-Soo Kim, Gi Jin Kim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-17T06:21:41.297093-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1396</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1396</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1396</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Mesenchymal stem cells (MSCs) have great potential for cell therapy in regenerative medicine, including liver disease. Even though ongoing research is dedicated to the goal of bringing MSCs to clinical applications, further understanding of the complex underlying mechanisms is required. Autophagy, a type II programmed cell death, controls cellular recycling through the lysosomal system in damaged cells or tissues. However, it is still unknown whether MSCs can trigger autophagy to enhance regeneration and/or to provide a therapeutic effect as cellular survival promoters. We therefore investigated autophagy's activation in carbon tetrachloride (CCl<sub>4</sub>)-injured rat liver following transplantation with chorionic plate-derived mesenchymal stem cells (CP-MSCs) isolated from placenta. The expression markers for apoptosis, autophagy, and cell survival and liver regeneration were analyzed. Whereas caspase 3/7 activities were reduced (<em>p</em> &lt; .05), the expression levels of hypoxia inducible factor-1α (HIF-1α) and factors for autophagy, survival and regeneration were significantly increased by CP-MSCs transplantation. Decreased necrotic cells (<em>p</em> &lt; .05) and increased autophagic signals (<em>p</em> &lt; .005) were observed in CCl<sub>4</sub>-treated primary rat hepatocytes during <em>in vitro</em> co-culture with CP-MSCs. Furthermore, the upregulation of HIF-1α promotes the regeneration of damaged hepatic cells through an autophagic mechanism marked by increased levels of LC3 II. These results suggest that the administration of CP-MSCs promotes repair by systemically concomitant mechanisms involving HIF-1α and autophagy. These findings provide further understanding of the mechanisms involved in these processes and will help develop new cell-based therapeutic strategies for regenerative medicine in liver disease.</p></div>
]]></content:encoded><description>

Mesenchymal stem cells (MSCs) have great potential for cell therapy in regenerative medicine, including liver disease. Even though ongoing research is dedicated to the goal of bringing MSCs to clinical applications, further understanding of the complex underlying mechanisms is required. Autophagy, a type II programmed cell death, controls cellular recycling through the lysosomal system in damaged cells or tissues. However, it is still unknown whether MSCs can trigger autophagy to enhance regeneration and/or to provide a therapeutic effect as cellular survival promoters. We therefore investigated autophagy's activation in carbon tetrachloride (CCl4)-injured rat liver following transplantation with chorionic plate-derived mesenchymal stem cells (CP-MSCs) isolated from placenta. The expression markers for apoptosis, autophagy, and cell survival and liver regeneration were analyzed. Whereas caspase 3/7 activities were reduced (p &lt; .05), the expression levels of hypoxia inducible factor-1α (HIF-1α) and factors for autophagy, survival and regeneration were significantly increased by CP-MSCs transplantation. Decreased necrotic cells (p &lt; .05) and increased autophagic signals (p &lt; .005) were observed in CCl4-treated primary rat hepatocytes during in vitro co-culture with CP-MSCs. Furthermore, the upregulation of HIF-1α promotes the regeneration of damaged hepatic cells through an autophagic mechanism marked by increased levels of LC3 II. These results suggest that the administration of CP-MSCs promotes repair by systemically concomitant mechanisms involving HIF-1α and autophagy. These findings provide further understanding of the mechanisms involved in these processes and will help develop new cell-based therapeutic strategies for regenerative medicine in liver disease.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1394" xmlns="http://purl.org/rss/1.0/"><title>Epigenetic Regulation of SOX9 by the NF-κB Signaling Pathway in Pancreatic Cancer Stem Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1394</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Epigenetic Regulation of SOX9 by the NF-κB Signaling Pathway in Pancreatic Cancer Stem Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lei Sun, Lesley A. Mathews, Stephanie M. Cabarcas, Xiaohu Zhang, Acong Yang, Ying Zhang, Matthew R. Young, Kimberly D. Klarmann, Jonathan R. Keller, William L. Farrar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-17T06:21:07.628223-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1394</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1394</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1394</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Pancreatic cancer is the fourth leading cause of cancer-related mortality in the world. Pancreatic cancer can be localized, locally advanced or metastatic. The median 1- and 5-year survival rates are 25% and 6%, respectively. Epigenetic modifications such as DNA methylation play a significant role during both normal human development and cancer progression. To investigate epigenetic regulation of genes in the tumor-initiating population of pancreatic cancer cells, which are also termed cancer stem cells (CSCs), we conducted epigenetic arrays in PANC1 and HPAC pancreatic cancer cell lines and compared the global DNA methylation status of CpG promoters in invasive cells, demonstrated to be CSCs, to their non-invasive counterparts, or non-CSCs. Our results suggested that the NF-κB pathway is one of the most activated pathways in pancreatic CSCs. In agreement with this, we determined that upon treatment with NF-κB pathway inhibitors, the stem cell-like properties of cells are significantly disrupted. Moreover, SOX9, demethylated in CSCs, is shown to play a crucial role in the invasion process. Additionally, we found a potential NF-κB binding site located in the SOX9 promoter, and determined that the NF-κB subunit p65 positively regulates SOX9 expression by binding to its promoter directly. This interaction can be efficiently blocked by NF-κB inhibitors. Thus, our work establishes a link between the classical NF-κB signaling transduction pathway and the invasiveness of pancreatic CSCs, which may result in the identification of novel signals and molecules that function at an epigenetic level, and could potentially be targeted for pharmaceutical investigations and clinical trials.</p></div>
]]></content:encoded><description>

Pancreatic cancer is the fourth leading cause of cancer-related mortality in the world. Pancreatic cancer can be localized, locally advanced or metastatic. The median 1- and 5-year survival rates are 25% and 6%, respectively. Epigenetic modifications such as DNA methylation play a significant role during both normal human development and cancer progression. To investigate epigenetic regulation of genes in the tumor-initiating population of pancreatic cancer cells, which are also termed cancer stem cells (CSCs), we conducted epigenetic arrays in PANC1 and HPAC pancreatic cancer cell lines and compared the global DNA methylation status of CpG promoters in invasive cells, demonstrated to be CSCs, to their non-invasive counterparts, or non-CSCs. Our results suggested that the NF-κB pathway is one of the most activated pathways in pancreatic CSCs. In agreement with this, we determined that upon treatment with NF-κB pathway inhibitors, the stem cell-like properties of cells are significantly disrupted. Moreover, SOX9, demethylated in CSCs, is shown to play a crucial role in the invasion process. Additionally, we found a potential NF-κB binding site located in the SOX9 promoter, and determined that the NF-κB subunit p65 positively regulates SOX9 expression by binding to its promoter directly. This interaction can be efficiently blocked by NF-κB inhibitors. Thus, our work establishes a link between the classical NF-κB signaling transduction pathway and the invasiveness of pancreatic CSCs, which may result in the identification of novel signals and molecules that function at an epigenetic level, and could potentially be targeted for pharmaceutical investigations and clinical trials.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1379" xmlns="http://purl.org/rss/1.0/"><title>Erythroid versus Myeloid Lineage Commitment: Regulating the Master Regulators</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1379</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Erythroid versus Myeloid Lineage Commitment: Regulating the Master Regulators</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Linda Wolff, Rita Humeniuk</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-05T01:13:40.506748-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1379</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1379</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1379</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Developmental processes, like blood formation, are orchestrated by transcriptional networks. Those transcriptional networks are highly responsive to various environmental stimuli and affect common precursors resulting in increased production of cells of the erythroid lineage or myeloid lineage (granulocytes, neutrophils, and macrophages). A significant body of knowledge has accumulated describing transcription factors that drive differentiation of these two major cellular pathways, in particular the antagonistic master regulators such as GATA-1 and PU.1. However, little is known about factors that work upstream of master regulators to enhance differentiation towards one lineage. These functions become especially important under various stress conditions like sudden loss of red blood cells or pathogen infection. This review describes recent studies that begin to provide evidence for such factors. An increased understanding of factors regulating cellular commitment will advance our understanding of diseases etiology like anemia, cancer and possibly other blood related disorders.</p></div>
]]></content:encoded><description>

Developmental processes, like blood formation, are orchestrated by transcriptional networks. Those transcriptional networks are highly responsive to various environmental stimuli and affect common precursors resulting in increased production of cells of the erythroid lineage or myeloid lineage (granulocytes, neutrophils, and macrophages). A significant body of knowledge has accumulated describing transcription factors that drive differentiation of these two major cellular pathways, in particular the antagonistic master regulators such as GATA-1 and PU.1. However, little is known about factors that work upstream of master regulators to enhance differentiation towards one lineage. These functions become especially important under various stress conditions like sudden loss of red blood cells or pathogen infection. This review describes recent studies that begin to provide evidence for such factors. An increased understanding of factors regulating cellular commitment will advance our understanding of diseases etiology like anemia, cancer and possibly other blood related disorders.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1378" xmlns="http://purl.org/rss/1.0/"><title>Hematopoietic stem cell transplantation: Targeting the thymus</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1378</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hematopoietic stem cell transplantation: Targeting the thymus</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stéphanie C. de Barros, Valérie S. Zimmermann, Naomi Taylor</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T01:13:51.130088-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1378</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1378</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1378</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Translational And Clinical Research</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Allogeneic hematopoietic stem cell (HSC) transplantation can cure patients suffering from diverse genetic and acquired diseases as well as cancers. Nevertheless, under conditions where T cell reconstitution is critical, the entry of donor progenitors into the thymus remains a major bottleneck. It is assumed that following the intravenous injection of HSC, they first home to the BM. More committed progenitors can then be exported to the thymus in response to a myriad of signals regulating thymus seeding. Notably though, the thymus is not continually receptive to the import of hematopoietic progenitors. Furthermore, as stem cells with self-renewing capacity do not take up residence in the thymus under physiological conditions, the periodic colonization of the thymus is essential for the sustained differentiation of T lymphocytes. As such, we and others have invested significant efforts into exploring avenues that might foster a long-term thymus-autonomous differentiation. Here, we review strategic approaches that have resulted in long-term T cell differentiation in immunodeficient (SCID) mice, even across histocompatibility barriers. These include the forced thymic entry of BM precursors by their direct intrathymic injection as well as the transplantation of neonatal thymi. The capacity of the thymus to support hematopoietic progenitors with renewal potential will hopefully promote the development of new therapeutic strategies aimed at enhancing T cell differentiation in patients undergoing HSC transplantation.</p></div>
]]></content:encoded><description>

Allogeneic hematopoietic stem cell (HSC) transplantation can cure patients suffering from diverse genetic and acquired diseases as well as cancers. Nevertheless, under conditions where T cell reconstitution is critical, the entry of donor progenitors into the thymus remains a major bottleneck. It is assumed that following the intravenous injection of HSC, they first home to the BM. More committed progenitors can then be exported to the thymus in response to a myriad of signals regulating thymus seeding. Notably though, the thymus is not continually receptive to the import of hematopoietic progenitors. Furthermore, as stem cells with self-renewing capacity do not take up residence in the thymus under physiological conditions, the periodic colonization of the thymus is essential for the sustained differentiation of T lymphocytes. As such, we and others have invested significant efforts into exploring avenues that might foster a long-term thymus-autonomous differentiation. Here, we review strategic approaches that have resulted in long-term T cell differentiation in immunodeficient (SCID) mice, even across histocompatibility barriers. These include the forced thymic entry of BM precursors by their direct intrathymic injection as well as the transplantation of neonatal thymi. The capacity of the thymus to support hematopoietic progenitors with renewal potential will hopefully promote the development of new therapeutic strategies aimed at enhancing T cell differentiation in patients undergoing HSC transplantation.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1388" xmlns="http://purl.org/rss/1.0/"><title>IFN-γ and TNF-α Synergistically Induce Mesenchymal Stem Cell Impairment and Tumorigenesis via NFκB Signaling</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1388</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">IFN-γ and TNF-α Synergistically Induce Mesenchymal Stem Cell Impairment and Tumorigenesis via NFκB Signaling</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lei Wang, Yinghua Zhao, Yi Liu, Kentaro Akiyama, Chider Chen, Cunye Qu, Yan Jin, Songtao Shi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T01:12:51.71797-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1388</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1388</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1388</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>An inflammatory microenvironment may cause organ degenerative diseases and malignant tumors. However, the precise mechanisms of inflammation-induced diseases are not fully understood. Here we show that the proinflammatory cytokines interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) synergistically impair self-renewal and differentiation of mesenchymal stem cells (MSCs) <em>via</em> nuclear factor κB (NFκB)--mediated activation of Mothers against decapentaplegic homolog 7 (SMAD7) in ovariectomized (OVX) mice. More interestingly, a long-term elevated levels of IFN-γ and TNF-α result in significantly increased susceptibility to malignant transformation in MSCs through NFκB--mediated upregulation of the oncogenes <em>c-Fos</em> and <em>c-Myc</em>. Depletion of either IFN-γ or TNF-α in OVX mice abolishes MSC impairment and the tendency toward malignant transformation with no NFκB--mediated oncogene activation. Systemic administration of aspirin, which significantly reduces the levels of IFN-γ and TNF-α, results in blockage of MSC deficiency and tumorigenesis by inhibition of NF-κB/SMAD7 and NFκB/c-FOS and c-MYC pathways in OVX mice. In summary, this study reveals that inflammation factors, such as IFN-γ and TNF-α, synergistically induce MSC deficiency <em>via</em> NFκB/SMAD7 signaling and tumorigenesis <em>via</em> NFκB--mediated oncogene activation.</p></div>
]]></content:encoded><description>

An inflammatory microenvironment may cause organ degenerative diseases and malignant tumors. However, the precise mechanisms of inflammation-induced diseases are not fully understood. Here we show that the proinflammatory cytokines interferon γ (IFN-γ) and tumor necrosis factor α (TNF-α) synergistically impair self-renewal and differentiation of mesenchymal stem cells (MSCs) via nuclear factor κB (NFκB)--mediated activation of Mothers against decapentaplegic homolog 7 (SMAD7) in ovariectomized (OVX) mice. More interestingly, a long-term elevated levels of IFN-γ and TNF-α result in significantly increased susceptibility to malignant transformation in MSCs through NFκB--mediated upregulation of the oncogenes c-Fos and c-Myc. Depletion of either IFN-γ or TNF-α in OVX mice abolishes MSC impairment and the tendency toward malignant transformation with no NFκB--mediated oncogene activation. Systemic administration of aspirin, which significantly reduces the levels of IFN-γ and TNF-α, results in blockage of MSC deficiency and tumorigenesis by inhibition of NF-κB/SMAD7 and NFκB/c-FOS and c-MYC pathways in OVX mice. In summary, this study reveals that inflammation factors, such as IFN-γ and TNF-α, synergistically induce MSC deficiency via NFκB/SMAD7 signaling and tumorigenesis via NFκB--mediated oncogene activation.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1386" xmlns="http://purl.org/rss/1.0/"><title>Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem-cell transplantation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1386</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Alterations in the cellular immune compartment of patients treated with third-party mesenchymal stromal cells following allogeneic hematopoietic stem-cell transplantation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Regina Jitschin, Dimitrios Mougiakakos, Lena Von Bahr, Simon Völkl, Guido Moll, Olle Ringden, Rolf Kiessling, Stig Linder, Katarina Le Blanc</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T01:12:29.783416-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1386</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1386</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1386</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Translational And Clinical Research</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Adoptive transfer of third-party mesenchymal stromal cells (MSCs) has emerged as a promising tool for the treatment of steroid-refractory GVHD. Despite numerous <em>in vitro</em> studies and preclinical models, little is known about their effects on the patients' immune system. We assessed immune alterations in the T-cell, B-cell, NK-cell, dendritic cell, and monocytic compartments of steroid-refractory GVHD patients 30, 90, and 180 days after MSC (n=6) or placebo (n=5) infusion respectively. Infused MSCs were bioactive as suggested by the significant reduction of epithelial cell death, which represents a biomarker for acute GVHD. There were several indications that MSCs shift the patients' immune system towards a more tolerogenic profile. Most importantly infusion of MSCs was associated with increased levels of regulatory (FOXP3<sup>+</sup> and IL-10<sup>+</sup>) T-cells, reduced pro-inflammatory IL-17<sup>+</sup> T(Th17)-cells, and skewing towards type-2 T-helper cell responses. Furthermore IL-2, which has been recently shown to exert a positive immune modulating effect in GVHD patients, was higher in the MSC patients at all evaluated time points during six months after MSC-infusion. Overall, our findings will contribute to the refinement of monitoring tools, for assessing MSC treatment-efficacy and increase our understanding regarding the MSCs' <em>in vivo</em> effects.</p></div>
]]></content:encoded><description>

Adoptive transfer of third-party mesenchymal stromal cells (MSCs) has emerged as a promising tool for the treatment of steroid-refractory GVHD. Despite numerous in vitro studies and preclinical models, little is known about their effects on the patients' immune system. We assessed immune alterations in the T-cell, B-cell, NK-cell, dendritic cell, and monocytic compartments of steroid-refractory GVHD patients 30, 90, and 180 days after MSC (n=6) or placebo (n=5) infusion respectively. Infused MSCs were bioactive as suggested by the significant reduction of epithelial cell death, which represents a biomarker for acute GVHD. There were several indications that MSCs shift the patients' immune system towards a more tolerogenic profile. Most importantly infusion of MSCs was associated with increased levels of regulatory (FOXP3+ and IL-10+) T-cells, reduced pro-inflammatory IL-17+ T(Th17)-cells, and skewing towards type-2 T-helper cell responses. Furthermore IL-2, which has been recently shown to exert a positive immune modulating effect in GVHD patients, was higher in the MSC patients at all evaluated time points during six months after MSC-infusion. Overall, our findings will contribute to the refinement of monitoring tools, for assessing MSC treatment-efficacy and increase our understanding regarding the MSCs' in vivo effects.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1385" xmlns="http://purl.org/rss/1.0/"><title>Uterine Vasculature Remodelling in Human Pregnancy Involves Functional Macro-chimerism by Endothelial Colony Forming Cells of fetal origin</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1385</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Uterine Vasculature Remodelling in Human Pregnancy Involves Functional Macro-chimerism by Endothelial Colony Forming Cells of fetal origin</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter I. Sipos, Willem Rens, Hélène Schlecht, Xiaohu Fan, Mark Wareing, Christina Hayward, Carl A. Hubel, Stephane Bourque, Philip N. Baker, Sandra T. Davidge, Colin P. Sibley, Ian P. Crocker</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T01:12:07.87649-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1385</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1385</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1385</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The potency of adult-derived circulating progenitor Endothelial Colony Forming Cells (ECFCs) is drastically surpassed by their fetal counterparts. Human pregnancy is associated with robust intensification of blood flow and vascular expansion in the uterus, crucial for placental perfusion and fetal supply. Here we investigate whether fetal ECFCs transmigrate to maternal bloodstream and home to locations of maternal vasculogenesis, primarily the pregnant uterus. In the first instance, endothelial-like cells, originating from mouse fetuses expressing paternal <em>eGFP</em>, were identified within uterine endothelia. Subsequently, LacZ or eGFP-labelled human fetal ECFCs, transplanted into immuno-deficient (NOD/SCID) fetuses on D15.5 pregnancy, showed similar integration into the mouse uterus by term. Mature endothelial controls (HUVECs), similarly introduced, were unequivocally absent. In humans, <em>SRY</em> was detected in 6/12 myometrial microvessels obtained from women delivering male babies. The copy number was calculated at 175 [IQR 149-471] fetal cells/mm<sup>2</sup> endothelium, constituting 12.5% of maternal vessel lumina. Cross-sections of similar human vessels, hybridized for Y-chromosome, positively identified endothelial-associated fetal cells. It appears that through ECFC donation, fetuses assist maternal uterine vascular expansion in pregnancy; potentiating placental perfusion and consequently their own fetal supply. In addition to fetal growth, this cellular mechanism holds implications for materno-fetal immune-interactions and long-term maternal vascular health.</p></div>
]]></content:encoded><description>

The potency of adult-derived circulating progenitor Endothelial Colony Forming Cells (ECFCs) is drastically surpassed by their fetal counterparts. Human pregnancy is associated with robust intensification of blood flow and vascular expansion in the uterus, crucial for placental perfusion and fetal supply. Here we investigate whether fetal ECFCs transmigrate to maternal bloodstream and home to locations of maternal vasculogenesis, primarily the pregnant uterus. In the first instance, endothelial-like cells, originating from mouse fetuses expressing paternal eGFP, were identified within uterine endothelia. Subsequently, LacZ or eGFP-labelled human fetal ECFCs, transplanted into immuno-deficient (NOD/SCID) fetuses on D15.5 pregnancy, showed similar integration into the mouse uterus by term. Mature endothelial controls (HUVECs), similarly introduced, were unequivocally absent. In humans, SRY was detected in 6/12 myometrial microvessels obtained from women delivering male babies. The copy number was calculated at 175 [IQR 149-471] fetal cells/mm2 endothelium, constituting 12.5% of maternal vessel lumina. Cross-sections of similar human vessels, hybridized for Y-chromosome, positively identified endothelial-associated fetal cells. It appears that through ECFC donation, fetuses assist maternal uterine vascular expansion in pregnancy; potentiating placental perfusion and consequently their own fetal supply. In addition to fetal growth, this cellular mechanism holds implications for materno-fetal immune-interactions and long-term maternal vascular health.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1383" xmlns="http://purl.org/rss/1.0/"><title>Arrayed lentiviral barcoding for quantification analysis of hematopoietic dynamics</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1383</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Arrayed lentiviral barcoding for quantification analysis of hematopoietic dynamics</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeanne Grosselin, Karine Sii-Felice, Emmanuel Payen, Stany Chretien, Diana Tronik-Le Roux, Philippe Leboulch</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T01:11:38.415549-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1383</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1383</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1383</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Our understanding of system dynamics of mixed cell populations in whole organisms has benefited from the advent of individual cell marking by non-arrayed DNA barcodes subsequently analyzed by high-throughput DNA sequencing. However, key limitations include statistical biases compromising quantification and the lack of applicability to deconvolute individual cell fate <em>in vivo</em> after pooling single cells differentially exposed to different conditions <em>ex vivo</em>. Here, we have derived an arrayed lentiviral library of DNA barcodes and obtained a proof-of-concept of its resolving capacity by quantifying hematopoietic regeneration after engraftment of mice with genetically modified autologous cells. This method has helped clarify and bridge the seemingly opposed clonal-succession and continuous-recruitment models of hematopoietic stem cell behavior and revealed that myeloid-lymphoid biases are common occurrences in steady-state hematopoiesis. Arrayed lentiviral barcoding should prove a versatile and powerful approach to deconvolute cell dynamics <em>in vivo</em> with applications in hematology, embryology and cancer biology.</p></div>
]]></content:encoded><description>

Our understanding of system dynamics of mixed cell populations in whole organisms has benefited from the advent of individual cell marking by non-arrayed DNA barcodes subsequently analyzed by high-throughput DNA sequencing. However, key limitations include statistical biases compromising quantification and the lack of applicability to deconvolute individual cell fate in vivo after pooling single cells differentially exposed to different conditions ex vivo. Here, we have derived an arrayed lentiviral library of DNA barcodes and obtained a proof-of-concept of its resolving capacity by quantifying hematopoietic regeneration after engraftment of mice with genetically modified autologous cells. This method has helped clarify and bridge the seemingly opposed clonal-succession and continuous-recruitment models of hematopoietic stem cell behavior and revealed that myeloid-lymphoid biases are common occurrences in steady-state hematopoiesis. Arrayed lentiviral barcoding should prove a versatile and powerful approach to deconvolute cell dynamics in vivo with applications in hematology, embryology and cancer biology.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1382" xmlns="http://purl.org/rss/1.0/"><title>Repression of Zeb1 and Hypoxia Cause Sequential MET and Induction of Aid, Oct4, and Dnmt1, Leading to Immortalization and Multipotential Reprogramming of Fibroblasts in Spheres</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1382</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Repression of Zeb1 and Hypoxia Cause Sequential MET and Induction of Aid, Oct4, and Dnmt1, Leading to Immortalization and Multipotential Reprogramming of Fibroblasts in Spheres</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yongqing Liu, Partha Mukhopadhyay, M. Michele Pisano, Xiaoqin Lu, Li Huang, Qingxian Lu, Douglas C. Dean</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T01:11:13.790083-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1382</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1382</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1382</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Here, we demonstrate that sphere formation triggers immortalization and stable reprogramming of mouse fibroblasts. Cell contact signaling in spheres causes downregulation of the EMT transcription factor Zeb1 leading to rapid mesenchymal-to-epithelial transition. And, hypoxia within spheres together with loss of Zeb1 repression synergize to cause superinduction of Hif1a, which in turn leads to induction of the DNA demethylase Aid/Aicda, demethylation of the <em>Oct4</em> promoter/enhancer and multipotency. Oct4 and Nanog expression diminish when cells are removed from the hypoxic environment of spheres and placed in monolayer culture, but the cells retain multipotential capacity, demonstrating stable reprogramming and a gene expression pattern resembling adult stem cells. Oct4 has been shown to induce Dnmt1 in mesenchymal stem cells, and we link Oct4 and Dnmt1 to silencing of cell cycle inhibitory cyclin dependent kinase inhibitors and Arf, and immortalization of the reprogrammed fibroblasts. Sphere formation then represents a novel and rapid protocol for immortalization and stable reprogramming of fibroblasts to multipotency that does not require exogenous expression of a stem cell factor or a lineage-specifying transcription factor.</p></div>
]]></content:encoded><description>

Here, we demonstrate that sphere formation triggers immortalization and stable reprogramming of mouse fibroblasts. Cell contact signaling in spheres causes downregulation of the EMT transcription factor Zeb1 leading to rapid mesenchymal-to-epithelial transition. And, hypoxia within spheres together with loss of Zeb1 repression synergize to cause superinduction of Hif1a, which in turn leads to induction of the DNA demethylase Aid/Aicda, demethylation of the Oct4 promoter/enhancer and multipotency. Oct4 and Nanog expression diminish when cells are removed from the hypoxic environment of spheres and placed in monolayer culture, but the cells retain multipotential capacity, demonstrating stable reprogramming and a gene expression pattern resembling adult stem cells. Oct4 has been shown to induce Dnmt1 in mesenchymal stem cells, and we link Oct4 and Dnmt1 to silencing of cell cycle inhibitory cyclin dependent kinase inhibitors and Arf, and immortalization of the reprogrammed fibroblasts. Sphere formation then represents a novel and rapid protocol for immortalization and stable reprogramming of fibroblasts to multipotency that does not require exogenous expression of a stem cell factor or a lineage-specifying transcription factor.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1391" xmlns="http://purl.org/rss/1.0/"><title>CD24 and CD44 Mark Human Intestinal Epithelial Cell Populations with Characteristics of Active and Facultative Stem Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1391</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CD24 and CD44 Mark Human Intestinal Epithelial Cell Populations with Characteristics of Active and Facultative Stem Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adam D. Gracz, Megan K. Fuller, Fengchao Wang, Linheng Li, Matthias Stelzner, James C.Y. Dunn, Martin G. Martin, Scott T. Magness</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-04T00:53:27.984866-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1391</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1391</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1391</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Recent seminal studies have rapidly advanced the understanding of intestinal epithelial stem cell (IESC) biology in murine models. However, the lack of techniques suitable for isolation and subsequent downstream analysis of IESCs from human tissue has hindered the application of these findings toward the development of novel diagnostics and therapies with direct clinical relevance. This study demonstrates that the cluster of differentiation genes <em>CD24</em> and <em>CD44</em> are differentially expressed across LGR5 positive “active” stem cells as well as <em>HOPX</em> positive “facultative” stem cells. Fluorescence-activated cell sorting enables differential enrichment of <em>LGR5</em> cells (CD24-/CD44+) and <em>HOPX</em> (CD24+/CD44+) cells for gene expression analysis and culture. These findings provide the fundamental methodology and basic cell surface signature necessary for isolating and studying intestinal stem cell populations in human physiology and disease.</p></div>
]]></content:encoded><description>

Recent seminal studies have rapidly advanced the understanding of intestinal epithelial stem cell (IESC) biology in murine models. However, the lack of techniques suitable for isolation and subsequent downstream analysis of IESCs from human tissue has hindered the application of these findings toward the development of novel diagnostics and therapies with direct clinical relevance. This study demonstrates that the cluster of differentiation genes CD24 and CD44 are differentially expressed across LGR5 positive “active” stem cells as well as HOPX positive “facultative” stem cells. Fluorescence-activated cell sorting enables differential enrichment of LGR5 cells (CD24-/CD44+) and HOPX (CD24+/CD44+) cells for gene expression analysis and culture. These findings provide the fundamental methodology and basic cell surface signature necessary for isolating and studying intestinal stem cell populations in human physiology and disease.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1387" xmlns="http://purl.org/rss/1.0/"><title>Periodontal Ligament Stem Cells Regulate B Lymphocyte Function via Programmed Cell Death Protein 1</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1387</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Periodontal Ligament Stem Cells Regulate B Lymphocyte Function via Programmed Cell Death Protein 1</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ousheng Liu, Junji Xu, Gang Ding, Dayong Liu, Zhipeng Fan, Chunmei Zhang, Wanjun Chen, Yaozhong Ding, Zhangui Tang, Songlin Wang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-03T05:25:39.532257-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1387</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1387</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1387</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Periodontal ligament stem cells (PDLSCs) have provided novel cell sources for tooth and periodontal tissue regeneration. Allogeneic PDLSCs can reconstruct periodontal ligament tissue that has been damaged by periodontal diseases and regulate T cell immunity. However, the effect of PDLSCs on B cells remains unknown. Here, we treated periodontitis in a miniature pig model using allogeneic PDLSCs and showed a reduction of humoral immunity in the animals. When co-cultured with normal B cells, human PDLSCs (hPDLSCs) had similar effects as bone marrow mesenchymal stem cells in suppressing B cell proliferation, differentiation, and migration, while intriguingly, hPDLSCs increased B cell viability by secreting interleukin-6. Mechanistically, hPDLSCs suppressed B cell activation through cell-to-cell contact mostly mediated by programmed cell death protein 1 and programmed cell death 1 ligand 1. Our data revealed a previously unrecognized function of PDLSCs in regulating humoral immune responses, which may represent a novel therapeutic strategy for immune-related disorders.</p></div>
]]></content:encoded><description>

Periodontal ligament stem cells (PDLSCs) have provided novel cell sources for tooth and periodontal tissue regeneration. Allogeneic PDLSCs can reconstruct periodontal ligament tissue that has been damaged by periodontal diseases and regulate T cell immunity. However, the effect of PDLSCs on B cells remains unknown. Here, we treated periodontitis in a miniature pig model using allogeneic PDLSCs and showed a reduction of humoral immunity in the animals. When co-cultured with normal B cells, human PDLSCs (hPDLSCs) had similar effects as bone marrow mesenchymal stem cells in suppressing B cell proliferation, differentiation, and migration, while intriguingly, hPDLSCs increased B cell viability by secreting interleukin-6. Mechanistically, hPDLSCs suppressed B cell activation through cell-to-cell contact mostly mediated by programmed cell death protein 1 and programmed cell death 1 ligand 1. Our data revealed a previously unrecognized function of PDLSCs in regulating humoral immune responses, which may represent a novel therapeutic strategy for immune-related disorders.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1389" xmlns="http://purl.org/rss/1.0/"><title>Disease-causing Mitochondrial Heteroplasmy Segregated within Induced Pluripotent Stem Cell Clones Derived from A MELAS Patient</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1389</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Disease-causing Mitochondrial Heteroplasmy Segregated within Induced Pluripotent Stem Cell Clones Derived from A MELAS Patient</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clifford D.L. Folmes, Almudena Martinez-Fernandez, Ester Perales-Clemente, Xing Li, Amber McDonald, Devin Oglesbee, Sybil C. Hrstka, Carmen Perez-Terzic, Andre Terzic, Timothy J. Nelson</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-03T05:24:44.426997-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1389</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1389</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1389</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Mitochondrial diseases display pathological phenotypes according to the mixture of mutant versus wild-type mitochondrial DNA (mtDNA), known as heteroplasmy. We herein examined the impact of nuclear reprogramming and clonal isolation of induced pluripotent stem cells (iPSC) on mitochondrial heteroplasmy. Patient-derived dermal fibroblasts with a prototypical mitochondrial deficiency diagnosed as MELAS demonstrated mitochondrial dysfunction with reduced oxidative reserve due to heteroplasmy at position G13513A in the ND5 subunit of complex I. Bioengineered iPSC clones acquired pluripotency with multi-lineage differentiation capacity and demonstrated reduction in mitochondrial density and oxygen consumption distinguishing them from the somatic source. Consistent with the cellular mosaicism of the original patient-derived fibroblasts, the MELAS-iPSC clones contained a similar range of mtDNA heteroplasmy of the disease-causing mutation with identical profiles in the remaining mtDNA. High-heteroplasmy iPSC clones were used to demonstrate that extended stem cell passaging was sufficient to purge mutant mtDNA, resulting in isogenic iPSC subclones with various degrees of disease-causing genotypes. Upon comparative differentiation of iPSC clones, improved cardiogenic yield was associated with iPSC clones containing lower heteroplasmy compared to isogenic clones with high heteroplasmy. Thus, mtDNA heteroplasmic segregation within patient-derived stem cell lines enables direct comparison of genotype/phenotype relationships in progenitor cells and lineage-restricted progeny, and indicates that cell fate decisions are regulated as a function of mtDNA mutation load. The novel nuclear reprogramming-based model system introduces a disease-in-a-dish tool to examine the impact of mutant genotypes for MELAS patients in bioengineered tissues and a cellular probe for molecular features of individual mitochondrial diseases.</p></div>
]]></content:encoded><description>

Mitochondrial diseases display pathological phenotypes according to the mixture of mutant versus wild-type mitochondrial DNA (mtDNA), known as heteroplasmy. We herein examined the impact of nuclear reprogramming and clonal isolation of induced pluripotent stem cells (iPSC) on mitochondrial heteroplasmy. Patient-derived dermal fibroblasts with a prototypical mitochondrial deficiency diagnosed as MELAS demonstrated mitochondrial dysfunction with reduced oxidative reserve due to heteroplasmy at position G13513A in the ND5 subunit of complex I. Bioengineered iPSC clones acquired pluripotency with multi-lineage differentiation capacity and demonstrated reduction in mitochondrial density and oxygen consumption distinguishing them from the somatic source. Consistent with the cellular mosaicism of the original patient-derived fibroblasts, the MELAS-iPSC clones contained a similar range of mtDNA heteroplasmy of the disease-causing mutation with identical profiles in the remaining mtDNA. High-heteroplasmy iPSC clones were used to demonstrate that extended stem cell passaging was sufficient to purge mutant mtDNA, resulting in isogenic iPSC subclones with various degrees of disease-causing genotypes. Upon comparative differentiation of iPSC clones, improved cardiogenic yield was associated with iPSC clones containing lower heteroplasmy compared to isogenic clones with high heteroplasmy. Thus, mtDNA heteroplasmic segregation within patient-derived stem cell lines enables direct comparison of genotype/phenotype relationships in progenitor cells and lineage-restricted progeny, and indicates that cell fate decisions are regulated as a function of mtDNA mutation load. The novel nuclear reprogramming-based model system introduces a disease-in-a-dish tool to examine the impact of mutant genotypes for MELAS patients in bioengineered tissues and a cellular probe for molecular features of individual mitochondrial diseases.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1390" xmlns="http://purl.org/rss/1.0/"><title>Corneal Endothelial Cell Fate is Maintained by LGR5 via the Regulation of Hedgehog and Wnt Pathway</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1390</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Corneal Endothelial Cell Fate is Maintained by LGR5 via the Regulation of Hedgehog and Wnt Pathway</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kana Hirata-Tominaga, Takahiro Nakamura, Naoki Okumura, Satoshi Kawasaki, Eunduck P. Kay, Yann Barrandon, Noriko Koizumi, Shigeru Kinoshita</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-03T05:24:17.336454-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1390</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1390</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1390</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a target of Wnt signaling, is reportedly a marker of intestine, stomach, and hair follicle stem cells in mice. To gain a novel insight into the role of LGR5 in human corneal tissue, we performed gain- and loss-of-function studies. The findings of this study show for the first time that LGR5 is uniquely expressed in the peripheral region of human corneal endothelial cells and that LGR5<sup>(+)</sup> cells have some stem/progenitor cell characteristics, and that in human corneal endothelium, LGR5 is the target molecule and negative feedback regulator of the Hedgehog (HH) signaling pathway. Interestingly, the findings of this study show that persistent LGR5 expression maintained endothelial cell phenotypes and inhibited mesenchymal transformation (MT) through the Wnt pathway. Moreover, R-spondin-1, an LGR5 ligand, dramatically accelerated corneal endothelial cell proliferation and also inhibited MT through the Wnt pathway. These findings provide new insights into the underlying homeostatic regulation of human corneal endothelial stem/progenitor cells by LGR5 via the HH and Wnt pathways.</p></div>
]]></content:encoded><description>

Leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5), a target of Wnt signaling, is reportedly a marker of intestine, stomach, and hair follicle stem cells in mice. To gain a novel insight into the role of LGR5 in human corneal tissue, we performed gain- and loss-of-function studies. The findings of this study show for the first time that LGR5 is uniquely expressed in the peripheral region of human corneal endothelial cells and that LGR5(+) cells have some stem/progenitor cell characteristics, and that in human corneal endothelium, LGR5 is the target molecule and negative feedback regulator of the Hedgehog (HH) signaling pathway. Interestingly, the findings of this study show that persistent LGR5 expression maintained endothelial cell phenotypes and inhibited mesenchymal transformation (MT) through the Wnt pathway. Moreover, R-spondin-1, an LGR5 ligand, dramatically accelerated corneal endothelial cell proliferation and also inhibited MT through the Wnt pathway. These findings provide new insights into the underlying homeostatic regulation of human corneal endothelial stem/progenitor cells by LGR5 via the HH and Wnt pathways.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1393" xmlns="http://purl.org/rss/1.0/"><title>PEDF Promotes Self-Renewal of Limbal Stem Cell and Accelerates Corneal Epithelial Wound Healing</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1393</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">PEDF Promotes Self-Renewal of Limbal Stem Cell and Accelerates Corneal Epithelial Wound Healing</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tsung-Chuan Ho, Show-Li Chen, Ju-Yun Wu, Mei-Ying Ho, Lee-Jen Chen, Jui-Wen Hsieh, Huey-Chuan Cheng, Yeou-Ping Tsao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-03T05:23:47.617434-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1393</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1393</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1393</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regenerative Medicine</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Limbal epithelial stem cell (LSC) transplantation is a prevalent therapeutic method for patients with LSC deficiency. The maintenance of stem cell characteristics in the process of culture expansion is critical for the success of ocular surface reconstruction. Pigment epithelial-derived factor (PEDF) increased the numbers of holoclone in LSC monolayer culture and preserved the stemness of LSC in suspension culture by evidence of ΔNp63α, Bmi-1 and ABCG2 expression. BrdU pulse-labeling assay also demonstrated that PEDF stimulated LSCs proliferation. In air-lift culture of limbal equivalent, PEDF was capable of increasing the numbers of ΔNp63α-positive cells. The mitogenic effect of PEDF was found to be mediated by the phosphorylations of p38 MAPK and STAT3 in LSCs. Synthetic 44-mer PEDF (residues 78-121) was as effective as the full length PEDF in LSC expansion in suspension culture and limbal equivalent formation, as well as the activation of p38 MAPK and STAT3. In mice subjecting to mechanical removal of cornea epithelium, 44-mer PEDF facilitated corneal wound healing. Microscopically, 44-mer PEDF advanced the early proliferative response in limbus, increased the proliferation of ΔNp63α-positive cells both in limbus and in epithelial healing front, and assisted the repopulation of limbus in the late phase of wound healing. In conclusion, the capability of expanding LSC in cell culture and in animal indicates the potential of PEDF and its fragment (e.g., 44-mer PEDF) in ameliorating limbal stem cell deficiency; and their uses as therapeutics for treating corneal wound.</p></div>
]]></content:encoded><description>

Limbal epithelial stem cell (LSC) transplantation is a prevalent therapeutic method for patients with LSC deficiency. The maintenance of stem cell characteristics in the process of culture expansion is critical for the success of ocular surface reconstruction. Pigment epithelial-derived factor (PEDF) increased the numbers of holoclone in LSC monolayer culture and preserved the stemness of LSC in suspension culture by evidence of ΔNp63α, Bmi-1 and ABCG2 expression. BrdU pulse-labeling assay also demonstrated that PEDF stimulated LSCs proliferation. In air-lift culture of limbal equivalent, PEDF was capable of increasing the numbers of ΔNp63α-positive cells. The mitogenic effect of PEDF was found to be mediated by the phosphorylations of p38 MAPK and STAT3 in LSCs. Synthetic 44-mer PEDF (residues 78-121) was as effective as the full length PEDF in LSC expansion in suspension culture and limbal equivalent formation, as well as the activation of p38 MAPK and STAT3. In mice subjecting to mechanical removal of cornea epithelium, 44-mer PEDF facilitated corneal wound healing. Microscopically, 44-mer PEDF advanced the early proliferative response in limbus, increased the proliferation of ΔNp63α-positive cells both in limbus and in epithelial healing front, and assisted the repopulation of limbus in the late phase of wound healing. In conclusion, the capability of expanding LSC in cell culture and in animal indicates the potential of PEDF and its fragment (e.g., 44-mer PEDF) in ameliorating limbal stem cell deficiency; and their uses as therapeutics for treating corneal wound.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1392" xmlns="http://purl.org/rss/1.0/"><title>Essential role of sox2 for the establishment and maintenance of the germ cell line</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1392</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Essential role of sox2 for the establishment and maintenance of the germ cell line</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Federica Campolo, Manuele Gori, Rebecca Favaro, Silvia Nicolis, Manuela Pellegrini, Flavia Botti, Pellegrino Rossi, Emmanuele A. Jannini, Susanna Dolci</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-03T05:23:15.585607-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1392</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1392</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1392</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Sox2 is a pluripotency-conferring gene expressed in primordial germ cells (PGCs) and postnatal oocytes, but the role it plays during germ cell development and early embryogenesis is unknown. Since Sox2 ablation causes early embryonic lethality shortly after blastocyst implantation, we generated mice bearing Sox2-conditional deletion in germ cells at different stages of their development through the Cre/loxP recombination system. Embryos lacking Sox2 in PGCs show a dramatic decrease of germ cell numbers at the time of their specification. At later stages, we found that Sox2 is strictly required for PGC proliferation. On the contrary Sox2 deletion in meiotic oocytes does not impair postnatal oogenesis and early embryogenesis, indicating that it is not essential for oocyte maturation nor for zygotic development. We also show that Sox2 regulates <em>Kit</em> expression in PGCs and binds to discrete transcriptional regulatory sequences of this gene, which is known to be important for PGCs survival and proliferation. Sox2 also stimulates the expression of <em>Zfp148</em> which is required for normal development of fetal germ cells, and <em>Rif1</em>, a potential regulator of PGC pluripotency.</p></div>
]]></content:encoded><description>

Sox2 is a pluripotency-conferring gene expressed in primordial germ cells (PGCs) and postnatal oocytes, but the role it plays during germ cell development and early embryogenesis is unknown. Since Sox2 ablation causes early embryonic lethality shortly after blastocyst implantation, we generated mice bearing Sox2-conditional deletion in germ cells at different stages of their development through the Cre/loxP recombination system. Embryos lacking Sox2 in PGCs show a dramatic decrease of germ cell numbers at the time of their specification. At later stages, we found that Sox2 is strictly required for PGC proliferation. On the contrary Sox2 deletion in meiotic oocytes does not impair postnatal oogenesis and early embryogenesis, indicating that it is not essential for oocyte maturation nor for zygotic development. We also show that Sox2 regulates Kit expression in PGCs and binds to discrete transcriptional regulatory sequences of this gene, which is known to be important for PGCs survival and proliferation. Sox2 also stimulates the expression of Zfp148 which is required for normal development of fetal germ cells, and Rif1, a potential regulator of PGC pluripotency.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1380" xmlns="http://purl.org/rss/1.0/"><title>Promotion of Osteoblast Differentiation in Mesenchymal Cells Through Cbl-Mediated Control of STAT5 Activity</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1380</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Promotion of Osteoblast Differentiation in Mesenchymal Cells Through Cbl-Mediated Control of STAT5 Activity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">François-Xavier Dieudonne, Nicolas Severe, Martin BiossE-Duplan, Jing-Jie Weng, Yeu Su, Pierre J. Marie</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-26T08:24:27.309598-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1380</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1380</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1380</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The identification of the molecular mechanisms controlling the degradation of regulatory proteins in mesenchymal stromal cells (MSC) may provide clues to promote MSC osteogenic differentiation and bone regeneration. Ubiquitin ligase-dependent degradation of proteins is an important process governing cell fate. In this study, we investigated the role of the E3 ubiquitin ligase c-Cbl in MSC osteoblast differentiation and identified the mechanisms involved in this effect. Using distinct shRNA targeting c-Cbl, we showed that c-Cbl silencing promotes osteoblast differentiation in murine and human MSC, as demonstrated by increased alkaline phosphatase activity, expression of phenotypic osteoblast marker genes (RUNX2, ALP, type 1 collagen) and matrix mineralization <em>in vitro</em>. Co-immunoprecipitation analyses showed that c-Cbl interacts with the transcription factor STAT5, and that STAT5 forms a complex with RUNX2, a master transcription factor controlling osteoblastogenesis. Silencing c-Cbl decreased c-Cbl-mediated STAT5 ubiquitination, increased STAT5 protein level and phosphorylation and enhanced STAT5 and RUNX2 transcriptional activity. The expression of IGF-1, a target gene of STAT5, was increased by c-Cbl silencing in MSC and in bone marrow stromal cells isolated from c-Cbl deficient mice, suggesting that IGF-1 contributes to osteoblast differentiation induced by c-Cbl silencing in MSC. Consistent with these findings, pharmacological inhibition of STAT5 activity, or neutralization of IGF-1 activity, abrogated the positive effect of c-Cbl knockdown on MSC osteogenic differentiation. Taken together, the data provide a novel functional mechanism by which the ubiquitin ligase c-Cbl regulates the osteoblastic differentiation program in mesenchymal cells by controlling Cbl-mediated STAT5 degradation and activity.</p></div>
]]></content:encoded><description>

The identification of the molecular mechanisms controlling the degradation of regulatory proteins in mesenchymal stromal cells (MSC) may provide clues to promote MSC osteogenic differentiation and bone regeneration. Ubiquitin ligase-dependent degradation of proteins is an important process governing cell fate. In this study, we investigated the role of the E3 ubiquitin ligase c-Cbl in MSC osteoblast differentiation and identified the mechanisms involved in this effect. Using distinct shRNA targeting c-Cbl, we showed that c-Cbl silencing promotes osteoblast differentiation in murine and human MSC, as demonstrated by increased alkaline phosphatase activity, expression of phenotypic osteoblast marker genes (RUNX2, ALP, type 1 collagen) and matrix mineralization in vitro. Co-immunoprecipitation analyses showed that c-Cbl interacts with the transcription factor STAT5, and that STAT5 forms a complex with RUNX2, a master transcription factor controlling osteoblastogenesis. Silencing c-Cbl decreased c-Cbl-mediated STAT5 ubiquitination, increased STAT5 protein level and phosphorylation and enhanced STAT5 and RUNX2 transcriptional activity. The expression of IGF-1, a target gene of STAT5, was increased by c-Cbl silencing in MSC and in bone marrow stromal cells isolated from c-Cbl deficient mice, suggesting that IGF-1 contributes to osteoblast differentiation induced by c-Cbl silencing in MSC. Consistent with these findings, pharmacological inhibition of STAT5 activity, or neutralization of IGF-1 activity, abrogated the positive effect of c-Cbl knockdown on MSC osteogenic differentiation. Taken together, the data provide a novel functional mechanism by which the ubiquitin ligase c-Cbl regulates the osteoblastic differentiation program in mesenchymal cells by controlling Cbl-mediated STAT5 degradation and activity.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1377" xmlns="http://purl.org/rss/1.0/"><title>Endogenous Distal Airway Progenitor Cells, Lung Mechanics, and Disproportionate Lobar Growth following Long-Term Post- Pneumonectomy in Mice</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1377</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Endogenous Distal Airway Progenitor Cells, Lung Mechanics, and Disproportionate Lobar Growth following Long-Term Post- Pneumonectomy in Mice</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philip Eisenhauer, Benjamin Earle, Roberto Loi, Viranuj Sueblinvong, Meagan Goodwin, Gilman B. Allen, Lennart Lundblad, Melissa R. Mazan, Andrew M. Hoffman, Daniel J. Weiss</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-26T08:24:05.789744-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1377</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1377</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1377</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Utilizing a model of post-pneumonectomy (PNY) compensatory lung growth in mice, we previously observed an increase in numbers of a putative endogenous distal airway progenitor cell population (CCSP<sup>pos</sup>/pro-SPC<sup>pos</sup> cells located at bronchoalveolar duct junctions (BADJ)), at 3, 7, and 14 days after pneumonectomy, returning to baseline at 28 days post-PNY. As the origin of these cells is poorly understood, we evaluated whether bone marrow cells contributed to the pool of these or other cells during prolonged post-PNY lung regrowth. Naïve and sex-mismatched chimeric mice underwent left PNY and were evaluated at 1, 2 and 3 months for numbers of BADJ CCSP<sup>pos</sup>/pro-SPC<sup>pos</sup> cells and presence of donor-derived marrow cells engrafted as airway or alveolar epithelium. Non-chimeric mice were also examined at 12 months after PNY for numbers of BADJ CCSP<sup>pos</sup>/pro-SPC<sup>pos</sup> cells. Notably, the right accessory lobe (RAL) continued to grow disproportionately over 12 months, a novel finding not previously described. Assessment of lung mechanics demonstrated an increase in lung stiffness following PNY, which significantly diminished over one year, but remained elevated relative to 1 year-old naïve controls. However, the number of CCSP<sup>pos</sup>/pro-SPC<sup>pos</sup> BADJ cells ≥1 month following PNY was equivalent to that found in naïve controls even after 12 months of continued RAL growth. Notably, no donor bone marrow-derived cells engrafted as airway or alveolar epithelial cells, including those at the BADJ, up to 3 months after PNY. These studies suggest that lung epithelial cells, including CCSP<sup>pos</sup>/pro-SPC<sup>pos</sup> cells, are not replenished from marrow-derived cells during post-PNY lung growth in mice.</p></div>
]]></content:encoded><description>

Utilizing a model of post-pneumonectomy (PNY) compensatory lung growth in mice, we previously observed an increase in numbers of a putative endogenous distal airway progenitor cell population (CCSPpos/pro-SPCpos cells located at bronchoalveolar duct junctions (BADJ)), at 3, 7, and 14 days after pneumonectomy, returning to baseline at 28 days post-PNY. As the origin of these cells is poorly understood, we evaluated whether bone marrow cells contributed to the pool of these or other cells during prolonged post-PNY lung regrowth. Naïve and sex-mismatched chimeric mice underwent left PNY and were evaluated at 1, 2 and 3 months for numbers of BADJ CCSPpos/pro-SPCpos cells and presence of donor-derived marrow cells engrafted as airway or alveolar epithelium. Non-chimeric mice were also examined at 12 months after PNY for numbers of BADJ CCSPpos/pro-SPCpos cells. Notably, the right accessory lobe (RAL) continued to grow disproportionately over 12 months, a novel finding not previously described. Assessment of lung mechanics demonstrated an increase in lung stiffness following PNY, which significantly diminished over one year, but remained elevated relative to 1 year-old naïve controls. However, the number of CCSPpos/pro-SPCpos BADJ cells ≥1 month following PNY was equivalent to that found in naïve controls even after 12 months of continued RAL growth. Notably, no donor bone marrow-derived cells engrafted as airway or alveolar epithelial cells, including those at the BADJ, up to 3 months after PNY. These studies suggest that lung epithelial cells, including CCSPpos/pro-SPCpos cells, are not replenished from marrow-derived cells during post-PNY lung growth in mice.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1376" xmlns="http://purl.org/rss/1.0/"><title>NPRA Signaling Regulates Stem Cell Recruitment and Angiogenesis: A Model to Study Linkage Between Inflammation and Tumorigenesis</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1376</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">NPRA Signaling Regulates Stem Cell Recruitment and Angiogenesis: A Model to Study Linkage Between Inflammation and Tumorigenesis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jaya Mallela, Sowndharya Ravi, Frantz Jean Louis, Bianca Mulaney, Michael Cheung, Ujjwala Sree Garapati, Vignesh Chinnasamy, Chunyan Wang, Srinivas Nagaraj, Shyam S Mohapatra, Subhra Mohapatra</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-26T08:23:43.767492-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1376</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1376</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1376</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Natriuretic peptide receptor A (NPRA), the signaling receptor for the cardiac hormone, atrial natriuretic peptide (ANP), is expressed abundantly in inflamed/injured tissues and tumors. NPRA deficiency substantially decreases tissue inflammation and inhibits tumor growth. However, the precise mechanism of NPRA function and whether it links inflammation and tumorigenesis remains unknown. Since both injury repair or tumor growth require stem cell recruitment and angiogenesis, we examined the role of NPRA signaling in tumor angiogenesis as a model of tissue injury repair in this study. In <em>in vitro</em> cultures aortas from NPRA-KO mice show significantly lower angiogenic response compared to wild type counterparts. The NPRA antagonist that decreases NPRA expression, inhibit lipopolysaccharide-induced angiogenesis. The reduction in angiogenesis correlates with decreased expression of vascular endothelial growth factor (VEGF) and chemokine (C-X-C motif) Receptor 4 (CXCR4) implicating a cell recruitment defect. To test whether NPRA regulates migration of cells to tumors, mesenchymal stem cells (MSCs) were administered i.v. and the results showed that MSCs fail to migrate to the tumor microenvironment in NPRA-KO mice. However, co-implanting tumor cells with MSCs, increases angiogenesis and tumorigenesis in NPRA-KO mice, in part by promoting expression of CXCR4 and its ligand, stromal-derived factor 1α (SDF1α). Taken together, these results demonstrate that NPRA signaling regulates stem cell recruitment and angiogenesis leading to tumor growth. Thus, NPRA signaling provides a key linkage between inflammation and tumorigenesis, and NPRA may be a target for drug development against cancers and tissue injury repair.</p></div>
]]></content:encoded><description>

Natriuretic peptide receptor A (NPRA), the signaling receptor for the cardiac hormone, atrial natriuretic peptide (ANP), is expressed abundantly in inflamed/injured tissues and tumors. NPRA deficiency substantially decreases tissue inflammation and inhibits tumor growth. However, the precise mechanism of NPRA function and whether it links inflammation and tumorigenesis remains unknown. Since both injury repair or tumor growth require stem cell recruitment and angiogenesis, we examined the role of NPRA signaling in tumor angiogenesis as a model of tissue injury repair in this study. In in vitro cultures aortas from NPRA-KO mice show significantly lower angiogenic response compared to wild type counterparts. The NPRA antagonist that decreases NPRA expression, inhibit lipopolysaccharide-induced angiogenesis. The reduction in angiogenesis correlates with decreased expression of vascular endothelial growth factor (VEGF) and chemokine (C-X-C motif) Receptor 4 (CXCR4) implicating a cell recruitment defect. To test whether NPRA regulates migration of cells to tumors, mesenchymal stem cells (MSCs) were administered i.v. and the results showed that MSCs fail to migrate to the tumor microenvironment in NPRA-KO mice. However, co-implanting tumor cells with MSCs, increases angiogenesis and tumorigenesis in NPRA-KO mice, in part by promoting expression of CXCR4 and its ligand, stromal-derived factor 1α (SDF1α). Taken together, these results demonstrate that NPRA signaling regulates stem cell recruitment and angiogenesis leading to tumor growth. Thus, NPRA signaling provides a key linkage between inflammation and tumorigenesis, and NPRA may be a target for drug development against cancers and tissue injury repair.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1375" xmlns="http://purl.org/rss/1.0/"><title>Native Adipose Stromal Cells (ASCs) Egress from Adipose Tissue in vivo: Evidence During Lymph Node Activation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1375</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Native Adipose Stromal Cells (ASCs) Egress from Adipose Tissue in vivo: Evidence During Lymph Node Activation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marta Gil-Ortega, Lucile Garidou, Corinne Barreau, Marie Maumus, Ludovic Breasson, Geneviève Tavernier, Concha F. García-Prieto, Anne Bouloumié, Louis Casteilla, Coralie Sengenès</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-26T08:23:14.489928-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1375</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1375</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1375</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Adipose tissue (AT) has become accepted as a source of multipotent progenitor cells, the adipose derived stroma/stem cells (ASCs). In this regard, considerable work has been performed to harvest and characterize this cell population as well as to investigate the mechanisms by which transplanted ASCs mediate tissue regeneration. In contrast the endogenous release of native ASCs by AT has been poorly investigated. In the present work, we show that native ASCs egress from murine AT. Indeed, we demonstrated that the release of native ASCs from AT can be evidenced both using an <em>ex vivo</em> perfusion model that we set-up and <em>in vivo</em>. Such a mobilization process is controlled by CXCR4 chemokine receptor. In addition, once mobilized from AT, circulating ASCs were found to navigate through lymph fluid and to home into lymph nodes (LN). Therefore we demonstrated that, during the LN activation, the fat depot encapsulating the activated LN releases native ASCs, which in turn invade the activated LN. Moreover, the ASCs invading the LN were vizualized in close physical interaction with podoplanin and ER-TR7 positive structures corresponding to the stromal network composing the LN. This dynamic was impaired with CXCR4 neutralizing antibody. Taken together, these data provide robust evidences that native ASCs can traffic <em>in vivo</em> and that AT might provide stromal cells to activated LNs.</p></div>
]]></content:encoded><description>

Adipose tissue (AT) has become accepted as a source of multipotent progenitor cells, the adipose derived stroma/stem cells (ASCs). In this regard, considerable work has been performed to harvest and characterize this cell population as well as to investigate the mechanisms by which transplanted ASCs mediate tissue regeneration. In contrast the endogenous release of native ASCs by AT has been poorly investigated. In the present work, we show that native ASCs egress from murine AT. Indeed, we demonstrated that the release of native ASCs from AT can be evidenced both using an ex vivo perfusion model that we set-up and in vivo. Such a mobilization process is controlled by CXCR4 chemokine receptor. In addition, once mobilized from AT, circulating ASCs were found to navigate through lymph fluid and to home into lymph nodes (LN). Therefore we demonstrated that, during the LN activation, the fat depot encapsulating the activated LN releases native ASCs, which in turn invade the activated LN. Moreover, the ASCs invading the LN were vizualized in close physical interaction with podoplanin and ER-TR7 positive structures corresponding to the stromal network composing the LN. This dynamic was impaired with CXCR4 neutralizing antibody. Taken together, these data provide robust evidences that native ASCs can traffic in vivo and that AT might provide stromal cells to activated LNs.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1374" xmlns="http://purl.org/rss/1.0/"><title>NuRD Blocks ReprogAramming of Mouse Somatic Cells into Pluripotent Stem Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1374</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">NuRD Blocks ReprogAramming of Mouse Somatic Cells into Pluripotent Stem Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Min Luo, Te Ling, Wenbing Xie, He Sun, Yonggang Zhou, Qiaoyun Zhu, Meili Shen, Le Zong, Guoliang Lyu, Yun Zhao, Tao Ye, Jun Gu, Wei Tao, Zhigang Lu, Ingrid Grummt</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-26T08:22:43.404303-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1374</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1374</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1374</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) by overexpression of a defined set of transcription factors requires epigenetic changes of pluripotency genes. Nuclear reprogramming is an inefficient process and the molecular mechanisms that reset the epigenetic state during iPSC generation are largely unknown. Here we show that down-regulation of the NuRD (Nucleosome Remodeling and Deacetylation) complex is required for efficient reprogramming. Overexpression of Mbd3, a subunit of NuRD, inhibits induction of iPSCs by establishing heterochromatic features and silencing ES cell-specific marker genes, including <em>Oct4</em> and <em>Nanog</em>. Depletion of Mbd3, on the other hand, improves reprogramming efficiency and facilitates the formation of pluripotent stem cells that are capable of generating viable chimeric mice, even in the absence of <em>c-Myc</em> or <em>Sox2</em>. The results establish Mbd3/NuRD as an important epigenetic regulator that restricts the expression of key pluripotency genes, suggesting that drug-induced downregulation of Mbd3/NuRD may be a powerful means to improve the efficiency and fidelity of reprogramming.</p></div>
]]></content:encoded><description>

Reprogramming of somatic cells into induced pluripotent stem cells (iPSCs) by overexpression of a defined set of transcription factors requires epigenetic changes of pluripotency genes. Nuclear reprogramming is an inefficient process and the molecular mechanisms that reset the epigenetic state during iPSC generation are largely unknown. Here we show that down-regulation of the NuRD (Nucleosome Remodeling and Deacetylation) complex is required for efficient reprogramming. Overexpression of Mbd3, a subunit of NuRD, inhibits induction of iPSCs by establishing heterochromatic features and silencing ES cell-specific marker genes, including Oct4 and Nanog. Depletion of Mbd3, on the other hand, improves reprogramming efficiency and facilitates the formation of pluripotent stem cells that are capable of generating viable chimeric mice, even in the absence of c-Myc or Sox2. The results establish Mbd3/NuRD as an important epigenetic regulator that restricts the expression of key pluripotency genes, suggesting that drug-induced downregulation of Mbd3/NuRD may be a powerful means to improve the efficiency and fidelity of reprogramming.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1373" xmlns="http://purl.org/rss/1.0/"><title>Tumorigenic Potential of miR-18A* in Glioma Initiating Cells Requires NOTCH-1 Signaling</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1373</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tumorigenic Potential of miR-18A* in Glioma Initiating Cells Requires NOTCH-1 Signaling</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laurent Turchi, David N. Debruyne, Fabien Almairac, Virginie Virolle, Mohamed Fareh, Yasmine Neirijnck, Fanny Burel-Vandenbos, Philippe Paquis, Marie-Pierre Junier, Ellen Van Obberghen-Schilling, Hervé Chneiweiss, Thierry Virolle</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-26T08:22:20.595888-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1373</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1373</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1373</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Stem cell-like properties of Glioma initiating Cells (GiCs) fuel glioblastoma (GBM) development by providing the different cell types that comprise the tumor. It is therefore likely that the molecular circuitries that regulate their decision to self-renew or commit to a more differentiated state may offer targets for future innovative therapies. In previous micro-RNA profiling studies to search for regulators of stem cell plasticity we identified miR-18a* as a potential candidate and its expression correlated with the stemness state. Here, using human GiCs we found that miR-18a* expression promotes clonal proliferation in vitro and tumorigenicity in vivo. Mechanistically, ERK-dependent induction of miR-18a* directly represses expression of DLL3, an autocrine inhibitor of NOTCH, thus enhancing the level of activated NOTCH-1. Activated NOTCH-1 in turn is required for sustained ERK activation. This feedforward loop, driven by miR-18a*, is required to turn on the SHH-GLI-NANOG network, essential for GiC self-renewal. Hence, by tightly regulating expression of DLL3, miR-18a* constitutes an important signaling mediator for fine tuning the level of GiC self-renewal.</p></div>
]]></content:encoded><description>

Stem cell-like properties of Glioma initiating Cells (GiCs) fuel glioblastoma (GBM) development by providing the different cell types that comprise the tumor. It is therefore likely that the molecular circuitries that regulate their decision to self-renew or commit to a more differentiated state may offer targets for future innovative therapies. In previous micro-RNA profiling studies to search for regulators of stem cell plasticity we identified miR-18a* as a potential candidate and its expression correlated with the stemness state. Here, using human GiCs we found that miR-18a* expression promotes clonal proliferation in vitro and tumorigenicity in vivo. Mechanistically, ERK-dependent induction of miR-18a* directly represses expression of DLL3, an autocrine inhibitor of NOTCH, thus enhancing the level of activated NOTCH-1. Activated NOTCH-1 in turn is required for sustained ERK activation. This feedforward loop, driven by miR-18a*, is required to turn on the SHH-GLI-NANOG network, essential for GiC self-renewal. Hence, by tightly regulating expression of DLL3, miR-18a* constitutes an important signaling mediator for fine tuning the level of GiC self-renewal.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1368" xmlns="http://purl.org/rss/1.0/"><title>Nicotinamide Overcomes Pluripotency Deficits and Reprogramming Barriers</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1368</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Nicotinamide Overcomes Pluripotency Deficits and Reprogramming Barriers</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Myung Jin Son, Mi-Young Son, Binna Seol, Min-Jeong Kim, Chae Hwa Yoo, Myung-Kwan Han, Yee Sook Cho</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-25T01:56:57.367896-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1368</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1368</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1368</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cross-talk between intracellular signaling pathways has been extensively studied to understand the pluripotency of human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs); however, the contribution of NAD<sup>+</sup>-dependent pathways remains largely unknown. Here, we show that NAD<sup>+</sup> depletion by FK866 (a potent inhibitor of NAD<sup>+</sup> biosynthesis) was fatal in hPSCs, particularly when deriving pluripotent cells from somatic cells and maintaining pluripotency. NAD and its precursors (nicotinamide (NAM) and nicotinic acid (NA)) fully replenished the NAD<sup>+</sup> depletion by FK866 in hPSCs. However, only NAM effectively enhanced the reprogramming efficiency and kinetics of hiPSC generation and was also significantly advantageous for the maintenance of undifferentiated hPSCs. Our molecular and functional studies reveal that NAM lowers the barriers to reprogramming by accelerating cell proliferation and protecting cells from apoptosis and senescence by alleviating oxidative stress, reactive oxygen species (ROS) accumulation, and subsequent mitochondrial membrane potential collapse. We provide evidence that the positive effects of NAM (occurring at concentrations well above the physiological range) on pluripotency control are molecularly associated with the repression of p53, p21, and p16. Our findings establish that adequate intracellular NAD<sup>+</sup> content is crucial for pluripotency; the distinct effects of NAM on pluripotency may be dependent not only on its metabolic advantage as a NAD<sup>+</sup> precursor but also on the ability of NAM to enhance resistance to cellular stress.</p></div>
]]></content:encoded><description>

Cross-talk between intracellular signaling pathways has been extensively studied to understand the pluripotency of human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and human induced pluripotent stem cells (hiPSCs); however, the contribution of NAD+-dependent pathways remains largely unknown. Here, we show that NAD+ depletion by FK866 (a potent inhibitor of NAD+ biosynthesis) was fatal in hPSCs, particularly when deriving pluripotent cells from somatic cells and maintaining pluripotency. NAD and its precursors (nicotinamide (NAM) and nicotinic acid (NA)) fully replenished the NAD+ depletion by FK866 in hPSCs. However, only NAM effectively enhanced the reprogramming efficiency and kinetics of hiPSC generation and was also significantly advantageous for the maintenance of undifferentiated hPSCs. Our molecular and functional studies reveal that NAM lowers the barriers to reprogramming by accelerating cell proliferation and protecting cells from apoptosis and senescence by alleviating oxidative stress, reactive oxygen species (ROS) accumulation, and subsequent mitochondrial membrane potential collapse. We provide evidence that the positive effects of NAM (occurring at concentrations well above the physiological range) on pluripotency control are molecularly associated with the repression of p53, p21, and p16. Our findings establish that adequate intracellular NAD+ content is crucial for pluripotency; the distinct effects of NAM on pluripotency may be dependent not only on its metabolic advantage as a NAD+ precursor but also on the ability of NAM to enhance resistance to cellular stress.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1370" xmlns="http://purl.org/rss/1.0/"><title>Current Concepts in Bone Marrow Microenvironmental Regulation of Hematopoietic Stem and Progenitor Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1370</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Current Concepts in Bone Marrow Microenvironmental Regulation of Hematopoietic Stem and Progenitor Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julianne N. P. Smith, Laura M. Calvi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-18T06:54:21.48832-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1370</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1370</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1370</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Within the microanatomy of mammalian bone, hematopoietic stem and progenitor cells (HSPCs) interact with numerous cell types and molecules. Throughout development as well as in adulthood, the local microenvironment of HSPCs plays an instructive role in stem cell fate. Here we will discuss recent reports on these regulatory interactions. While a comprehensive report on all the cellular components of the HSC niche is beyond the scope of this concise review, we have specifically chosen to highlight topics with therapeutic relevance, where clinical translation can be envisioned within the near future. A comprehensive summary of cellular components of the niche identified so far is included.</p></div>
]]></content:encoded><description>

Within the microanatomy of mammalian bone, hematopoietic stem and progenitor cells (HSPCs) interact with numerous cell types and molecules. Throughout development as well as in adulthood, the local microenvironment of HSPCs plays an instructive role in stem cell fate. Here we will discuss recent reports on these regulatory interactions. While a comprehensive report on all the cellular components of the HSC niche is beyond the scope of this concise review, we have specifically chosen to highlight topics with therapeutic relevance, where clinical translation can be envisioned within the near future. A comprehensive summary of cellular components of the niche identified so far is included.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1371" xmlns="http://purl.org/rss/1.0/"><title>Gene Regulatory Networks Mediating Canonical Wnt Signal Directed Control of Pluripotency and Differentiation in Embryo Stem Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1371</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Gene Regulatory Networks Mediating Canonical Wnt Signal Directed Control of Pluripotency and Differentiation in Embryo Stem Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaoxiao Zhang, Kevin A. Peterson, X. Shirley Liu, Andrew P. McMahon, Shinsuke Ohba</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-15T03:43:20.116075-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1371</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1371</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1371</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Canonical Wnt signaling supports the pluripotency of embryonic stem cells (ESCs) but also promotes differentiation of early mammalian cell lineages. To explain these paradoxical observations, we explored the gene regulatory networks at play. Canonical Wnt signaling is intertwined with the pluripotency network comprising Nanog, Oct4, and Sox2 in mouse ESCs. In defined media supporting the derivation and propagation of ESCs, Tcf3 and β-catenin interact with Oct4; Tcf3 binds to Sox motif within Oct-Sox composite motifs that are also bound by Oct4-Sox2 complexes. Further, canonical Wnt signaling up-regulates the activity of the <em>Pou5f1</em> distal enhancer via the Sox motif <em>in ESCs</em>. When viewed in the context of published studies on Tcf3 and β-catenin mutants, our findings suggest Tcf3 counters pluripotency by competition with Sox2 at these sites, and Tcf3 inhibition is blocked by β-catenin entry into this complex. Wnt pathway stimulation also triggers β-catenin association at regulatory elements with classic Lef/Tcf motifs associated with differentiation programs. The failure to activate these targets in the presence of a MEK/ERK inhibitor essential for ESC culture suggests MEK/ERK signaling and canonical Wnt signaling combine to promote ESC differentiation.</p></div>
]]></content:encoded><description>

Canonical Wnt signaling supports the pluripotency of embryonic stem cells (ESCs) but also promotes differentiation of early mammalian cell lineages. To explain these paradoxical observations, we explored the gene regulatory networks at play. Canonical Wnt signaling is intertwined with the pluripotency network comprising Nanog, Oct4, and Sox2 in mouse ESCs. In defined media supporting the derivation and propagation of ESCs, Tcf3 and β-catenin interact with Oct4; Tcf3 binds to Sox motif within Oct-Sox composite motifs that are also bound by Oct4-Sox2 complexes. Further, canonical Wnt signaling up-regulates the activity of the Pou5f1 distal enhancer via the Sox motif in ESCs. When viewed in the context of published studies on Tcf3 and β-catenin mutants, our findings suggest Tcf3 counters pluripotency by competition with Sox2 at these sites, and Tcf3 inhibition is blocked by β-catenin entry into this complex. Wnt pathway stimulation also triggers β-catenin association at regulatory elements with classic Lef/Tcf motifs associated with differentiation programs. The failure to activate these targets in the presence of a MEK/ERK inhibitor essential for ESC culture suggests MEK/ERK signaling and canonical Wnt signaling combine to promote ESC differentiation.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1372" xmlns="http://purl.org/rss/1.0/"><title>Developing Rods Transplanted into the Degenerating Retina of Crx-knockout Mice Exhibit Neural Activity Similar to Native Photoreceptors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1372</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Developing Rods Transplanted into the Degenerating Retina of Crx-knockout Mice Exhibit Neural Activity Similar to Native Photoreceptors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kohei Homma, Satoshi Okamoto, Michiko Mandai, Norimoto Gotoh, Harsha K. Rajasimha, Yi-Sheng Chang, Shan Chen, Wei Li, Tiziana Cogliati, Anand Swaroop, Masayo Takahashi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-14T00:02:05.220203-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1372</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1372</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1372</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regenerative Medicine</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Replacement of dysfunctional or dying photoreceptors offers a promising approach for retinal neurodegenerative diseases, including age-related macular degeneration and retinitis pigmentosa. Several studies have demonstrated the integration and differentiation of developing rod photoreceptors when transplanted in wild type or degenerating retina; however, the physiology and function of the donor cells are not adequately defined. Here, we describe the physiological properties of developing rod photoreceptors that are tagged with GFP driven by the promoter of rod differentiation factor, <em>Nrl</em>. GFP-tagged developing rods show Ca<sup>2+</sup> responses and rectifier outward currents that are smaller than those observed in fully developed photoreceptors, suggesting their immature developmental state. These immature rods also exhibit hyperpolarization-activated current (I<sub>h</sub>) induced by the activation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. When transplanted into the subretinal space of wild type or retinal degeneration mice, GFP-tagged developing rods can integrate into the photoreceptor outer nuclear layer in wild-type mouse retina, and exhibit Ca<sup>2+</sup> responses and membrane current comparable to native rod photoreceptors. A proportion of grafted rods develop rhodopsin-positive outer segment-like structures within two weeks after transplantation into the retina of Crx-knockout mice, and produce rectifier outward current and I<sub>h</sub> upon membrane depolarization and hyperpolarization. GFP-positive rods derived from induced pluripotent stem (iPS) cells also display similar membrane current I<sub>h</sub> as native developing rod photoreceptors, express rod-specific phototransduction genes, and HCN-1 channels. We conclude that <em>Nrl</em>-promoter driven GFP-tagged donor photoreceptors exhibit physiological characteristics of rods and that iPS cell-derived rods <em>in vitro</em> may provide a renewable source for cell replacement therapy.</p></div>
]]></content:encoded><description>

Replacement of dysfunctional or dying photoreceptors offers a promising approach for retinal neurodegenerative diseases, including age-related macular degeneration and retinitis pigmentosa. Several studies have demonstrated the integration and differentiation of developing rod photoreceptors when transplanted in wild type or degenerating retina; however, the physiology and function of the donor cells are not adequately defined. Here, we describe the physiological properties of developing rod photoreceptors that are tagged with GFP driven by the promoter of rod differentiation factor, Nrl. GFP-tagged developing rods show Ca2+ responses and rectifier outward currents that are smaller than those observed in fully developed photoreceptors, suggesting their immature developmental state. These immature rods also exhibit hyperpolarization-activated current (Ih) induced by the activation of hyperpolarization-activated cyclic nucleotide-gated (HCN) channels. When transplanted into the subretinal space of wild type or retinal degeneration mice, GFP-tagged developing rods can integrate into the photoreceptor outer nuclear layer in wild-type mouse retina, and exhibit Ca2+ responses and membrane current comparable to native rod photoreceptors. A proportion of grafted rods develop rhodopsin-positive outer segment-like structures within two weeks after transplantation into the retina of Crx-knockout mice, and produce rectifier outward current and Ih upon membrane depolarization and hyperpolarization. GFP-positive rods derived from induced pluripotent stem (iPS) cells also display similar membrane current Ih as native developing rod photoreceptors, express rod-specific phototransduction genes, and HCN-1 channels. We conclude that Nrl-promoter driven GFP-tagged donor photoreceptors exhibit physiological characteristics of rods and that iPS cell-derived rods in vitro may provide a renewable source for cell replacement therapy.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1369" xmlns="http://purl.org/rss/1.0/"><title>Pim1 serine/threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1369</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pim1 serine/threonine Kinase Regulates the Number and Functions of Murine Hematopoietic Stem Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ningfei An, Ying-Wei Lin, Sandeep Mahajan, Joshua N. Kellner, Yong Wang, Zihai Li, Andrew S. Kraft, Yubin Kang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-14T00:01:43.384616-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1369</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1369</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1369</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The genes and pathways that govern the functions and expansion of hematopoietic stem cells (HSC) are not completely understood. In the current study, we investigated the roles of serine/threonine Pim kinases in hematopoiesis in mice. We generated PIM1 transgenic mice (Pim1-Tx) over-expressing human <em>PIM1</em> driven by <em>vav</em> hematopoietic promoter/regulatory elements. Compared to wild-type littermates, Pim1-Tx mice showed enhanced hematopoiesis as demonstrated by increased numbers of Lin<sup>−</sup>Sca-1<sup>+</sup>c-Kit<sup>+</sup> (LSK) hematopoietic stem/progenitor cells and cobblestone area forming cells, higher BrdU incorporation in long-term HSC population, and a better ability to reconstitute lethally irradiated mice. We then extended our study using <em>Pim1</em><sup>−/−</sup>, <em>Pim2</em><sup>−/−</sup>, <em>Pim3</em><sup>−/−</sup> single knockout (KO) mice. HSCs from <em>Pim1</em><sup>−/−</sup> KO mice showed impaired long-term hematopoietic repopulating capacity in secondary and competitive transplantations. Interestingly, these defects were not observed in HSCs from <em>Pim2</em><sup>−/−</sup> or <em>Pim3</em><sup>−/−</sup> KO mice. Limiting dilution competitive transplantation assay estimated that the frequency of LSKCD34<sup>−</sup> HSCs was reduced by ∼28-fold in <em>Pim1</em><sup>−/−</sup> KO mice compared to wild-type littermates. Mechanistic studies demonstrated an important role of Pim1 kinase in regulating HSC cell proliferation and survival. Finally, our PCR array and confirmatory RT-PCR studies identified several genes including Lef-1, Pax5 and Gata1 in HSCs that were affected by Pim1 deletion. Our data provide the first direct evidence for the important role of Pim1 kinase in the regulation of HSCs. Our study also dissects out the relative role of individual Pim kinase in HSC functions and regulation.</p></div>
]]></content:encoded><description>

The genes and pathways that govern the functions and expansion of hematopoietic stem cells (HSC) are not completely understood. In the current study, we investigated the roles of serine/threonine Pim kinases in hematopoiesis in mice. We generated PIM1 transgenic mice (Pim1-Tx) over-expressing human PIM1 driven by vav hematopoietic promoter/regulatory elements. Compared to wild-type littermates, Pim1-Tx mice showed enhanced hematopoiesis as demonstrated by increased numbers of Lin−Sca-1+c-Kit+ (LSK) hematopoietic stem/progenitor cells and cobblestone area forming cells, higher BrdU incorporation in long-term HSC population, and a better ability to reconstitute lethally irradiated mice. We then extended our study using Pim1−/−, Pim2−/−, Pim3−/− single knockout (KO) mice. HSCs from Pim1−/− KO mice showed impaired long-term hematopoietic repopulating capacity in secondary and competitive transplantations. Interestingly, these defects were not observed in HSCs from Pim2−/− or Pim3−/− KO mice. Limiting dilution competitive transplantation assay estimated that the frequency of LSKCD34− HSCs was reduced by ∼28-fold in Pim1−/− KO mice compared to wild-type littermates. Mechanistic studies demonstrated an important role of Pim1 kinase in regulating HSC cell proliferation and survival. Finally, our PCR array and confirmatory RT-PCR studies identified several genes including Lef-1, Pax5 and Gata1 in HSCs that were affected by Pim1 deletion. Our data provide the first direct evidence for the important role of Pim1 kinase in the regulation of HSCs. Our study also dissects out the relative role of individual Pim kinase in HSC functions and regulation.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1367" xmlns="http://purl.org/rss/1.0/"><title>Epigenetic Re-programming of the Germ Cell Nuclear Factor Gene is Required for Proper Differentiation of Induced Pluripotent Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1367</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Epigenetic Re-programming of the Germ Cell Nuclear Factor Gene is Required for Proper Differentiation of Induced Pluripotent Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hongran Wang, Xiaohong Wang, Xueping Xu, Thomas P. Zwaka, Austin J. Cooney</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-14T00:01:19.991119-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1367</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1367</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1367</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Somatic cells have been reprogrammed into induced pluripotent stem (iPS) cells that recapitulate the pluripotent nature of embryonic stem (ES) cells. Reduced pluripotency and variable differentiation capacities have hampered progress with this technology for applications in regeneration medicine. We have previously shown that Germ Cell Nuclear Factor (Gcnf) is required for the repression of pluripotency genes during ES cell differentiation and embryonic development. Here we report that iPS cell lines, in which the <em>Gcnf</em> gene was properly re-programmed, allowing expression of <em>Gcnf</em>, repress pluripotency genes during subsequent differentiation. In contrast, iPS clones in which the <em>Gcnf</em> gene was not re-programmed maintained pluripotency gene expression during differentiation and did not differentiate properly either <em>in vivo</em> or <em>in vitro</em>. These mal-reprogrammed cells re-capitulated the phenotype of <em>Gcnf</em> knock out (<em>Gcnf</em><sup>−/−</sup>) ES cells. Re-introduction of <em>Gcnf</em> into either the <em>Gcnf</em> negative iPS cells or the <em>Gcnf</em><sup>−/−</sup> ES cells, rescued repression of Oct4 during differentiation. Our findings establish a key role for <em>Gcnf</em> as a regulator of iPS cell pluripotency gene expression. It also demonstrates that reactivation of the Gcnf gene may serve as a marker to distinguish completely re-programmed iPS cells from incompletely pluripotent cells, which would make therapeutic use of iPS cells safer and more practical as it would reduce the oncogenic potential of iPS cells.</p></div>
]]></content:encoded><description>

Somatic cells have been reprogrammed into induced pluripotent stem (iPS) cells that recapitulate the pluripotent nature of embryonic stem (ES) cells. Reduced pluripotency and variable differentiation capacities have hampered progress with this technology for applications in regeneration medicine. We have previously shown that Germ Cell Nuclear Factor (Gcnf) is required for the repression of pluripotency genes during ES cell differentiation and embryonic development. Here we report that iPS cell lines, in which the Gcnf gene was properly re-programmed, allowing expression of Gcnf, repress pluripotency genes during subsequent differentiation. In contrast, iPS clones in which the Gcnf gene was not re-programmed maintained pluripotency gene expression during differentiation and did not differentiate properly either in vivo or in vitro. These mal-reprogrammed cells re-capitulated the phenotype of Gcnf knock out (Gcnf−/−) ES cells. Re-introduction of Gcnf into either the Gcnf negative iPS cells or the Gcnf−/− ES cells, rescued repression of Oct4 during differentiation. Our findings establish a key role for Gcnf as a regulator of iPS cell pluripotency gene expression. It also demonstrates that reactivation of the Gcnf gene may serve as a marker to distinguish completely re-programmed iPS cells from incompletely pluripotent cells, which would make therapeutic use of iPS cells safer and more practical as it would reduce the oncogenic potential of iPS cells.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1366" xmlns="http://purl.org/rss/1.0/"><title>Heterogeneous Nuclear Ribonucleoprotein A2/B1 Regulates the Selfrenewal and Pluripotency of Human Embryonic Stem Cells via the Control of the G1/S Transition</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1366</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Heterogeneous Nuclear Ribonucleoprotein A2/B1 Regulates the Selfrenewal and Pluripotency of Human Embryonic Stem Cells via the Control of the G1/S Transition</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hong Seo Choi, Hyun Min Lee, Young-Joo Jang, Cheorl-Ho Kim, Chun Jeih Ryu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-14T00:00:59.414437-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1366</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1366</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1366</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Self-renewal and pluripotency of human embryonic stem cells (hESCs) are a complex biological process for maintaining hESC stemness. However, the molecular mechanisms underlying these special properties of hESCs are not fully understood. Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) is a multifunctional RNA-binding protein whose expression is related to cell proliferation and carcinogenesis. In this study, we found that hnRNP A2/B1 expression was localized to undifferentiated hESCs, and decreased upon differentiation of hESCs. hnRNP A2/B1 knockdown reduced the number of alkaline phosphatase-positive colonies in hESCs and led to a decrease in the expression of pluripotency-associated transcription factors OCT4, NANOG and SOX2, indicating that hnRNP A2/B1 is essential for hESC self-renewal and pluripotency. hnRNP A2/B1 knockdown increased the expression of gene markers associated with the early development of three germ layers, and promoted the process of epithelial-mesenchymal transition, suggesting that hnRNP A2/B1 is required for maintaining the undifferentiated and epithelial phenotypes of hESCs. hnRNP A2/B1 knockdown inhibited hESC proliferation and induced cell cycle arrest in the G0/G1 phase before differentiation via degradation of cyclin D1, cyclin E, and Cdc25A. hnRNP A2/B1 knockdown increased p27 expression and induced phosphorylation of p53 and Chk1, suggesting that hnRNP A2/B1 also regulates the G1/S transition of hESC cell cycle through the control of p27 expression and p53 and Chk1 activity. Analysis of signaling molecules further revealed that hnRNP A2/B1 regulated hESC proliferation in a PI3K/Akt-dependent manner. These findings provide for the first time mechanistic insights into how hnRNP A2/B1 regulates hESC self-renewal and pluripotency.</p></div>
]]></content:encoded><description>

Self-renewal and pluripotency of human embryonic stem cells (hESCs) are a complex biological process for maintaining hESC stemness. However, the molecular mechanisms underlying these special properties of hESCs are not fully understood. Heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) is a multifunctional RNA-binding protein whose expression is related to cell proliferation and carcinogenesis. In this study, we found that hnRNP A2/B1 expression was localized to undifferentiated hESCs, and decreased upon differentiation of hESCs. hnRNP A2/B1 knockdown reduced the number of alkaline phosphatase-positive colonies in hESCs and led to a decrease in the expression of pluripotency-associated transcription factors OCT4, NANOG and SOX2, indicating that hnRNP A2/B1 is essential for hESC self-renewal and pluripotency. hnRNP A2/B1 knockdown increased the expression of gene markers associated with the early development of three germ layers, and promoted the process of epithelial-mesenchymal transition, suggesting that hnRNP A2/B1 is required for maintaining the undifferentiated and epithelial phenotypes of hESCs. hnRNP A2/B1 knockdown inhibited hESC proliferation and induced cell cycle arrest in the G0/G1 phase before differentiation via degradation of cyclin D1, cyclin E, and Cdc25A. hnRNP A2/B1 knockdown increased p27 expression and induced phosphorylation of p53 and Chk1, suggesting that hnRNP A2/B1 also regulates the G1/S transition of hESC cell cycle through the control of p27 expression and p53 and Chk1 activity. Analysis of signaling molecules further revealed that hnRNP A2/B1 regulated hESC proliferation in a PI3K/Akt-dependent manner. These findings provide for the first time mechanistic insights into how hnRNP A2/B1 regulates hESC self-renewal and pluripotency.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1365" xmlns="http://purl.org/rss/1.0/"><title>Oct4 Interaction with Hmgb2 Regulates Akt Signaling and Pluripotency</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1365</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Oct4 Interaction with Hmgb2 Regulates Akt Signaling and Pluripotency</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pearl A. Campbell, Michael A. Rudnicki</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-14T00:00:48.491874-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1365</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1365</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1365</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In pluripotent stem cells, bivalent domains mark the promoters of developmentally regulated loci. Histones in these chromatin regions contain coincident epigenetic modifications of gene activation and repression. How these marks are transmitted to maintain the pluripotent state in daughter progeny remains poorly understood. Our study demonstrates that Oct4 post-translational modifications (PTMs) form a positive feedback loop, which promote Akt activation and interaction with Hmgb2 and the SET Complex. This preserves H3K27me3 modifications in daughter progeny and maintains the pluripotent gene expression signature in mESCs. However, if Oct4 is not phosphorylated, a negative feedback loop is formed that inactivates Akt and initiates the DNA damage response. Oct4 sumoylation then is required for G1/S progression and transmission of the repressive H3K27me3 mark. Therefore, PTMs regulate the ability of Oct4 to direct the spatio-temporal formation of activating and repressing complexes to orchestrate chromatin plasticity and pluripotency. Our work highlights a previously unappreciated role for Oct4 PTM-dependent interactions in maintaining restrained Akt signaling and promoting a primitive epigenetic state.</p></div>
]]></content:encoded><description>

In pluripotent stem cells, bivalent domains mark the promoters of developmentally regulated loci. Histones in these chromatin regions contain coincident epigenetic modifications of gene activation and repression. How these marks are transmitted to maintain the pluripotent state in daughter progeny remains poorly understood. Our study demonstrates that Oct4 post-translational modifications (PTMs) form a positive feedback loop, which promote Akt activation and interaction with Hmgb2 and the SET Complex. This preserves H3K27me3 modifications in daughter progeny and maintains the pluripotent gene expression signature in mESCs. However, if Oct4 is not phosphorylated, a negative feedback loop is formed that inactivates Akt and initiates the DNA damage response. Oct4 sumoylation then is required for G1/S progression and transmission of the repressive H3K27me3 mark. Therefore, PTMs regulate the ability of Oct4 to direct the spatio-temporal formation of activating and repressing complexes to orchestrate chromatin plasticity and pluripotency. Our work highlights a previously unappreciated role for Oct4 PTM-dependent interactions in maintaining restrained Akt signaling and promoting a primitive epigenetic state.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1364" xmlns="http://purl.org/rss/1.0/"><title>Transplantation of Mesenchymal Stem Cells Promotes Tissue Regeneration in a Glaucoma Model through Laser-induced Paracrine Factor Secretion and Progenitor Cell Recruitment</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1364</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Transplantation of Mesenchymal Stem Cells Promotes Tissue Regeneration in a Glaucoma Model through Laser-induced Paracrine Factor Secretion and Progenitor Cell Recruitment</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Renaud Manuguerra-Gagné, Patrick R. Boulos, Ahmed Ammar, François A. Leblond, Gorazd Krosl, Vincent Pichette, Mark R. Lesk, Denis-Claude Roy</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-03-14T00:00:24.843318-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1364</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1364</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1364</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regenerative Medicine</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Among bone marrow cells, hematopoietic and mesenchymal components can contribute to repair damaged organs. Such cells are usually used in acute diseases but few options are available for the treatment of chronic disorders. In the present study, we have used a laser-induced model of open angle glaucoma (OAG) to evaluate the potential of bone marrow cell populations and the mechanisms involved in tissue repair. In addition, we investigated laser-induced tissue remodeling as a method of targeting effector cells into damaged tissues. We demonstrate that among bone marrow cells, mesenchymal stem cells (MSC) induce trabecular meshwork (TM) regeneration. MSC injection into the ocular anterior chamber lead to far more efficient decrease in intraocular pressure (IOP) (P&lt;0.001) and healing than hematopoietic cells. This robust effect was attributable to paracrine factors from stressed MSC, as injection of conditioned medium from MSC exposed to low but not to normal oxygen levels resulted in an immediate decrease in IOP. Moreover, MSC and their secreted factors induced reactivation of a progenitor cell pool found in the ciliary body and increased cellular proliferation. Proliferating cells were observed within the chamber angle for at least 1 month. Laser-induced remodeling was able to target MSC to damaged areas with ensuing specific increases in ocular progenitor cells. Thus, our results identify MSC and their secretum as crucial mediators of tissue repair in OAG through reactivation of local neural progenitors. In addition, laser treatment could represent an appealing strategy to promote MSC-mediated progenitor cell recruitment and tissue repair in chronic diseases.</p></div>
]]></content:encoded><description>

Among bone marrow cells, hematopoietic and mesenchymal components can contribute to repair damaged organs. Such cells are usually used in acute diseases but few options are available for the treatment of chronic disorders. In the present study, we have used a laser-induced model of open angle glaucoma (OAG) to evaluate the potential of bone marrow cell populations and the mechanisms involved in tissue repair. In addition, we investigated laser-induced tissue remodeling as a method of targeting effector cells into damaged tissues. We demonstrate that among bone marrow cells, mesenchymal stem cells (MSC) induce trabecular meshwork (TM) regeneration. MSC injection into the ocular anterior chamber lead to far more efficient decrease in intraocular pressure (IOP) (P&lt;0.001) and healing than hematopoietic cells. This robust effect was attributable to paracrine factors from stressed MSC, as injection of conditioned medium from MSC exposed to low but not to normal oxygen levels resulted in an immediate decrease in IOP. Moreover, MSC and their secreted factors induced reactivation of a progenitor cell pool found in the ciliary body and increased cellular proliferation. Proliferating cells were observed within the chamber angle for at least 1 month. Laser-induced remodeling was able to target MSC to damaged areas with ensuing specific increases in ocular progenitor cells. Thus, our results identify MSC and their secretum as crucial mediators of tissue repair in OAG through reactivation of local neural progenitors. In addition, laser treatment could represent an appealing strategy to promote MSC-mediated progenitor cell recruitment and tissue repair in chronic diseases.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1363" xmlns="http://purl.org/rss/1.0/"><title>A Subpopulation of Individual Neural Progenitors in the Mammalian Dorsal Pallium Generates Both Projection Neurons and Interneurons vitro</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1363</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">A Subpopulation of Individual Neural Progenitors in the Mammalian Dorsal Pallium Generates Both Projection Neurons and Interneurons vitro</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuqun Cai, Yue Zhang, Qin Shen, John L. R. Rubenstein, Zhengang Yang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-18T04:34:42.08393-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1363</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1363</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1363</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>There are two major classes of neurons in nervous systems: projection neurons and interneurons. During Drosophila nervous system development, a subpopulation of individual stem/progenitor cells gives rise to both motor neurons and interneurons. However, it remains unknown whether individual stem/progenitor cells in the mammalian brain also have the potential to give rise to both projection neurons and interneurons. Here we present evidence that single mouse neocortical progenitors generated both projection neurons and GABAergic interneurons based on studies using fluorescence-activated cell sorting (to obtain individual progenitors) and in vitro clonal analysis using time-lapse video microscopy and immunostaining. We determined that a subpopulation of individual dorsal pallial progenitors from E11.5 Dlx5/6-cre-IRES-EGFP and GAD67-GFP mice can generate both GFP-negative/Tbr1-positive (GFP<sup>-</sup>/Tbr1+)/Tuj1+ cells and GFP+/Sp8+/calretinin+/Tuj1+ cells. The GFP<sup>-</sup>/Tbr1+/Tuj1+ cells had morphological features of cultured projection neurons. Quantitative analysis of the reconstructed lineage trees derived from single progenitors showed that the projection neuron lineage appeared earlier than the interneuron lineage; however, more interneuron-like cells were produced than projection neuron-like cells. Thus, our results provide direct in vitro evidence that individual progenitors of the mammalian dorsal pallium can generate both projection neurons and interneurons.</p></div>
]]></content:encoded><description>

There are two major classes of neurons in nervous systems: projection neurons and interneurons. During Drosophila nervous system development, a subpopulation of individual stem/progenitor cells gives rise to both motor neurons and interneurons. However, it remains unknown whether individual stem/progenitor cells in the mammalian brain also have the potential to give rise to both projection neurons and interneurons. Here we present evidence that single mouse neocortical progenitors generated both projection neurons and GABAergic interneurons based on studies using fluorescence-activated cell sorting (to obtain individual progenitors) and in vitro clonal analysis using time-lapse video microscopy and immunostaining. We determined that a subpopulation of individual dorsal pallial progenitors from E11.5 Dlx5/6-cre-IRES-EGFP and GAD67-GFP mice can generate both GFP-negative/Tbr1-positive (GFP-/Tbr1+)/Tuj1+ cells and GFP+/Sp8+/calretinin+/Tuj1+ cells. The GFP-/Tbr1+/Tuj1+ cells had morphological features of cultured projection neurons. Quantitative analysis of the reconstructed lineage trees derived from single progenitors showed that the projection neuron lineage appeared earlier than the interneuron lineage; however, more interneuron-like cells were produced than projection neuron-like cells. Thus, our results provide direct in vitro evidence that individual progenitors of the mammalian dorsal pallium can generate both projection neurons and interneurons.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1362" xmlns="http://purl.org/rss/1.0/"><title>Oct4 and Canonical Wnt Signaling Regulate the Cardiac Lineage Factor Mesp1 through a Tcf/Lef-Oct4 Composite Element</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1362</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Oct4 and Canonical Wnt Signaling Regulate the Cardiac Lineage Factor Mesp1 through a Tcf/Lef-Oct4 Composite Element</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yongqing Li, Wei Yu, Austin J. Cooney, Robert J. Schwartz, Yu Liu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-18T04:34:27.978796-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1362</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1362</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1362</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Oct4 is the gatekeeper of stem cell pluripotency, but recent evidences also support Oct4 as a key regulator of germ layer formation and lineage commitment. How Oct4 contributes to lineage commitment is not well understood. We identified a Tcf/Lef-Oct4 composite site in the promoter of the cardiac mesoderm gene Mesp1, with a nucleotide sequence identical to the previously established Sox2-Oct4 composite site. This Tcf/Lef-Oct4 composite site mediated synergistic activation of the Mesp1 promoter by Oct4 and canonical Wnt signaling. Transcription ternary complexes were formed with Oct4 and Wnt terminal components, Lef1. Point mutations on the Tcf/Lef-Oct4 composite site impaired Oct4 and Lef1 binding, and Mesp1-β-gal transgene reporter expression during mouse embryogenesis. In ZHBTc4 murine ES cells, the loss of Oct4 during differentiation impaired Mesp1 expression and the development of the cardiac program. This Tcf/Lef-Oct4 composite site appears to be a unique nodal point regulatory element that may drive pluripotency via Sox2-Oct4 and switch on lineage-related genes through Oct4's recruitment of Tcf/Lef factors.</p></div>
]]></content:encoded><description>

Oct4 is the gatekeeper of stem cell pluripotency, but recent evidences also support Oct4 as a key regulator of germ layer formation and lineage commitment. How Oct4 contributes to lineage commitment is not well understood. We identified a Tcf/Lef-Oct4 composite site in the promoter of the cardiac mesoderm gene Mesp1, with a nucleotide sequence identical to the previously established Sox2-Oct4 composite site. This Tcf/Lef-Oct4 composite site mediated synergistic activation of the Mesp1 promoter by Oct4 and canonical Wnt signaling. Transcription ternary complexes were formed with Oct4 and Wnt terminal components, Lef1. Point mutations on the Tcf/Lef-Oct4 composite site impaired Oct4 and Lef1 binding, and Mesp1-β-gal transgene reporter expression during mouse embryogenesis. In ZHBTc4 murine ES cells, the loss of Oct4 during differentiation impaired Mesp1 expression and the development of the cardiac program. This Tcf/Lef-Oct4 composite site appears to be a unique nodal point regulatory element that may drive pluripotency via Sox2-Oct4 and switch on lineage-related genes through Oct4's recruitment of Tcf/Lef factors.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1361" xmlns="http://purl.org/rss/1.0/"><title>Mesenchymal Stromal Cell Atrophy in Co-culture Increases Aggressiveness of Transformed cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1361</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Mesenchymal Stromal Cell Atrophy in Co-culture Increases Aggressiveness of Transformed cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria D. Castellone, Lilja E. Laatikainen, Juha P. Laurila, Angela Langella, Peiman Hematti, Andrea Soricelli, Marco Salvatore, Mikko O. Laukkanen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T06:20:46.469403-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1361</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1361</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1361</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Mesenchymal stromal cells (MSC) are able to influence the growth abilities of transformed cells. Here, we show that papillary thyroid cancer TPC1 and HEK 293T cells interact physically with human primary bone marrow-derived MSCs followed by evanescence of MSC cytoplasm. Interestingly, transformed cells were able to connect only to apoptotic MSCs that had lost their migration ability, whereas naïve MSCs, avoided the direct contact. The interaction stimulated the proliferation of the co-cultured transformed cells, activated mitogen and stress signaling, and increased resistance to cytotoxins. Consistent with <em>in vitro</em> data, the MSC interaction stimulated transformed cells had enhanced ability to grow and metastasize <em>in vivo</em>. The parental control cells showed mild tumorigenicity as compared to MSC interaction stimulated cells yielding measurable tumors in 31 days and seven days, respectively. Our co-culture model system describe how adjacent transformed cells absorb stromal cells thereby leading to the stroma-driven evolution of moderately carcinogenic cells to highly aggressive metastatic cells.</p></div>
]]></content:encoded><description>

Mesenchymal stromal cells (MSC) are able to influence the growth abilities of transformed cells. Here, we show that papillary thyroid cancer TPC1 and HEK 293T cells interact physically with human primary bone marrow-derived MSCs followed by evanescence of MSC cytoplasm. Interestingly, transformed cells were able to connect only to apoptotic MSCs that had lost their migration ability, whereas naïve MSCs, avoided the direct contact. The interaction stimulated the proliferation of the co-cultured transformed cells, activated mitogen and stress signaling, and increased resistance to cytotoxins. Consistent with in vitro data, the MSC interaction stimulated transformed cells had enhanced ability to grow and metastasize in vivo. The parental control cells showed mild tumorigenicity as compared to MSC interaction stimulated cells yielding measurable tumors in 31 days and seven days, respectively. Our co-culture model system describe how adjacent transformed cells absorb stromal cells thereby leading to the stroma-driven evolution of moderately carcinogenic cells to highly aggressive metastatic cells.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1360" xmlns="http://purl.org/rss/1.0/"><title>Matrix Remodeling Maintains ESC Self-Renewal by Activating Stat3</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1360</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Matrix Remodeling Maintains ESC Self-Renewal by Activating Stat3</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Laralynne M. Przybyla, Thorold W. Theunissen, Rudolf Jaenisch, Joel Voldman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T06:20:25.534333-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1360</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1360</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1360</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>While a variety of natural and synthetic matrices have been used to influence embryonic stem cell (ESC) self-renewal or differentiation, and ESCs also deposit a rich matrix of their own, the mechanisms behind how extracellular matrix affects cell fate are largely unexplored. The ESC matrix is continuously remodeled by matrix metalloproteinases (MMPs), a process that we find is enhanced by the presence of mouse embryonic fibroblast feeders in a paracrine manner. Matrix remodeling by MMPs aids in the self-renewal of ESCs, as inhibition of MMPs inhibits the ability of ESCs to self-renew. We also find that addition of the interstitial collagenase MMP1 is sufficient to maintain long-term LIF-independent mESC self-renewal in a dose-dependent manner. This remarkable ability is due to the presence of endogenously produced self-renewal-inducing signals, including the LIF-family ligand CNTF, that are normally trapped within the ECM and become exposed upon MMP-induced matrix remodeling to signal through JAK and Stat3. These results uncover a new role for feeder cells in maintaining self-renewal and show that mESCs normally produce sufficient levels of autocrine-acting pro-self-renewal ligands.</p></div>
]]></content:encoded><description>

While a variety of natural and synthetic matrices have been used to influence embryonic stem cell (ESC) self-renewal or differentiation, and ESCs also deposit a rich matrix of their own, the mechanisms behind how extracellular matrix affects cell fate are largely unexplored. The ESC matrix is continuously remodeled by matrix metalloproteinases (MMPs), a process that we find is enhanced by the presence of mouse embryonic fibroblast feeders in a paracrine manner. Matrix remodeling by MMPs aids in the self-renewal of ESCs, as inhibition of MMPs inhibits the ability of ESCs to self-renew. We also find that addition of the interstitial collagenase MMP1 is sufficient to maintain long-term LIF-independent mESC self-renewal in a dose-dependent manner. This remarkable ability is due to the presence of endogenously produced self-renewal-inducing signals, including the LIF-family ligand CNTF, that are normally trapped within the ECM and become exposed upon MMP-induced matrix remodeling to signal through JAK and Stat3. These results uncover a new role for feeder cells in maintaining self-renewal and show that mESCs normally produce sufficient levels of autocrine-acting pro-self-renewal ligands.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1359" xmlns="http://purl.org/rss/1.0/"><title>Human Fetal Hepatic Progenitor Cells Are Distinct from, but Closely Related to, Hematopoietic Stem/Progenitor Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1359</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Human Fetal Hepatic Progenitor Cells Are Distinct from, but Closely Related to, Hematopoietic Stem/Progenitor Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qingfeng Chen, Maroun Khoury, Gino Limmon, Mahesh Choolani, Jerry KY Chan, Jianzhu Chen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T06:19:48.011597-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1359</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1359</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1359</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Much controversy surrounds the identity and origin of human hepatic stem and progenitor cells in part because of a lack of small animal models in which the developmental potential of isolated candidate cell populations can be functionally evaluated. We show here that adoptive transfer of CD34<sup>+</sup> cells from human fetal liver into sublethally irradiated NOD-SCID Il2rg<sup>−/−</sup> (NSG) mice leads to an efficient development of not only human hematopoietic cells but also human hepatocyte-like cells in the liver of the recipient mice. Using this simple <em>in vivo</em> assay in combination with cell fractionation, we show that CD34<sup>+</sup> fetal liver cells can be separated into three distinct subpopulations: CD34<sup>hi</sup>CD133<sup>hi</sup>, CD34<sup>lo</sup>CD133<sup>lo</sup>, and CD34<sup>hi</sup>CD133<sup>neg</sup>. The CD34<sup>hi</sup>CD133<sup>hi</sup> population contains hematopoietic stem/progenitor cells (HSPCs) as they give rise to T cells, B cells, NK cells, dendritic cells, and monocytes/macrophages in NSG mice and CFU-GEMM cells <em>in vitro</em>. The CD34<sup>lo</sup>CD133<sup>lo</sup> population does not give rise to hematopoietic cells, but reproducibly generates hepatocyte-like cells in NSG mice and <em>in vitro</em>. The CD34<sup>hi</sup>CD133<sup>neg</sup> population only gives rise to CFU-GM and BFU-E <em>in vitro</em>. Furthermore, we show that the CD34<sup>lo</sup>CD133<sup>lo</sup> cells express hematopoietic, hepatic, and mesenchymal markers, including CD34, CD133, CD117, EpCAM, CD73, albumin, α-fetal protein and vimentin and transcriptionally are more closely related to HSPCs than to mature hepatocytes. These results show that CD34<sup>lo</sup>CD133<sup>lo</sup> fetal liver cells possess the hepatic progenitor cell properties and that human hepatic and hematopoietic progenitor cells are distinct, although they may originate from the same precursors in the fetal liver.</p></div>
]]></content:encoded><description>

Much controversy surrounds the identity and origin of human hepatic stem and progenitor cells in part because of a lack of small animal models in which the developmental potential of isolated candidate cell populations can be functionally evaluated. We show here that adoptive transfer of CD34+ cells from human fetal liver into sublethally irradiated NOD-SCID Il2rg−/− (NSG) mice leads to an efficient development of not only human hematopoietic cells but also human hepatocyte-like cells in the liver of the recipient mice. Using this simple in vivo assay in combination with cell fractionation, we show that CD34+ fetal liver cells can be separated into three distinct subpopulations: CD34hiCD133hi, CD34loCD133lo, and CD34hiCD133neg. The CD34hiCD133hi population contains hematopoietic stem/progenitor cells (HSPCs) as they give rise to T cells, B cells, NK cells, dendritic cells, and monocytes/macrophages in NSG mice and CFU-GEMM cells in vitro. The CD34loCD133lo population does not give rise to hematopoietic cells, but reproducibly generates hepatocyte-like cells in NSG mice and in vitro. The CD34hiCD133neg population only gives rise to CFU-GM and BFU-E in vitro. Furthermore, we show that the CD34loCD133lo cells express hematopoietic, hepatic, and mesenchymal markers, including CD34, CD133, CD117, EpCAM, CD73, albumin, α-fetal protein and vimentin and transcriptionally are more closely related to HSPCs than to mature hepatocytes. These results show that CD34loCD133lo fetal liver cells possess the hepatic progenitor cell properties and that human hepatic and hematopoietic progenitor cells are distinct, although they may originate from the same precursors in the fetal liver.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1358" xmlns="http://purl.org/rss/1.0/"><title>MELK-dependent FOXM1 Phosphorylation is Essential for Proliferation of Glioma Stem Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1358</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">MELK-dependent FOXM1 Phosphorylation is Essential for Proliferation of Glioma Stem Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kaushal Joshi, Yeshavanth Banasavadi-Siddegowda, Xiaokui Mo, Sung-hak Kim, Ping Mao, Cenk Kig, Diana Nardini, Robert W. Sobol, Lionel M.L. Chow, Harley I. Kornblum, Ronald Waclaw, Monique Beullens, Ichiro Nakano</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T06:19:33.275895-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1358</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1358</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1358</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Glioblastoma multiforme (GBM) is a life-threatening brain tumor. Accumulating evidence suggests that eradication of glioma stem-like cells (GSCs) in GBM is essential to achieve cure. The transcription factor FOXM1 has recently gained attention as a master regulator of mitotic progression of cancer cells in various organs. Here, we demonstrate that FOXM1 forms a protein complex with the mitotic kinase MELK in GSCs, leading to phosphorylation and activation of FOXM1 in a MELK kinase-dependent manner. This MELK-dependent activation of <em>FOXM1</em> results in a subsequent increase in mitotic regulatory genes in GSCs. MELK-driven FOXM1 activation is regulated by the binding and subsequent trans-phosphorylation of FOXM1 by another kinase PLK1. Using mouse neural progenitors (NPCs), we found that transgenic expression of FOXM1 enhances, while siRNA-mediated gene silencing diminishes neurosphere formation, suggesting that FOXM1 is required for NPC growth. During tumorigenesis, FOXM1 expression sequentially increases as cells progress from NPCs, to pre-tumorigenic progenitors and GSCs. The antibiotic Siomycin A disrupts MELK-mediated FOXM1 signaling with a greater sensitivity in GSC compared to NSC. Treatment with the first-line chemotherapy agent for GBM, Temozolomide, paradoxically enriches for both FOXM1 (+) and MELK (+) cells in GBM cells, and addition of Siomycin A to Temozolomide treatment in mice harboring GSC-derived intracranial tumors enhances the effects of the latter. Collectively, our data indicate that FOXM1 signaling through its direct interaction with MELK regulates key mitotic genes in GSCs in a PLK1-dependent manner and thus, this protein complex is a potential therapeutic target for GBM.</p></div>
]]></content:encoded><description>

Glioblastoma multiforme (GBM) is a life-threatening brain tumor. Accumulating evidence suggests that eradication of glioma stem-like cells (GSCs) in GBM is essential to achieve cure. The transcription factor FOXM1 has recently gained attention as a master regulator of mitotic progression of cancer cells in various organs. Here, we demonstrate that FOXM1 forms a protein complex with the mitotic kinase MELK in GSCs, leading to phosphorylation and activation of FOXM1 in a MELK kinase-dependent manner. This MELK-dependent activation of FOXM1 results in a subsequent increase in mitotic regulatory genes in GSCs. MELK-driven FOXM1 activation is regulated by the binding and subsequent trans-phosphorylation of FOXM1 by another kinase PLK1. Using mouse neural progenitors (NPCs), we found that transgenic expression of FOXM1 enhances, while siRNA-mediated gene silencing diminishes neurosphere formation, suggesting that FOXM1 is required for NPC growth. During tumorigenesis, FOXM1 expression sequentially increases as cells progress from NPCs, to pre-tumorigenic progenitors and GSCs. The antibiotic Siomycin A disrupts MELK-mediated FOXM1 signaling with a greater sensitivity in GSC compared to NSC. Treatment with the first-line chemotherapy agent for GBM, Temozolomide, paradoxically enriches for both FOXM1 (+) and MELK (+) cells in GBM cells, and addition of Siomycin A to Temozolomide treatment in mice harboring GSC-derived intracranial tumors enhances the effects of the latter. Collectively, our data indicate that FOXM1 signaling through its direct interaction with MELK regulates key mitotic genes in GSCs in a PLK1-dependent manner and thus, this protein complex is a potential therapeutic target for GBM.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1357" xmlns="http://purl.org/rss/1.0/"><title>Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for crohn's fistula</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1357</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Autologous adipose tissue-derived stem cells treatment demonstrated favorable and sustainable therapeutic effect for crohn's fistula</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Woo Yong Lee, Kyu Joo Park, Yong Beom Cho, Sang Nam Yoon, Kee Ho Song, Do Sun Kim, Sang Hun Jung, Mihyung Kim, Hee-Won Yoo, Inok Kim, Hyunjoo Ha, Chang Sik Yu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T06:18:59.190781-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1357</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1357</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1357</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Translational And Clinical Research</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Fistula is a representative devastating complication in Crohn's patients due to refractory to conventional therapy and high recurrence. In our phase I clinical trial, adipose tissue-derived stem cells (ASCs) demonstrated their safety and therapeutic potential for healing fistulae associated with Crohn's disease. This study was carried out to evaluate the efficacy and safety of ASCs in patients with Crohn's fistulae. In this phase II study, forty-three patients were treated with ASCs. The amount of ASCs was proportioned to fistula size and fistula tract was filled with ASCs in combination with fibrin glue after intralesional injection of ASCs. Patients without complete closure of fistula at 8 weeks received a second injection of ASCs containing 1.5 times more cells than the first injection. Fistula healing at week 8 after final dose injection and its sustainability for 1 year were evaluated. Healing was defined as a complete closure of external opening without any sign of drainage and inflammation. A modified per-protocol (mPP) analysis showed that complete fistula healing was observed in 27/33 patients (82%) by 8 weeks after ASC injection. Of 27 patients with fistula healing, 26 patients completed additional observation study for 1 year and 23 patients (88%) sustained complete closure. There were no adverse events related to ASC administration. ASC treatment for patients with Crohn's fistulae was well-tolerated, with a favorable therapeutic outcome. Further, complete closure was well-sustained. These results strongly suggest that autologous ASC could be a novel treatment option for the Crohn's fistula with high risk of recurrence.</p></div>
]]></content:encoded><description>

Fistula is a representative devastating complication in Crohn's patients due to refractory to conventional therapy and high recurrence. In our phase I clinical trial, adipose tissue-derived stem cells (ASCs) demonstrated their safety and therapeutic potential for healing fistulae associated with Crohn's disease. This study was carried out to evaluate the efficacy and safety of ASCs in patients with Crohn's fistulae. In this phase II study, forty-three patients were treated with ASCs. The amount of ASCs was proportioned to fistula size and fistula tract was filled with ASCs in combination with fibrin glue after intralesional injection of ASCs. Patients without complete closure of fistula at 8 weeks received a second injection of ASCs containing 1.5 times more cells than the first injection. Fistula healing at week 8 after final dose injection and its sustainability for 1 year were evaluated. Healing was defined as a complete closure of external opening without any sign of drainage and inflammation. A modified per-protocol (mPP) analysis showed that complete fistula healing was observed in 27/33 patients (82%) by 8 weeks after ASC injection. Of 27 patients with fistula healing, 26 patients completed additional observation study for 1 year and 23 patients (88%) sustained complete closure. There were no adverse events related to ASC administration. ASC treatment for patients with Crohn's fistulae was well-tolerated, with a favorable therapeutic outcome. Further, complete closure was well-sustained. These results strongly suggest that autologous ASC could be a novel treatment option for the Crohn's fistula with high risk of recurrence.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1356" xmlns="http://purl.org/rss/1.0/"><title>Shockwaves Induce Osteogenic Differentiation of Human Mesenchymal Stem Cells through ATP Release and Activation of P2X7 Receptors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1356</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Shockwaves Induce Osteogenic Differentiation of Human Mesenchymal Stem Cells through ATP Release and Activation of P2X7 Receptors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dahui Sun, Wolfgang G. Junger, Changji Yuan, Wenyan Zhang, Yi Bao, Daming Qin, Chengxue Wang, Lei Tan, Baochang Qi, Dong Zhu, Xizheng Zhang, Tiecheng Yu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T06:18:24.110517-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1356</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1356</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1356</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Shockwave treatment promotes bone healing of non-union fracture. In this study, we investigated whether this effect could be due to ATP release-induced differentiation of human mesenchymal stem cells (hMSCs) into osteoprogenitor cells. Cultured bone marrow-derived hMSCs were subjected to shockwave treatment and ATP release was assessed. Osteogenic differentiation and mineralization of hMSCs were evaluated by examining alkaline phosphatase (ALP) activity, osteocalcin (OC) production, and calcium nodule formation. Expression of P2X7 receptors and c-fos and c-jun mRNA was determined with real-time RT-PCR. P2X7--siRNA, apyrase, P2 receptor antagonists, and p38 MAPK inhibitors were used to evaluate the roles of ATP release, P2X7 receptors, and p38 MAPK signaling in shockwave-induced osteogenic hMSCs differentiation. Shockwave treatment released significant amounts (∼7 μM) of ATP from hMSCs. Shockwaves and exogenous ATP induced c-fos and c-jun mRNA transcription, p38 MAPK activation, and hMSC differentiation. Removal of ATP with apyrase, targeting of P2X7 receptors with P2X7-siRNA or selective antagonists or blockade of p38 MAPK with SB203580 prevented osteogenic differentiation of hMSCs. Our findings indicate that shockwaves release cellular ATP that activates P2X7 receptors and downstream signaling events that caused osteogenic differentiation of hMSCs. We conclude that shockwave therapy promotes bone healing through P2X7 receptor signaling, which contributes to hMSC differentiation.</p></div>
]]></content:encoded><description>

Shockwave treatment promotes bone healing of non-union fracture. In this study, we investigated whether this effect could be due to ATP release-induced differentiation of human mesenchymal stem cells (hMSCs) into osteoprogenitor cells. Cultured bone marrow-derived hMSCs were subjected to shockwave treatment and ATP release was assessed. Osteogenic differentiation and mineralization of hMSCs were evaluated by examining alkaline phosphatase (ALP) activity, osteocalcin (OC) production, and calcium nodule formation. Expression of P2X7 receptors and c-fos and c-jun mRNA was determined with real-time RT-PCR. P2X7--siRNA, apyrase, P2 receptor antagonists, and p38 MAPK inhibitors were used to evaluate the roles of ATP release, P2X7 receptors, and p38 MAPK signaling in shockwave-induced osteogenic hMSCs differentiation. Shockwave treatment released significant amounts (∼7 μM) of ATP from hMSCs. Shockwaves and exogenous ATP induced c-fos and c-jun mRNA transcription, p38 MAPK activation, and hMSC differentiation. Removal of ATP with apyrase, targeting of P2X7 receptors with P2X7-siRNA or selective antagonists or blockade of p38 MAPK with SB203580 prevented osteogenic differentiation of hMSCs. Our findings indicate that shockwaves release cellular ATP that activates P2X7 receptors and downstream signaling events that caused osteogenic differentiation of hMSCs. We conclude that shockwave therapy promotes bone healing through P2X7 receptor signaling, which contributes to hMSC differentiation.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1353" xmlns="http://purl.org/rss/1.0/"><title>Pkcδ Is Required for Jagged-1 Induction of hMSC Osteogenic Differentiation</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1353</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pkcδ Is Required for Jagged-1 Induction of hMSC Osteogenic Differentiation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fengchang Zhu, Mariya T. Sweetwyne, Kurt D. Hankenson</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-13T04:30:22.920796-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1353</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1353</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1353</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue-Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>JAG1</em>, the gene for the Jagged-1 ligand (Jag1) in the Notch signaling pathway, is variably mutated in Alagille Syndrome (ALGS). ALGS patients have skeletal defects, and additionally <em>JAG1</em> has been shown to be associated with low bone mass through genome wide association studies. Plating human osteoblast precursors (mesenchymal stem cells -- hMSC) on Jag1 is sufficient to induce osteoblast differentiation; however, exposure of mouse MSC (mMSC) to Jag1 actually inhibits osteoblastogenesis. Overexpression of the notch-2 intracellular domain (NICD) is sufficient to mimic the effect of Jag1 on hMSC osteoblastogenesis, while blocking Notch signaling with a gamma-secretase inhibitor or with dominant negative mastermind inhibits Jag1 induced hMSC osteoblastogenesis. In pursuit of interacting signaling pathways, we discovered that treatment with a PKCδ inhibitor abrogates Jag1 induced hMSC osteoblastogenesis. Jag1 results in rapid PKCδ nuclear translocation and kinase activation. Furthermore, Jag1 stimulates the physical interaction of PKCδ with NICD. Collectively, these results suggest that Jag1 induces hMSC osteoblast differentiation through canonical Notch signaling and requires concomitant PKCδ signaling. This research also demonstrates potential deficiencies in using mouse models to study ALGS bone abnormalities.</p></div>
]]></content:encoded><description>

JAG1, the gene for the Jagged-1 ligand (Jag1) in the Notch signaling pathway, is variably mutated in Alagille Syndrome (ALGS). ALGS patients have skeletal defects, and additionally JAG1 has been shown to be associated with low bone mass through genome wide association studies. Plating human osteoblast precursors (mesenchymal stem cells -- hMSC) on Jag1 is sufficient to induce osteoblast differentiation; however, exposure of mouse MSC (mMSC) to Jag1 actually inhibits osteoblastogenesis. Overexpression of the notch-2 intracellular domain (NICD) is sufficient to mimic the effect of Jag1 on hMSC osteoblastogenesis, while blocking Notch signaling with a gamma-secretase inhibitor or with dominant negative mastermind inhibits Jag1 induced hMSC osteoblastogenesis. In pursuit of interacting signaling pathways, we discovered that treatment with a PKCδ inhibitor abrogates Jag1 induced hMSC osteoblastogenesis. Jag1 results in rapid PKCδ nuclear translocation and kinase activation. Furthermore, Jag1 stimulates the physical interaction of PKCδ with NICD. Collectively, these results suggest that Jag1 induces hMSC osteoblast differentiation through canonical Notch signaling and requires concomitant PKCδ signaling. This research also demonstrates potential deficiencies in using mouse models to study ALGS bone abnormalities.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1354" xmlns="http://purl.org/rss/1.0/"><title>Induced Pluripotent Stem Cells with a Pathological Mitochondrial DNA Deletion</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1354</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Induced Pluripotent Stem Cells with a Pathological Mitochondrial DNA Deletion</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anne B. C. Cherry, Katelyn E. Gagne, Erin M. McLoughlin, Anna Baccei, Bryan Gorman, Odelya Hartung, Justine D. Miller, Jin Zhang, Rebecca L. Zon, Tan A. Ince, Ellis J. Neufeld, Paul H. Lerou, Mark D. Fleming, George Q. Daley, Suneet Agarwal</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-08T21:26:08.838617-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1354</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1354</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1354</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In congenital mitochondrial DNA (mtDNA) disorders, a mixture of normal and mutated mtDNA (termed heteroplasmy) exists at varying levels in different tissues, which determines the severity and phenotypic expression of disease. Pearson marrow pancreas syndrome (PS) is a congenital bone marrow failure disorder caused by heteroplasmic deletions in mtDNA. The cause of the hematopoietic failure in PS is unknown, and adequate cellular and animal models are lacking. Induced pluripotent stem (iPS) cells are particularly amenable for studying mtDNA disorders, as cytoplasmic genetic material is retained during direct reprogramming. Here we derive and characterize iPS cells from a patient with PS. Taking advantage of the tendency for heteroplasmy to change with cell passage, we isolated isogenic PS-iPS cells without detectable levels of deleted mtDNA. We found that PS-iPS cells carrying a high burden of deleted mtDNA displayed differences in growth, mitochondrial function, and hematopoietic phenotype when differentiated <em>in vitro</em>, compared to isogenic iPS cells without deleted mtDNA. Our results demonstrate that reprogramming somatic cells from patients with mtDNA disorders can yield pluripotent stem cells with varying burdens of heteroplasmy that might be useful in the study and treatment of mitochondrial diseases.</p></div>
]]></content:encoded><description>

In congenital mitochondrial DNA (mtDNA) disorders, a mixture of normal and mutated mtDNA (termed heteroplasmy) exists at varying levels in different tissues, which determines the severity and phenotypic expression of disease. Pearson marrow pancreas syndrome (PS) is a congenital bone marrow failure disorder caused by heteroplasmic deletions in mtDNA. The cause of the hematopoietic failure in PS is unknown, and adequate cellular and animal models are lacking. Induced pluripotent stem (iPS) cells are particularly amenable for studying mtDNA disorders, as cytoplasmic genetic material is retained during direct reprogramming. Here we derive and characterize iPS cells from a patient with PS. Taking advantage of the tendency for heteroplasmy to change with cell passage, we isolated isogenic PS-iPS cells without detectable levels of deleted mtDNA. We found that PS-iPS cells carrying a high burden of deleted mtDNA displayed differences in growth, mitochondrial function, and hematopoietic phenotype when differentiated in vitro, compared to isogenic iPS cells without deleted mtDNA. Our results demonstrate that reprogramming somatic cells from patients with mtDNA disorders can yield pluripotent stem cells with varying burdens of heteroplasmy that might be useful in the study and treatment of mitochondrial diseases.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1352" xmlns="http://purl.org/rss/1.0/"><title>The Sox2-Oct4 Connection: Critical players in a much larger Interdependent Network Integrated at Multiple Levels</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1352</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The Sox2-Oct4 Connection: Critical players in a much larger Interdependent Network Integrated at Multiple Levels</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Angie Rizzino</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-08T21:25:47.383194-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1352</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1352</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1352</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The transcription factors Sox2 and Oct4 have been a major focus of stem cell biology since the discovery, more than 10 years ago, that they play critical roles during embryogenesis. Early work established that these two transcription factors work together to regulate genes required for the self-renewal and pluripotency of embryonic stem cells (ESC). Surprisingly, small changes (∼2-fold) in the levels of either Oct4 or Sox2 induces the differentiation of ESC. Consequently, ESC must maintain the levels of these two transcription factors within narrow limits. Genome-wide binding studies and unbiased proteomic screens have been conducted to decipher the complex roles played by Oct4 and Sox2 in the transcriptional circuitry of ESC. Together, these and other studies provide a comprehensive understanding of the molecular machinery that sustains the self-renewal of ESC and restrains their differentiation. Importantly, these studies paint a landscape in which Oct4 and Sox2 are part of a much larger interdependent network composed of many transcription factors that are interconnected at multiple levels of function.</p></div>
]]></content:encoded><description>

The transcription factors Sox2 and Oct4 have been a major focus of stem cell biology since the discovery, more than 10 years ago, that they play critical roles during embryogenesis. Early work established that these two transcription factors work together to regulate genes required for the self-renewal and pluripotency of embryonic stem cells (ESC). Surprisingly, small changes (∼2-fold) in the levels of either Oct4 or Sox2 induces the differentiation of ESC. Consequently, ESC must maintain the levels of these two transcription factors within narrow limits. Genome-wide binding studies and unbiased proteomic screens have been conducted to decipher the complex roles played by Oct4 and Sox2 in the transcriptional circuitry of ESC. Together, these and other studies provide a comprehensive understanding of the molecular machinery that sustains the self-renewal of ESC and restrains their differentiation. Importantly, these studies paint a landscape in which Oct4 and Sox2 are part of a much larger interdependent network composed of many transcription factors that are interconnected at multiple levels of function.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1349" xmlns="http://purl.org/rss/1.0/"><title>Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma-initiating Cells that Infiltrate Peritumoral Tissue</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1349</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cellular Plasticity Confers Migratory and Invasive Advantages to a Population of Glioblastoma-initiating Cells that Infiltrate Peritumoral Tissue</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patricia Ruiz-Ontañon, Jose L. Orgaz, Beatriz Aldaz, Alberto Elosegui-Artola, Juan Martino, Maria T. Berciano, Juan A. Montero, Lara Grande, Lorena Nogueira, Santiago Diaz-Moralli, Azucena Esparís-Ogando, Alfonso Vazquez-Barquero, Miguel Lafarga, Atanasio Pandiella, Marta Cascante, Victor Segura, Jose A. Martinez-Climent, Victoria Sanz-Moreno, Jose L. Fernandez-Luna</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-08T21:25:14.075344-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1349</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1349</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1349</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Glioblastoma (GBM) is associated with infiltration of peritumoral parenchyma by isolated tumor cells that leads to tumor regrowth. Recently, GBM stem-like or initiating cells (GICs) have been identified in the peritumoral (PT) area, but whether these GICs have enhanced migratory and invasive capabilities compared with GICs from the tumor mass (TM) is presently unknown. We isolated GICs from the infiltrated PT tissue and the TM of three patients and found that PT cells have an advantage over TM cells in 2D and 3D migration and invasion assays. Interestingly, PT cells display a high plasticity in protrusion formation and cell shape and their migration is insensitive to substrate stiffness, which represent advantages to infiltrate microenvironments of different rigidity. Furthermore, mouse and chicken embryo xenografts revealed that only PT cells showed a dispersed distribution pattern, closely associated to blood vessels. Consistent with cellular plasticity, simultaneous Rac and RhoA activation is required for the enhanced invasive capacity of PT cells. Moreover, Rho GTPase signaling modulators αVβ3 and p27 play key roles in GIC invasiveness. Of note, p27 is upregulated in TM cells and inhibits RhoA activity. Gene silencing of p27 increased the invasive capacity of TM GICs. Additionally, β3 integrin is upregulated in PT cells. Blockade of dimeric integrin αVβ3, a Rac activator, reduced the invasive capacity of PT GICs in vitro and abrogated the spreading of PT cells into chicken embryos. Thus, our results describe the invasive features acquired by a unique subpopulation of GICs that infiltrate neighbouring tissue.</p></div>
]]></content:encoded><description>

Glioblastoma (GBM) is associated with infiltration of peritumoral parenchyma by isolated tumor cells that leads to tumor regrowth. Recently, GBM stem-like or initiating cells (GICs) have been identified in the peritumoral (PT) area, but whether these GICs have enhanced migratory and invasive capabilities compared with GICs from the tumor mass (TM) is presently unknown. We isolated GICs from the infiltrated PT tissue and the TM of three patients and found that PT cells have an advantage over TM cells in 2D and 3D migration and invasion assays. Interestingly, PT cells display a high plasticity in protrusion formation and cell shape and their migration is insensitive to substrate stiffness, which represent advantages to infiltrate microenvironments of different rigidity. Furthermore, mouse and chicken embryo xenografts revealed that only PT cells showed a dispersed distribution pattern, closely associated to blood vessels. Consistent with cellular plasticity, simultaneous Rac and RhoA activation is required for the enhanced invasive capacity of PT cells. Moreover, Rho GTPase signaling modulators αVβ3 and p27 play key roles in GIC invasiveness. Of note, p27 is upregulated in TM cells and inhibits RhoA activity. Gene silencing of p27 increased the invasive capacity of TM GICs. Additionally, β3 integrin is upregulated in PT cells. Blockade of dimeric integrin αVβ3, a Rac activator, reduced the invasive capacity of PT GICs in vitro and abrogated the spreading of PT cells into chicken embryos. Thus, our results describe the invasive features acquired by a unique subpopulation of GICs that infiltrate neighbouring tissue.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1355" xmlns="http://purl.org/rss/1.0/"><title>In vivo Imaging of the Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1355</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">In vivo Imaging of the Therapeutic Efficacy and Fate of Bimodal Engineered Stem Cells in Malignant Brain Tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jordi Martinez-Quintanilla, Deepak Bhere, Pedram Heidari, Derek He, Umar Mahmood, Khalid Shah</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-06T23:29:21.479463-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1355</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1355</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1355</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Translational And Clinical Research</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Therapeutically engineered stem cells (SC) are emerging as a very effective tumor specific therapeutic approach for different cancer types. However, the assessment of the long-term fate of therapeutic SC post-tumor treatment is critical if such promising therapies are to be increasingly translated into clinical practice. In this study, we have developed an efficient stem cell based therapeutic strategy that simultaneously allows killing of tumor cells and assessment and eradication of SC post highly malignant glioblastoma multiforme (GBM) brain tumor treatment. Mesenchymal stem cells (MSC) engineered to co-express the prodrug converting enzyme, herpes simplex virus thymidine kinase (HSV-TK) and a potent and secretable variant of tumor necrosis factor apoptosis-inducing ligand (S-TRAIL) induced caspase mediated GBM cell death and showed selective MSC sensitization to the prodrug ganciclovir (GCV). A significant decrease in tumor growth and a subsequent increase in survival were observed when mice bearing a highly aggressive GBM were treated with MSC co-expressing S-TRAIL and HSV-TK. Furthermore, the systemic administration of GCV post-tumor treatment selectively eliminated therapeutic MSC expressing HSV-TK <em>in vitro</em> and <em>in vivo</em>, which was monitored in real time by positron emission-computed tomography (PET) imaging utilizing 18F-FHBG, a substrate for HSV-TK. These findings demonstrate the development and validation of a novel therapeutic strategy that has implications in translating stem cell based therapies in cancer patients.</p></div>
]]></content:encoded><description>

Therapeutically engineered stem cells (SC) are emerging as a very effective tumor specific therapeutic approach for different cancer types. However, the assessment of the long-term fate of therapeutic SC post-tumor treatment is critical if such promising therapies are to be increasingly translated into clinical practice. In this study, we have developed an efficient stem cell based therapeutic strategy that simultaneously allows killing of tumor cells and assessment and eradication of SC post highly malignant glioblastoma multiforme (GBM) brain tumor treatment. Mesenchymal stem cells (MSC) engineered to co-express the prodrug converting enzyme, herpes simplex virus thymidine kinase (HSV-TK) and a potent and secretable variant of tumor necrosis factor apoptosis-inducing ligand (S-TRAIL) induced caspase mediated GBM cell death and showed selective MSC sensitization to the prodrug ganciclovir (GCV). A significant decrease in tumor growth and a subsequent increase in survival were observed when mice bearing a highly aggressive GBM were treated with MSC co-expressing S-TRAIL and HSV-TK. Furthermore, the systemic administration of GCV post-tumor treatment selectively eliminated therapeutic MSC expressing HSV-TK in vitro and in vivo, which was monitored in real time by positron emission-computed tomography (PET) imaging utilizing 18F-FHBG, a substrate for HSV-TK. These findings demonstrate the development and validation of a novel therapeutic strategy that has implications in translating stem cell based therapies in cancer patients.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1350" xmlns="http://purl.org/rss/1.0/"><title>Targeting the Cytosolic Innate Immune Receptors RIG-I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1350</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Targeting the Cytosolic Innate Immune Receptors RIG-I and MDA5 Effectively Counteracts Cancer Cell Heterogeneity in Glioblastoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin Glas, Christoph Coch, Daniel Trageser, Juliane Daßler, Matthias Simon, Philipp Koch, Jerome Mertens, Tamara Quandel, Raphaela Gorris, Roman Reinartz, Anja Wieland, Marec von Lehe, Annette Pusch, Kristin Roy, Martin Schlee, Harald Neumann, Rolf Fimmers, Ulrich Herrlinger, Oliver Brüstle, Gunther Hartmann, Robert Besch, Björn Scheffler</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-06T23:27:31.885083-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1350</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1350</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1350</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Cellular heterogeneity, e.g. the intratumoral coexistence of cancer cells with and without stem cell characteristics, represents a potential root of therapeutic resistance and a significant challenge for modern drug development in glioblastoma (GBM). We propose here that activation of the innate immune system by stimulation of innate immune receptors involved in antiviral and antitumor responses can similarly target different malignant populations of glioma cells. We used short-term expanded patient-specific primary human GBM cells to study the stimulation of the cytosolic nucleic acid receptors melanoma differentiation-associated gene 5 (MDA5) and retinoic acid-inducible gene I (RIG-I). Specifically, we analyzed cells from the tumor core vs. ‘residual GBM cells’ derived from the tumor resection margin as well as stem cell-enriched primary cultures vs. specimens without stem cell properties. A portfolio of human, non-tumor neural cells was used as a control for these studies. The expression of RIG-I and MDA5 could be induced in all of these cells. Receptor stimulation with their respective ligands, p(I:C) and 3pRNA, led to <em>in vitro</em> evidence for an effective activation of the innate immune system. Most intriguingly, all investigated cancer cell populations additionally responded with a pronounced induction of apoptotic signaling cascades revealing a second, direct mechanism of antitumor activity. By contrast, p(I:C) and 3pRNA induced only little toxicity in human non-malignant neural cells. Granted that the challenge of effective CNS delivery can be overcome, targeting of RIG-I and MDA5 could thus become a quintessential strategy to encounter heterogeneous cancers in the sophisticated environments of the brain.</p></div>
]]></content:encoded><description>

Cellular heterogeneity, e.g. the intratumoral coexistence of cancer cells with and without stem cell characteristics, represents a potential root of therapeutic resistance and a significant challenge for modern drug development in glioblastoma (GBM). We propose here that activation of the innate immune system by stimulation of innate immune receptors involved in antiviral and antitumor responses can similarly target different malignant populations of glioma cells. We used short-term expanded patient-specific primary human GBM cells to study the stimulation of the cytosolic nucleic acid receptors melanoma differentiation-associated gene 5 (MDA5) and retinoic acid-inducible gene I (RIG-I). Specifically, we analyzed cells from the tumor core vs. ‘residual GBM cells’ derived from the tumor resection margin as well as stem cell-enriched primary cultures vs. specimens without stem cell properties. A portfolio of human, non-tumor neural cells was used as a control for these studies. The expression of RIG-I and MDA5 could be induced in all of these cells. Receptor stimulation with their respective ligands, p(I:C) and 3pRNA, led to in vitro evidence for an effective activation of the innate immune system. Most intriguingly, all investigated cancer cell populations additionally responded with a pronounced induction of apoptotic signaling cascades revealing a second, direct mechanism of antitumor activity. By contrast, p(I:C) and 3pRNA induced only little toxicity in human non-malignant neural cells. Granted that the challenge of effective CNS delivery can be overcome, targeting of RIG-I and MDA5 could thus become a quintessential strategy to encounter heterogeneous cancers in the sophisticated environments of the brain.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1348" xmlns="http://purl.org/rss/1.0/"><title>Preclinical studies on human cell-based therapy in rodent ischemic stroke models: Where are we now after a decade?</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1348</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Preclinical studies on human cell-based therapy in rodent ischemic stroke models: Where are we now after a decade?</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wai Khay Leong, Martin D. Lewis, Simon A. Koblar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-06T23:26:21.654573-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1348</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1348</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1348</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regenerative Medicine</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Stroke, a debilitating brain insult, afflicts millions of individuals globally each year. In the last decade, researchers have investigated cell-based therapy as an alternative strategy to improve neurological outcome following stroke. This concise review critically examines preclinical reports using human adult and fetal stem/progenitor cells in rodent models of ischemic stroke. As we enter the second decade of study we should aim to optimize our collective likelihood to translational success for stroke victims worldwide. We advocate international consensus recommendations be developed for future preclinical research.</p></div>
]]></content:encoded><description>

Stroke, a debilitating brain insult, afflicts millions of individuals globally each year. In the last decade, researchers have investigated cell-based therapy as an alternative strategy to improve neurological outcome following stroke. This concise review critically examines preclinical reports using human adult and fetal stem/progenitor cells in rodent models of ischemic stroke. As we enter the second decade of study we should aim to optimize our collective likelihood to translational success for stroke victims worldwide. We advocate international consensus recommendations be developed for future preclinical research.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1344" xmlns="http://purl.org/rss/1.0/"><title>Wnt and Notch Signals Guide Embryonic Stem Cell Differentiation Into the Intestinal Lineages</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1344</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Wnt and Notch Signals Guide Embryonic Stem Cell Differentiation Into the Intestinal Lineages</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Soichiro Ogaki, Nobuaki Shiraki, Kazuhiko Kume, Shoen Kume</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-02-04T01:41:09.424389-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1344</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1344</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1344</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/Induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">N/A</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The studies of differentiation of mouse or human embryonic stem (ES) cells into specific cell types of the intestinal cells would provide insights to the understanding of intestinal development and ultimately yield cells for the use in future regenerative medicine. Here, using an <em>in vitro</em> differentiation procedure of pluripotent stem cells into definitive endoderm, inductive signals pathways guiding differentiation into intestinal cells was investigated. We found that activation of Wnt/β-catenin and inhibition of Notch signaling pathways, by simultaneous application of 6-bromoindirubin-3′-oxime (BIO), a glycogen synthase kinase (GSK)-3β inhibitor, and DAPT, a known γ-secretase inhibitor, efficiently induced intestinal differentiation of ES cells cultured on feeder cell. BIO and DAPT patterned the definitive endoderm (DE) at graded concentrations. Upon prolonged culture on feeder cells, all four intestinal differentiated cell types, the absorptive enterocytes and three types of secretory cells (goblet cells, enteroendocrine cells, Paneth cells), were efficiently differentiated from mouse and human ES cell-derived intestinal epithelium cells. Further investigation revealed that in the mouse ES cells, fibroblast growth factor (FGF) and bone morphogenetic protein (BMP) signaling act synergistically with BIO and DAPT to potentiate differentiation into the intestinal epithelium. However, in human ES cells, FGF signaling inhibited, and BMP signaling did not affect differentiation into the intestinal epithelium. We concluded that Wnt and Notch signaling function to pattern the anterior-posterior axis of the DE and control intestinal differentiation.</p></div>
]]></content:encoded><description>

The studies of differentiation of mouse or human embryonic stem (ES) cells into specific cell types of the intestinal cells would provide insights to the understanding of intestinal development and ultimately yield cells for the use in future regenerative medicine. Here, using an in vitro differentiation procedure of pluripotent stem cells into definitive endoderm, inductive signals pathways guiding differentiation into intestinal cells was investigated. We found that activation of Wnt/β-catenin and inhibition of Notch signaling pathways, by simultaneous application of 6-bromoindirubin-3′-oxime (BIO), a glycogen synthase kinase (GSK)-3β inhibitor, and DAPT, a known γ-secretase inhibitor, efficiently induced intestinal differentiation of ES cells cultured on feeder cell. BIO and DAPT patterned the definitive endoderm (DE) at graded concentrations. Upon prolonged culture on feeder cells, all four intestinal differentiated cell types, the absorptive enterocytes and three types of secretory cells (goblet cells, enteroendocrine cells, Paneth cells), were efficiently differentiated from mouse and human ES cell-derived intestinal epithelium cells. Further investigation revealed that in the mouse ES cells, fibroblast growth factor (FGF) and bone morphogenetic protein (BMP) signaling act synergistically with BIO and DAPT to potentiate differentiation into the intestinal epithelium. However, in human ES cells, FGF signaling inhibited, and BMP signaling did not affect differentiation into the intestinal epithelium. We concluded that Wnt and Notch signaling function to pattern the anterior-posterior axis of the DE and control intestinal differentiation.
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1331" xmlns="http://purl.org/rss/1.0/"><title>Concise Review: Maturation Phases of Human Pluripotent Stem Cell-Derived Cardiomyocytes</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1331</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Concise Review: Maturation Phases of Human Pluripotent Stem Cell-Derived Cardiomyocytes</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Claire Robertson, David D. Tran, Steven C. George</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1331</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1331</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1331</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">829</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">837</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Human pluripotent stem cell-derived cardiomyocytes (hPS-CM) may offer a number of advantages over previous cardiac models, however, questions of their immaturity complicate their adoption as a new in vitro model. hPS-CM differ from adult cardiomyocytes with respect to structure, proliferation, metabolism and electrophysiology, better approximating fetal cardiomyocytes. Time in culture appears to significantly impact phenotype, leading to what can be referred to as early and late hPS-CM. This work surveys the phenotype of hPS-CM, including structure, bioenergetics, sensitivity to damage, gene expression, and electrophysiology, including action potential, ion channels, and intracellular calcium stores, while contrasting fetal and adult CM with hPS-CM at early and late time points after onset of differentiation. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:829–837</p></div>
]]></content:encoded><description>

Human pluripotent stem cell-derived cardiomyocytes (hPS-CM) may offer a number of advantages over previous cardiac models, however, questions of their immaturity complicate their adoption as a new in vitro model. hPS-CM differ from adult cardiomyocytes with respect to structure, proliferation, metabolism and electrophysiology, better approximating fetal cardiomyocytes. Time in culture appears to significantly impact phenotype, leading to what can be referred to as early and late hPS-CM. This work surveys the phenotype of hPS-CM, including structure, bioenergetics, sensitivity to damage, gene expression, and electrophysiology, including action potential, ion channels, and intracellular calcium stores, while contrasting fetal and adult CM with hPS-CM at early and late time points after onset of differentiation. STEM CELLS 2013;31:829–837
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1340" xmlns="http://purl.org/rss/1.0/"><title>Concise Review: The Dynamics of Induced Pluripotency and Its Behavior Captured in Gene Network Motifs</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1340</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Concise Review: The Dynamics of Induced Pluripotency and Its Behavior Captured in Gene Network Motifs</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mauro J. Muraro, Hermannus Kempe, Pernette J. Verschure</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1340</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1340</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1340</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">838</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">848</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The flexibility of cellular identity is clearly demonstrated by the possibility to reprogram fully differentiated somatic cells to induced pluripotent stem (iPS) cells through forced expression of a set of transcription factors. The generation of iPS cells is of great interest as they provide a tremendous potential for regenerative medicine and an attractive platform to investigate pluripotency. Despite having gathered much attention, the molecular details and responsible gene regulatory networks during the reprogramming process are largely unresolved. In this review, we analyze the sequence and dynamics of reprogramming to construct a timeline of the molecular events taking place during induced pluripotency. We use this timeline as a road map to explore the distinct phases of the reprogramming process and to suggest gene network motifs that are able to describe its systems behavior. We conclude that the gene networks involved in reprogramming comprise several feedforward loops combined with autoregulatory behavior and one or more AND gate motifs that can explain the observed dynamics of induced pluripotency. Our proposed timeline and derived gene network motif behavior could serve as a tool to understand the systems behavior of reprogramming and identify key transitions and/or transcription factors that influence somatic cell reprogramming. Such a systems biology strategy could provide ways to define and explore the use of additional regulatory factors acting at defined gene network motifs to potentially overcome the current challenges of inefficient, slow, and partial somatic cell reprogramming and hence set ground of using iPS cells for clinical and therapeutic use. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:838–848</p></div>
]]></content:encoded><description>

The flexibility of cellular identity is clearly demonstrated by the possibility to reprogram fully differentiated somatic cells to induced pluripotent stem (iPS) cells through forced expression of a set of transcription factors. The generation of iPS cells is of great interest as they provide a tremendous potential for regenerative medicine and an attractive platform to investigate pluripotency. Despite having gathered much attention, the molecular details and responsible gene regulatory networks during the reprogramming process are largely unresolved. In this review, we analyze the sequence and dynamics of reprogramming to construct a timeline of the molecular events taking place during induced pluripotency. We use this timeline as a road map to explore the distinct phases of the reprogramming process and to suggest gene network motifs that are able to describe its systems behavior. We conclude that the gene networks involved in reprogramming comprise several feedforward loops combined with autoregulatory behavior and one or more AND gate motifs that can explain the observed dynamics of induced pluripotency. Our proposed timeline and derived gene network motif behavior could serve as a tool to understand the systems behavior of reprogramming and identify key transitions and/or transcription factors that influence somatic cell reprogramming. Such a systems biology strategy could provide ways to define and explore the use of additional regulatory factors acting at defined gene network motifs to potentially overcome the current challenges of inefficient, slow, and partial somatic cell reprogramming and hence set ground of using iPS cells for clinical and therapeutic use. STEM CELLS 2013;31:838–848
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1342" xmlns="http://purl.org/rss/1.0/"><title>Concise Review: Early Embryonic Erythropoiesis: Not so Primitive After All</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1342</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Concise Review: Early Embryonic Erythropoiesis: Not so Primitive After All</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Margaret H. Baron</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1342</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1342</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1342</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Regenerative Medicine</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">849</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">856</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>In the developing embryo, hematopoiesis begins with the formation of primitive erythroid cells (EryP), a distinct and transient red blood cell lineage. EryP play a vital role in oxygen delivery and in generating shear forces necessary for normal vascular development. Progenitors for EryP arise as a cohort within the blood islands of the mammalian yolk sac at the end of gastrulation. As a strong heartbeat is established, nucleated erythroblasts begin to circulate and to mature in a stepwise, nearly synchronous manner. Until relatively recently, these cells were thought to be “primitive” in that they seemed to more closely resemble the nucleated erythroid cells of lower vertebrates than the enucleated erythrocytes of mammals. It is now known that mammalian EryP do enucleate, but not until several days after entering the bloodstream. I will summarize the common and distinguishing characteristics of primitive versus definitive (adult-type) erythroid cells, review the development of EryP from the emergence of their progenitors through maturation and enucleation, and discuss pluripotent stem cells as models for erythropoiesis. Erythroid differentiation of both mouse and human pluripotent stem cells in vitro has thus far reproduced early but not late red blood cell ontogeny. Therefore, a deeper understanding of cellular and molecular mechanisms underlying the differences and similarities between the embryonic and adult erythroid lineages will be critical to improving methods for production of red blood cells for use in the clinic. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:849–856</p></div>
]]></content:encoded><description>

In the developing embryo, hematopoiesis begins with the formation of primitive erythroid cells (EryP), a distinct and transient red blood cell lineage. EryP play a vital role in oxygen delivery and in generating shear forces necessary for normal vascular development. Progenitors for EryP arise as a cohort within the blood islands of the mammalian yolk sac at the end of gastrulation. As a strong heartbeat is established, nucleated erythroblasts begin to circulate and to mature in a stepwise, nearly synchronous manner. Until relatively recently, these cells were thought to be “primitive” in that they seemed to more closely resemble the nucleated erythroid cells of lower vertebrates than the enucleated erythrocytes of mammals. It is now known that mammalian EryP do enucleate, but not until several days after entering the bloodstream. I will summarize the common and distinguishing characteristics of primitive versus definitive (adult-type) erythroid cells, review the development of EryP from the emergence of their progenitors through maturation and enucleation, and discuss pluripotent stem cells as models for erythropoiesis. Erythroid differentiation of both mouse and human pluripotent stem cells in vitro has thus far reproduced early but not late red blood cell ontogeny. Therefore, a deeper understanding of cellular and molecular mechanisms underlying the differences and similarities between the embryonic and adult erythroid lineages will be critical to improving methods for production of red blood cells for use in the clinic. STEM CELLS 2013;31:849–856
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1317" xmlns="http://purl.org/rss/1.0/"><title>CD133 Is Essential for Glioblastoma Stem Cell Maintenance</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1317</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CD133 Is Essential for Glioblastoma Stem Cell Maintenance</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paola Brescia, Barbara Ortensi, Lorenzo Fornasari, Daniel Levi, Giovanni Broggi, Giuliana Pelicci</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1317</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1317</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1317</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">857</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">869</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The role of the cell surface CD133 as a cancer stem cell marker in glioblastoma (GBM) has been widely investigated, since it identifies cells that are able to initiate neurosphere growth and form heterogeneous tumors when transplanted in immune-compromised mice. However, evidences of CD133-negative cells exhibiting similar properties have also been reported. Moreover, the functional role of CD133 in cancer stem/progenitor cells remains poorly understood. We studied the biological effects of CD133 downregulation in GBM patient-derived neurospheres. Our results indicate that there is not a hierarchical relation between CD133-positive and CD133-negative cells composing the neurospheres. Indeed, CD133 appears in an interconvertible state, changing its subcellular localization between the cytoplasm and the plasmamembrane of neurosphere cells. Silencing of CD133 in human GBM neurospheres using lentivirus-mediated short hairpin RNA impairs the self-renewal and tumorigenic capacity of neurosphere cells. These results imply that CD133 could be used as a therapeutic target in GBMs. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:857–869</p></div>
]]></content:encoded><description>

The role of the cell surface CD133 as a cancer stem cell marker in glioblastoma (GBM) has been widely investigated, since it identifies cells that are able to initiate neurosphere growth and form heterogeneous tumors when transplanted in immune-compromised mice. However, evidences of CD133-negative cells exhibiting similar properties have also been reported. Moreover, the functional role of CD133 in cancer stem/progenitor cells remains poorly understood. We studied the biological effects of CD133 downregulation in GBM patient-derived neurospheres. Our results indicate that there is not a hierarchical relation between CD133-positive and CD133-negative cells composing the neurospheres. Indeed, CD133 appears in an interconvertible state, changing its subcellular localization between the cytoplasm and the plasmamembrane of neurosphere cells. Silencing of CD133 in human GBM neurospheres using lentivirus-mediated short hairpin RNA impairs the self-renewal and tumorigenic capacity of neurosphere cells. These results imply that CD133 could be used as a therapeutic target in GBMs. STEM CELLS 2013;31:857–869
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1322" xmlns="http://purl.org/rss/1.0/"><title>Tumor-Specific Activation of the C-JUN/MELK Pathway Regulates Glioma Stem Cell Growth in a p53-Dependent Manner</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1322</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tumor-Specific Activation of the C-JUN/MELK Pathway Regulates Glioma Stem Cell Growth in a p53-Dependent Manner</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chunyu Gu, Yeshavanth K. Banasavadi-Siddegowda, Kaushal Joshi, Yuko Nakamura, Habibe Kurt, Snehalata Gupta, Ichiro Nakano</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1322</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1322</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1322</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">870</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">881</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Accumulated evidence suggests that glioma stem cells (GSCs) may contribute to therapy resistance in high-grade glioma (HGG). Although recent studies have shown that the serine/threonine kinase maternal embryonic leucine-zipper kinase (MELK) is abundantly expressed in various cancers, the function and mechanism of MELK remain elusive. Here, we demonstrate that MELK depletion by shRNA diminishes the growth of GSC-derived mouse intracranial tumors in vivo, induces glial fibrillary acidic protein (+) glial differentiation of GSCs leading to decreased malignancy of the resulting tumors, and prolongs survival periods of tumor-bearing mice. Tissue microarray analysis with 91 HGG tumors demonstrates that the proportion of MELK (+) cells is a statistically significant indicator of postsurgical survival periods. Mechanistically, MELK is regulated by the c-Jun NH(2)-terminal kinase (JNK) signaling and forms a complex with the oncoprotein c-JUN in GSCs but not in normal progenitors. MELK silencing induces p53 expression, whereas p53 inhibition induces MELK expression, indicating that MELK and p53 expression are mutually exclusive. Additionally, MELK silencing-mediated GSC apoptosis is partially rescued by both pharmacological p53 inhibition and p53 gene silencing, indicating that MELK action in GSCs is p53 dependent. Furthermore, irradiation of GSCs markedly elevates <em>MELK</em> mRNA and protein expression both in vitro and in vivo. Clinically, recurrent HGG tumors following the failure of radiation and chemotherapy exhibit a statistically significant elevation of MELK protein compared with untreated newly diagnosed HGG tumors. Together, our data indicate that GSCs, but not normal cells, depend on JNK-driven MELK/c-JUN signaling to regulate their survival, maintain GSCs in an immature state, and facilitate tumor radioresistance in a p53-dependent manner. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:870–881</p></div>
]]></content:encoded><description>

Accumulated evidence suggests that glioma stem cells (GSCs) may contribute to therapy resistance in high-grade glioma (HGG). Although recent studies have shown that the serine/threonine kinase maternal embryonic leucine-zipper kinase (MELK) is abundantly expressed in various cancers, the function and mechanism of MELK remain elusive. Here, we demonstrate that MELK depletion by shRNA diminishes the growth of GSC-derived mouse intracranial tumors in vivo, induces glial fibrillary acidic protein (+) glial differentiation of GSCs leading to decreased malignancy of the resulting tumors, and prolongs survival periods of tumor-bearing mice. Tissue microarray analysis with 91 HGG tumors demonstrates that the proportion of MELK (+) cells is a statistically significant indicator of postsurgical survival periods. Mechanistically, MELK is regulated by the c-Jun NH(2)-terminal kinase (JNK) signaling and forms a complex with the oncoprotein c-JUN in GSCs but not in normal progenitors. MELK silencing induces p53 expression, whereas p53 inhibition induces MELK expression, indicating that MELK and p53 expression are mutually exclusive. Additionally, MELK silencing-mediated GSC apoptosis is partially rescued by both pharmacological p53 inhibition and p53 gene silencing, indicating that MELK action in GSCs is p53 dependent. Furthermore, irradiation of GSCs markedly elevates MELK mRNA and protein expression both in vitro and in vivo. Clinically, recurrent HGG tumors following the failure of radiation and chemotherapy exhibit a statistically significant elevation of MELK protein compared with untreated newly diagnosed HGG tumors. Together, our data indicate that GSCs, but not normal cells, depend on JNK-driven MELK/c-JUN signaling to regulate their survival, maintain GSCs in an immature state, and facilitate tumor radioresistance in a p53-dependent manner. STEM CELLS 2013;31:870–881
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1345" xmlns="http://purl.org/rss/1.0/"><title>Lmo2 Induces Hematopoietic Stem Cell-Like Features in T-Cell Progenitor Cells Prior to Leukemia</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1345</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Lmo2 Induces Hematopoietic Stem Cell-Like Features in T-Cell Progenitor Cells Prior to Leukemia</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susan M. Cleveland, Stephen Smith, Rati Tripathi, Elizabeth M. Mathias, Charnise Goodings, Natalina Elliott, Dunfa Peng, Wael El-Rifai, Dajun Yi, Xi Chen, Liqi Li, Charles Mullighan, James R. Downing, Paul Love, Utpal P. Davé</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1345</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1345</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1345</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Cancer Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">882</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">894</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>LIM domain only 2</em> (<em>Lmo2</em>) is frequently deregulated in sporadic and gene therapy-induced acute T-cell lymphoblastic leukemia (T-ALL) where its overexpression is an important initiating mutational event. In transgenic and retroviral mouse models, <em>Lmo2</em> expression can be enforced in multiple hematopoietic lineages but leukemia only arises from T cells. These data suggest that <em>Lmo2</em> confers clonal growth advantage in T-cell progenitors. We analyzed proliferation, differentiation, and cell death in <em>CD2-Lmo2</em> transgenic thymic progenitor cells to understand the cellular effects of enforced <em>Lmo2</em> expression. Most impressively, <em>Lmo2</em> transgenic T-cell progenitor cells were blocked in differentiation, quiescent, and immortalized in vitro on OP9-DL1 stromal cells. These cellular effects were concordant with a transcriptional signature in <em>Lmo2</em> transgenic T-cell progenitor cells that is also present in hematopoietic stem cells (HSCs) and early T-cell precursor ALL. These results are significant in light of the crucial role of <em>Lmo2</em> in the maintenance of the HSC. The cellular effects and transcriptional effects have implications for <em>LMO2</em>-dependent leukemogenesis and the treatment of <em>LMO2</em>-induced T-ALL. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:882–894</p></div>
]]></content:encoded><description>

LIM domain only 2 (Lmo2) is frequently deregulated in sporadic and gene therapy-induced acute T-cell lymphoblastic leukemia (T-ALL) where its overexpression is an important initiating mutational event. In transgenic and retroviral mouse models, Lmo2 expression can be enforced in multiple hematopoietic lineages but leukemia only arises from T cells. These data suggest that Lmo2 confers clonal growth advantage in T-cell progenitors. We analyzed proliferation, differentiation, and cell death in CD2-Lmo2 transgenic thymic progenitor cells to understand the cellular effects of enforced Lmo2 expression. Most impressively, Lmo2 transgenic T-cell progenitor cells were blocked in differentiation, quiescent, and immortalized in vitro on OP9-DL1 stromal cells. These cellular effects were concordant with a transcriptional signature in Lmo2 transgenic T-cell progenitor cells that is also present in hematopoietic stem cells (HSCs) and early T-cell precursor ALL. These results are significant in light of the crucial role of Lmo2 in the maintenance of the HSC. The cellular effects and transcriptional effects have implications for LMO2-dependent leukemogenesis and the treatment of LMO2-induced T-ALL. STEM CELLS 2013;31:882–894
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1323" xmlns="http://purl.org/rss/1.0/"><title>Dynamic Migration and Cell-Cell Interactions of Early Reprogramming Revealed by High-Resolution Time-Lapse Imaging</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1323</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Dynamic Migration and Cell-Cell Interactions of Early Reprogramming Revealed by High-Resolution Time-Lapse Imaging</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cynthia M. Megyola, Yuan Gao, Alexandra M. Teixeira, Jijun Cheng, Kartoosh Heydari, Ee-Chun Cheng, Timothy Nottoli, Diane S. Krause, Jun Lu, Shangqin Guo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1323</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1323</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1323</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">895</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">905</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Discovery of the cellular and molecular mechanisms of induced pluripotency has been hampered by its low efficiency and slow kinetics. Here, we report an experimental system with multicolor time-lapse microscopy that permits direct observation of pluripotency induction at single cell resolution, with temporal intervals as short as 5 minutes. Using granulocyte-monocyte progenitors as source cells, we visualized nascent pluripotent cells that emerge from a hematopoietic state. We engineered a suite of image processing and analysis software to annotate the behaviors of the reprogramming cells, which revealed the highly dynamic cell-cell interactions associated with early reprogramming. We observed frequent cell migration, which can lead to sister colonies, satellite colonies, and colonies of mixed genetic makeup. In addition, we discovered a previously unknown morphologically distinct two-cell intermediate of reprogramming, which occurs prior to other reprogramming landmarks. By directly visualizing the reprogramming process with E-cadherin inhibition, we demonstrate that E-cadherin is required for proper cellular interactions from an early stage of reprogramming, including the two-cell intermediate. The detailed cell-cell interactions revealed by this imaging platform shed light on previously unappreciated early reprogramming dynamics. This experimental system could serve as a powerful tool to dissect the complex mechanisms of early reprogramming by focusing on the relevant but rare cells with superb temporal and spatial resolution. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:895–905</p></div>
]]></content:encoded><description>

Discovery of the cellular and molecular mechanisms of induced pluripotency has been hampered by its low efficiency and slow kinetics. Here, we report an experimental system with multicolor time-lapse microscopy that permits direct observation of pluripotency induction at single cell resolution, with temporal intervals as short as 5 minutes. Using granulocyte-monocyte progenitors as source cells, we visualized nascent pluripotent cells that emerge from a hematopoietic state. We engineered a suite of image processing and analysis software to annotate the behaviors of the reprogramming cells, which revealed the highly dynamic cell-cell interactions associated with early reprogramming. We observed frequent cell migration, which can lead to sister colonies, satellite colonies, and colonies of mixed genetic makeup. In addition, we discovered a previously unknown morphologically distinct two-cell intermediate of reprogramming, which occurs prior to other reprogramming landmarks. By directly visualizing the reprogramming process with E-cadherin inhibition, we demonstrate that E-cadherin is required for proper cellular interactions from an early stage of reprogramming, including the two-cell intermediate. The detailed cell-cell interactions revealed by this imaging platform shed light on previously unappreciated early reprogramming dynamics. This experimental system could serve as a powerful tool to dissect the complex mechanisms of early reprogramming by focusing on the relevant but rare cells with superb temporal and spatial resolution. STEM CELLS 2013;31:895–905
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1324" xmlns="http://purl.org/rss/1.0/"><title>Functional Involvements of Heterogeneous Nuclear Ribonucleoprotein A1 in Smooth Muscle Differentiation from Stem Cells In Vitro and In Vivo</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1324</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Functional Involvements of Heterogeneous Nuclear Ribonucleoprotein A1 in Smooth Muscle Differentiation from Stem Cells In Vitro and In Vivo</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuan Huang, Luyang Lin, Xiaotian Yu, Guanmei Wen, Xiangyuan Pu, Hanqing Zhao, Changcun Fang, Jianhua Zhu, Shu Ye, Li Zhang, Qingzhong Xiao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1324</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1324</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1324</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">906</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">917</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>To investigate the functional involvements of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) in smooth muscle cell (SMC) differentiation from stem cells, embryonic stem cells were cultivated on collagen IV-coated plates to allow for SMC differentiation. We found that hnRNPA1 gene and protein expression was upregulated significantly during differentiation and coexpressed with SMC differentiation markers in the stem cell-derived SMCs as well as embryonic SMCs of 12.5 days of mouse embryos. hnRNPA1 knockdown resulted in downregulation of smooth muscle markers and transcription factors, while enforced expression of hnRNPA1 enhanced the expression of these genes. Importantly, knockdown of hnRNPA1 also resulted in impairment of SMC differentiation in vivo. Moreover, we demonstrated that hnRNPA1 could transcriptionally regulate SMC gene expression through direct binding to promoters of Acta2 and Tagln genes using luciferase and chromatin immunoprecipitation assays. We further demonstrated that the binding sites for serum response factor (SRF), a well-investigated SMC transcription factor, within the promoter region of the Acta2 and Tagln genes were responsible for hnRNPA1-mediated Acta2 and Tagln gene expression using in vitro site-specific mutagenesis and luciferase activity analyses. Finally, we also demonstrated that hnRNPA1 upregulated the expression of SRF, myocyte-specific enhancer factor 2c (MEF2c), and myocardin through transcriptional activation and direct binding to promoters of the SRF, MEF2c, and Myocd genes. Our findings demonstrated that hnRNPA1 plays a functional role in SMC differentiation from stem cells in vitro and in vivo. This indicates that hnRNPA1 is a potential modulating target for deriving SMCs from stem cells and cardiovascular regenerative medicine. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:906–917</p></div>
]]></content:encoded><description>

To investigate the functional involvements of heterogeneous nuclear ribonucleoprotein A1 (hnRNPA1) in smooth muscle cell (SMC) differentiation from stem cells, embryonic stem cells were cultivated on collagen IV-coated plates to allow for SMC differentiation. We found that hnRNPA1 gene and protein expression was upregulated significantly during differentiation and coexpressed with SMC differentiation markers in the stem cell-derived SMCs as well as embryonic SMCs of 12.5 days of mouse embryos. hnRNPA1 knockdown resulted in downregulation of smooth muscle markers and transcription factors, while enforced expression of hnRNPA1 enhanced the expression of these genes. Importantly, knockdown of hnRNPA1 also resulted in impairment of SMC differentiation in vivo. Moreover, we demonstrated that hnRNPA1 could transcriptionally regulate SMC gene expression through direct binding to promoters of Acta2 and Tagln genes using luciferase and chromatin immunoprecipitation assays. We further demonstrated that the binding sites for serum response factor (SRF), a well-investigated SMC transcription factor, within the promoter region of the Acta2 and Tagln genes were responsible for hnRNPA1-mediated Acta2 and Tagln gene expression using in vitro site-specific mutagenesis and luciferase activity analyses. Finally, we also demonstrated that hnRNPA1 upregulated the expression of SRF, myocyte-specific enhancer factor 2c (MEF2c), and myocardin through transcriptional activation and direct binding to promoters of the SRF, MEF2c, and Myocd genes. Our findings demonstrated that hnRNPA1 plays a functional role in SMC differentiation from stem cells in vitro and in vivo. This indicates that hnRNPA1 is a potential modulating target for deriving SMCs from stem cells and cardiovascular regenerative medicine. STEM CELLS 2013;31:906–917
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1330" xmlns="http://purl.org/rss/1.0/"><title>Clonal Isolation of an Intermediate Pluripotent Stem Cell State</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1330</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clonal Isolation of an Intermediate Pluripotent Stem Cell State</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kuo-Hsuan Chang, Meng Li</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1330</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1330</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1330</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">918</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">927</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Pluripotent stem cells of different embryonic origin respond to distinct signaling pathways. Embryonic stem cells (ESCs), which are derived from the inner cell mass of preimplantation embryos, are dependent on LIF-Stat3 signaling, while epiblast stem cells (EpiSCs), which are established from postimplantation embryos, require activin-Smad2/3 signaling. Recent studies have revealed heterogeneity of ESCs and the presence of intermediate pluripotent stem cell populations, whose responsiveness to growth factors, gene expression patterns, and associated chromatic signatures are compatible to a state in between ESCs and EpiSCs. However, it remains unknown whether such cell populations represent a stable entity at single-cell level. Here, we describe the identification of clonal stem cells from mouse ESCs with global gene expression profiles representing such a state. These pluripotent stem cells display dual responsiveness to LIF-Stat3 and activin-Smad2/3 at single-cell level and thus named as intermediate epiblast stem cells (IESCs). Furthermore, these cells show accelerated temporal gene expression kinetics during embryoid body differentiation in vitro consistent with a more advanced differentiation stage than that of ESCs. The successful isolation of IESCs supports the notion that traverse from naïve ground state toward lineage commitment occurs gradually in which transition milestones can be captured as clonogenic entity. Our finding provides a new model to better understand the multiple pluripotent states. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:918–927</p></div>
]]></content:encoded><description>

Pluripotent stem cells of different embryonic origin respond to distinct signaling pathways. Embryonic stem cells (ESCs), which are derived from the inner cell mass of preimplantation embryos, are dependent on LIF-Stat3 signaling, while epiblast stem cells (EpiSCs), which are established from postimplantation embryos, require activin-Smad2/3 signaling. Recent studies have revealed heterogeneity of ESCs and the presence of intermediate pluripotent stem cell populations, whose responsiveness to growth factors, gene expression patterns, and associated chromatic signatures are compatible to a state in between ESCs and EpiSCs. However, it remains unknown whether such cell populations represent a stable entity at single-cell level. Here, we describe the identification of clonal stem cells from mouse ESCs with global gene expression profiles representing such a state. These pluripotent stem cells display dual responsiveness to LIF-Stat3 and activin-Smad2/3 at single-cell level and thus named as intermediate epiblast stem cells (IESCs). Furthermore, these cells show accelerated temporal gene expression kinetics during embryoid body differentiation in vitro consistent with a more advanced differentiation stage than that of ESCs. The successful isolation of IESCs supports the notion that traverse from naïve ground state toward lineage commitment occurs gradually in which transition milestones can be captured as clonogenic entity. Our finding provides a new model to better understand the multiple pluripotent states. STEM CELLS 2013;31:918–927
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1332" xmlns="http://purl.org/rss/1.0/"><title>The Four and a Half LIM-Domain 2 Controls Early Cardiac Cell Commitment and Expansion Via Regulating β-Catenin-Dependent Transcription</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1332</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">The Four and a Half LIM-Domain 2 Controls Early Cardiac Cell Commitment and Expansion Via Regulating β-Catenin-Dependent Transcription</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anke Renger, Maria-Patapia Zafiriou, Claudia Noack, Elena Pavlova, Alexander Becker, Krasimira Sharkova, Martin W. Bergmann, Ali El-Armouche, Wolfram-Hubertus Zimmermann, Laura C. Zelarayán</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1332</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1332</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1332</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">928</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">940</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>The multiphasic regulation of the Wnt/β-catenin canonical pathway is essential for cardiogenesis in vivo and in vitro. To achieve tight regulation of the Wnt/β-catenin signaling, tissue- and cell-specific coactivators and repressors need to be recruited. The identification of such factors may help to elucidate mechanisms leading to enhanced cardiac differentiation efficiency in vitro as well as promote regeneration in vivo. Using a yeast-two-hybrid screen, we identified four-and-a-half-LIM-domain 2 (FHL2) as a cardiac-specific β-catenin interaction partner and activator of Wnt/β-catenin-dependent transcription. We analyzed the role of this interaction for early cardiogenesis in an in vitro model by making use of embryoid body cultures from mouse embryonic stem cells (ESCs). In this model, stable FHL2 gain-of-function promoted mesodermal cell formation and cell proliferation while arresting cardiac differentiation in an early cardiogenic mesodermal progenitor state. Mechanistically, FHL2 overexpression enhanced nuclear accumulation of β-catenin and activated Wnt/β-catenin-dependent transcription leading to sustained upregulation of the early cardiogenic gene Igfbp5. In an alternative P19 cell model, transient FHL2 overexpression led to early activation of Wnt/β-catenin-dependent transcription, but not sustained high-level of Igfbp5 expression. This resulted in enhanced cardiogenesis. We propose that early Wnt/β-catenin-dependent transcriptional activation mediated by FHL2 is important for the transition to and expansion of early cardiogenic mesodermal cells. Collectively, our findings offer mechanistic insight into the early cardiogenic code and may be further exploited to enhance cardiac progenitor cell activity in vitro and in vivo. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:928–940</p></div>
]]></content:encoded><description>

The multiphasic regulation of the Wnt/β-catenin canonical pathway is essential for cardiogenesis in vivo and in vitro. To achieve tight regulation of the Wnt/β-catenin signaling, tissue- and cell-specific coactivators and repressors need to be recruited. The identification of such factors may help to elucidate mechanisms leading to enhanced cardiac differentiation efficiency in vitro as well as promote regeneration in vivo. Using a yeast-two-hybrid screen, we identified four-and-a-half-LIM-domain 2 (FHL2) as a cardiac-specific β-catenin interaction partner and activator of Wnt/β-catenin-dependent transcription. We analyzed the role of this interaction for early cardiogenesis in an in vitro model by making use of embryoid body cultures from mouse embryonic stem cells (ESCs). In this model, stable FHL2 gain-of-function promoted mesodermal cell formation and cell proliferation while arresting cardiac differentiation in an early cardiogenic mesodermal progenitor state. Mechanistically, FHL2 overexpression enhanced nuclear accumulation of β-catenin and activated Wnt/β-catenin-dependent transcription leading to sustained upregulation of the early cardiogenic gene Igfbp5. In an alternative P19 cell model, transient FHL2 overexpression led to early activation of Wnt/β-catenin-dependent transcription, but not sustained high-level of Igfbp5 expression. This resulted in enhanced cardiogenesis. We propose that early Wnt/β-catenin-dependent transcriptional activation mediated by FHL2 is important for the transition to and expansion of early cardiogenic mesodermal cells. Collectively, our findings offer mechanistic insight into the early cardiogenic code and may be further exploited to enhance cardiac progenitor cell activity in vitro and in vivo. STEM CELLS 2013;31:928–940
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1334" xmlns="http://purl.org/rss/1.0/"><title>Efficient Generation of Astrocytes from Human Pluripotent Stem Cells in Defined Conditions</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1334</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Efficient Generation of Astrocytes from Human Pluripotent Stem Cells in Defined Conditions</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Atossa Shaltouki, Jun Peng, Qiuyue Liu, Mahendra S. Rao, Xianmin Zeng</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1334</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1334</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1334</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">941</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">952</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Astrocytes can be generated from various tissue sources including human pluripotent stem cells (PSC). In this manuscript, we describe a chemically defined xeno-free medium culture system for rapidly generating astrocytes from neural stem cells derived from PSC. We show that astrocyte development <em>in vitro</em>, mimics normal development <em>in vivo</em>, and also passes through a CD44<sup>+</sup> astrocyte precursor stage. Astrocytes generated by our method display similar gene expression patterns, morphological characteristics and functional properties to primary astrocytes, and they survive and integrate after xenotransplantation. Whole genome expression profiling of astrocyte differentiation was performed at several time points of differentiation, and the results indicate the importance of known regulators and identify potential novel regulators and stage-specific lineage markers. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:941–952</p></div>
]]></content:encoded><description>

Astrocytes can be generated from various tissue sources including human pluripotent stem cells (PSC). In this manuscript, we describe a chemically defined xeno-free medium culture system for rapidly generating astrocytes from neural stem cells derived from PSC. We show that astrocyte development in vitro, mimics normal development in vivo, and also passes through a CD44+ astrocyte precursor stage. Astrocytes generated by our method display similar gene expression patterns, morphological characteristics and functional properties to primary astrocytes, and they survive and integrate after xenotransplantation. Whole genome expression profiling of astrocyte differentiation was performed at several time points of differentiation, and the results indicate the importance of known regulators and identify potential novel regulators and stage-specific lineage markers. STEM CELLS 2013;31:941–952
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1335" xmlns="http://purl.org/rss/1.0/"><title>Regulation of L-Threonine Dehydrogenase in Somatic Cell Reprogramming</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1335</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Regulation of L-Threonine Dehydrogenase in Somatic Cell Reprogramming</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chuanchun Han, Hao Gu, Jiaxu Wang, Weiguang Lu, Yide Mei, Mian Wu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1335</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1335</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1335</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">953</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">965</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Increasing evidence suggests that metabolic remodeling plays an important role in the regulation of somatic cell reprogramming. Threonine catabolism mediated by <span class="smallCaps">L</span>-threonine dehydrogenase (TDH) has been recognized as a specific metabolic trait of mouse embryonic stem cells. However, it remains unknown whether TDH-mediated threonine catabolism could regulate reprogramming. Here, we report TDH as a novel regulator of somatic cell reprogramming. Knockdown of TDH inhibits, whereas induction of TDH enhances reprogramming efficiency. Moreover, microRNA-9 post-transcriptionally regulates the expression of TDH and thereby inhibits reprogramming efficiency. Furthermore, protein arginine methyltransferase (PRMT5) interacts with TDH and mediates its post-translational arginine methylation. PRMT5 appears to regulate TDH enzyme activity through both methyltransferase-dependent and -independent mechanisms. Functionally, TDH-facilitated reprogramming efficiency is further enhanced by PRMT5. These results suggest that TDH-mediated threonine catabolism controls somatic cell reprogramming and indicate the importance of post-transcriptional and post-translational regulation of TDH. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:953–965</p></div>
]]></content:encoded><description>

Increasing evidence suggests that metabolic remodeling plays an important role in the regulation of somatic cell reprogramming. Threonine catabolism mediated by L-threonine dehydrogenase (TDH) has been recognized as a specific metabolic trait of mouse embryonic stem cells. However, it remains unknown whether TDH-mediated threonine catabolism could regulate reprogramming. Here, we report TDH as a novel regulator of somatic cell reprogramming. Knockdown of TDH inhibits, whereas induction of TDH enhances reprogramming efficiency. Moreover, microRNA-9 post-transcriptionally regulates the expression of TDH and thereby inhibits reprogramming efficiency. Furthermore, protein arginine methyltransferase (PRMT5) interacts with TDH and mediates its post-translational arginine methylation. PRMT5 appears to regulate TDH enzyme activity through both methyltransferase-dependent and -independent mechanisms. Functionally, TDH-facilitated reprogramming efficiency is further enhanced by PRMT5. These results suggest that TDH-mediated threonine catabolism controls somatic cell reprogramming and indicate the importance of post-transcriptional and post-translational regulation of TDH. STEM CELLS 2013;31:953–965
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1339" xmlns="http://purl.org/rss/1.0/"><title>Hypoxia Increases the Yield of Photoreceptors Differentiating from Mouse Embryonic Stem Cells and Improves the Modeling of Retinogenesis In Vitro</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1339</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hypoxia Increases the Yield of Photoreceptors Differentiating from Mouse Embryonic Stem Cells and Improves the Modeling of Retinogenesis In Vitro</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcela Garita-HernÁndez, Francisco Diaz-Corrales, Dunja Lukovic, Irene GonzÁlez-Guede, Andrea Diez-Lloret, M. Lourdes ValdÉs-SÁnchez, Simone Massalini, Slaven Erceg, Shomi S. Bhattacharya</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1339</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1339</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1339</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">966</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">978</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Retinitis pigmentosa (RP), a genetically heterogeneous group of diseases together with age-related macular degeneration (AMD), are the leading causes of permanent blindness and are characterized by the progressive dysfunction and death of the light sensing photoreceptors of the retina. Due to the limited regeneration capacity of the mammalian retina, the scientific community has invested significantly in trying to obtain retinal progenitor cells from embryonic stem cells (ESC). These represent an unlimited source of retinal cells, but it has not yet been possible to achieve specific populations, such as photoreceptors, efficiently enough to allow them to be used safely in the future as cell therapy of RP or AMD. In this study, we generated a high yield of photoreceptors from directed differentiation of mouse ESC (mESC) by recapitulating crucial phases of retinal development. We present a new protocol of differentiation, involving hypoxia and taking into account extrinsic and intrinsic cues. These include niche-specific conditions as well as the manipulation of the signaling pathways involved in retinal development. Our results show that hypoxia promotes and improves the differentiation of mESC toward photoreceptors. Different populations of retinal cells are increased in number under the hypoxic conditions applied, such as Crx-positive cells, S-Opsin-positive cells, and double positive cells for Rhodopsin and Recoverin, as shown by immunofluorescence analysis. For the first time, this manuscript reports the high efficiency of differentiation in vivo and the expression of mature rod photoreceptor markers in a large number of differentiated cells, transplanted in the subretinal space of wild-type mice. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:966–978</p></div>
]]></content:encoded><description>

Retinitis pigmentosa (RP), a genetically heterogeneous group of diseases together with age-related macular degeneration (AMD), are the leading causes of permanent blindness and are characterized by the progressive dysfunction and death of the light sensing photoreceptors of the retina. Due to the limited regeneration capacity of the mammalian retina, the scientific community has invested significantly in trying to obtain retinal progenitor cells from embryonic stem cells (ESC). These represent an unlimited source of retinal cells, but it has not yet been possible to achieve specific populations, such as photoreceptors, efficiently enough to allow them to be used safely in the future as cell therapy of RP or AMD. In this study, we generated a high yield of photoreceptors from directed differentiation of mouse ESC (mESC) by recapitulating crucial phases of retinal development. We present a new protocol of differentiation, involving hypoxia and taking into account extrinsic and intrinsic cues. These include niche-specific conditions as well as the manipulation of the signaling pathways involved in retinal development. Our results show that hypoxia promotes and improves the differentiation of mESC toward photoreceptors. Different populations of retinal cells are increased in number under the hypoxic conditions applied, such as Crx-positive cells, S-Opsin-positive cells, and double positive cells for Rhodopsin and Recoverin, as shown by immunofluorescence analysis. For the first time, this manuscript reports the high efficiency of differentiation in vivo and the expression of mature rod photoreceptor markers in a large number of differentiated cells, transplanted in the subretinal space of wild-type mice. STEM CELLS 2013;31:966–978
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1341" xmlns="http://purl.org/rss/1.0/"><title>Histone Acetyltransferase Cofactor Trrap Maintains Self-Renewal and Restricts Differentiation of Embryonic Stem Cells</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1341</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Histone Acetyltransferase Cofactor Trrap Maintains Self-Renewal and Restricts Differentiation of Embryonic Stem Cells</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carla Sawan, Hector Hernandez-Vargas, Rabih Murr, Fabrice Lopez, Thomas Vaissière, Akram Y. Ghantous, Cyrille Cuenin, Jean Imbert, Zhao-Qi Wang, Bing Ren, Zdenko Herceg</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1341</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1341</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1341</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">979</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">991</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Chromatin states are believed to play a key role in distinct patterns of gene expression essential for self-renewal and pluripotency of embryonic stem cells (ESCs); however, the genes governing the establishment and propagation of the chromatin signature characteristic of pluripotent cells are poorly understood. Here, we show that conditional deletion of the histone acetyltransferase cofactor Trrap in mouse ESCs triggers unscheduled differentiation associated with loss of histone acetylation, condensation of chromatin into distinct foci (heterochromatization), and uncoupling of H3K4 dimethylation and H3K27 trimethylation. Trrap loss results in downregulation of stemness master genes Nanog, Oct4, and Sox2 and marked upregulation of specific differentiation markers from the three germ layers. Chromatin immunoprecipitation-sequencing analysis of genome-wide binding revealed a significant overlap between Oct4 and Trrap binding in ESCs but not in differentiated mouse embryonic fibroblasts, further supporting a functional interaction between Trrap and Oct4 in the maintenance of stemness. Remarkably, failure to downregulate Trrap prevents differentiation of ESCs, suggesting that downregulation of Trrap may be a critical step guiding transcriptional reprogramming and differentiation of ESCs. These findings establish Trrap as a critical part of the mechanism that restricts differentiation and promotes the maintenance of key features of ESCs. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:979–991</p></div>
]]></content:encoded><description>

Chromatin states are believed to play a key role in distinct patterns of gene expression essential for self-renewal and pluripotency of embryonic stem cells (ESCs); however, the genes governing the establishment and propagation of the chromatin signature characteristic of pluripotent cells are poorly understood. Here, we show that conditional deletion of the histone acetyltransferase cofactor Trrap in mouse ESCs triggers unscheduled differentiation associated with loss of histone acetylation, condensation of chromatin into distinct foci (heterochromatization), and uncoupling of H3K4 dimethylation and H3K27 trimethylation. Trrap loss results in downregulation of stemness master genes Nanog, Oct4, and Sox2 and marked upregulation of specific differentiation markers from the three germ layers. Chromatin immunoprecipitation-sequencing analysis of genome-wide binding revealed a significant overlap between Oct4 and Trrap binding in ESCs but not in differentiated mouse embryonic fibroblasts, further supporting a functional interaction between Trrap and Oct4 in the maintenance of stemness. Remarkably, failure to downregulate Trrap prevents differentiation of ESCs, suggesting that downregulation of Trrap may be a critical step guiding transcriptional reprogramming and differentiation of ESCs. These findings establish Trrap as a critical part of the mechanism that restricts differentiation and promotes the maintenance of key features of ESCs. STEM CELLS 2013;31:979–991
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1338" xmlns="http://purl.org/rss/1.0/"><title>Lgr5-EGFP Marks Taste Bud Stem/Progenitor Cells in Posterior Tongue</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1338</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Lgr5-EGFP Marks Taste Bud Stem/Progenitor Cells in Posterior Tongue</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Karen K. Yee, Yan Li, Kevin M. Redding, Ken Iwatsuki, Robert F. Margolskee, Peihua Jiang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1338</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1338</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1338</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">992</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1000</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Until recently, reliable markers for adult stem cells have been lacking for many regenerative mammalian tissues. Lgr5 (leucine-rich repeat-containing G-protein-coupled receptor 5) has been identified as a marker for adult stem cells in intestine, stomach, and hair follicle; Lgr5-expressing cells give rise to all types of cells in these tissues. Taste epithelium also regenerates constantly, yet the identity of adult taste stem cells remains elusive. In this study, we found that Lgr5 is strongly expressed in cells at the bottom of trench areas at the base of circumvallate (CV) and foliate taste papillae and weakly expressed in the basal area of taste buds and that Lgr5-expressing cells in posterior tongue are a subset of K14-positive epithelial cells. Lineage-tracing experiments using an inducible Cre knockin allele in combination with <em>Rosa26-LacZ</em> and <em>Rosa26-tdTomato</em> reporter strains showed that Lgr5-expressing cells gave rise to taste cells, perigemmal cells, along with self-renewing cells at the bottom of trench areas at the base of CV and foliate papillae. Moreover, using subtype-specific taste markers, we found that Lgr5-expressing cell progeny include all three major types of adult taste cells. Our results indicate that Lgr5 may mark adult taste stem or progenitor cells in the posterior portion of the tongue. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:992–1000</p></div>
]]></content:encoded><description>

Until recently, reliable markers for adult stem cells have been lacking for many regenerative mammalian tissues. Lgr5 (leucine-rich repeat-containing G-protein-coupled receptor 5) has been identified as a marker for adult stem cells in intestine, stomach, and hair follicle; Lgr5-expressing cells give rise to all types of cells in these tissues. Taste epithelium also regenerates constantly, yet the identity of adult taste stem cells remains elusive. In this study, we found that Lgr5 is strongly expressed in cells at the bottom of trench areas at the base of circumvallate (CV) and foliate taste papillae and weakly expressed in the basal area of taste buds and that Lgr5-expressing cells in posterior tongue are a subset of K14-positive epithelial cells. Lineage-tracing experiments using an inducible Cre knockin allele in combination with Rosa26-LacZ and Rosa26-tdTomato reporter strains showed that Lgr5-expressing cells gave rise to taste cells, perigemmal cells, along with self-renewing cells at the bottom of trench areas at the base of CV and foliate papillae. Moreover, using subtype-specific taste markers, we found that Lgr5-expressing cell progeny include all three major types of adult taste cells. Our results indicate that Lgr5 may mark adult taste stem or progenitor cells in the posterior portion of the tongue. STEM CELLS 2013;31:992–1000
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1343" xmlns="http://purl.org/rss/1.0/"><title>Lin28a Regulates Germ Cell Pool Size and Fertility</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1343</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Lin28a Regulates Germ Cell Pool Size and Fertility</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gen Shinoda, T. Yvanka De Soysa, Marc T. Seligson, Akiko Yabuuchi, Yuko Fujiwara, Pei Yi Huang, John P. Hagan, Richard I. Gregory, Eric G. Moss, George Q. Daley</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1343</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1343</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1343</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1001</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1009</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Overexpression of <em>LIN28A</em> is associated with human germ cell tumors and promotes primordial germ cell (PGC) development from embryonic stem cells in vitro and in chimeric mice. Knockdown of <em>Lin28a</em> inhibits PGC development in vitro, but how constitutional <em>Lin28a</em> deficiency affects the mammalian reproductive system in vivo remains unknown. Here, we generated <em>Lin28a</em> knockout (KO) mice and found that <em>Lin28a</em> deficiency compromises the size of the germ cell pool in both males and females by affecting PGC proliferation during embryogenesis. Interestingly however, in <em>Lin28a</em> KO males, the germ cell pool partially recovers during postnatal expansion, while fertility remains impaired in both males and females mated to wild-type mice. Embryonic overexpression of <em>let-7</em>, a microRNA negatively regulated by <em>Lin28a</em>, reduces the germ cell pool, corroborating the role of the <em>Lin28a/let-7</em> axis in regulating the germ lineage. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:1001–1009</p></div>
]]></content:encoded><description>

Overexpression of LIN28A is associated with human germ cell tumors and promotes primordial germ cell (PGC) development from embryonic stem cells in vitro and in chimeric mice. Knockdown of Lin28a inhibits PGC development in vitro, but how constitutional Lin28a deficiency affects the mammalian reproductive system in vivo remains unknown. Here, we generated Lin28a knockout (KO) mice and found that Lin28a deficiency compromises the size of the germ cell pool in both males and females by affecting PGC proliferation during embryogenesis. Interestingly however, in Lin28a KO males, the germ cell pool partially recovers during postnatal expansion, while fertility remains impaired in both males and females mated to wild-type mice. Embryonic overexpression of let-7, a microRNA negatively regulated by Lin28a, reduces the germ cell pool, corroborating the role of the Lin28a/let-7 axis in regulating the germ lineage. STEM CELLS 2013;31:1001–1009
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1351" xmlns="http://purl.org/rss/1.0/"><title>Elevated Id2 Expression Results in Precocious Neural Stem Cell Depletion and Abnormal Brain Development</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1351</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Elevated Id2 Expression Results in Precocious Neural Stem Cell Depletion and Abnormal Brain Development</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hee Jung Park, Mingi Hong, Roderick T. Bronson, Mark A. Israel, Wayne N. Frankel, Kyuson Yun</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1351</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1351</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1351</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Tissue Specific Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1010</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1021</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p><em>Id2</em> is a helix-loop-helix transcription factor essential for normal development, and its expression is dysregulated in many human neurological conditions. Although it is speculated that elevated <em>Id2</em> levels contribute to the pathogenesis of these disorders, it is unknown whether dysregulated <em>Id2</em> expression is sufficient to perturb normal brain development or function. Here, we show that mice with elevated <em>Id2</em> expression during embryonic stages develop microcephaly, and that females in particular are prone to generalized tonic-clonic seizures. Analyses of <em>Id2</em> transgenic brains indicate that <em>Id2</em> activity is highly cell context specific: elevated <em>Id2</em> expression in naive neural stem cells (NSCs) in early neuroepithelium induces apoptosis and loss of NSCs and intermediate progenitors. Activation of <em>Id2</em> in maturing neuroepithelium results in less severe phenotypes and is accompanied by elevation of G1 cyclin expression and p53 target gene expression. In contrast, activation of <em>Id2</em> in committed intermediate progenitors has no significant phenotype. Functional analysis with <em>Id2-</em>overexpressing and <em>Id2-</em>null NSCs shows that <em>Id2</em> negatively regulates NSC self-renewal in vivo, in contrast to previous cell culture experiments. Deletion of <em>p53</em> function from <em>Id2</em>-transgenic brains rescues apoptosis and results in increased incidence of brain tumors. Furthermore, <em>Id2</em> overexpression normalizes the increased self-renewal of <em>p53-</em>null NSCs, suggesting that <em>Id2</em> activates and modulates the p53 pathway in NSCs. Together, these data suggest that elevated <em>Id2</em> expression in embryonic brains can cause deregulated NSC self-renewal, differentiation, and survival that manifest in multiple neurological outcomes in mature brains, including microcephaly, seizures, and brain tumors. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:1010–1021</p></div>
]]></content:encoded><description>

Id2 is a helix-loop-helix transcription factor essential for normal development, and its expression is dysregulated in many human neurological conditions. Although it is speculated that elevated Id2 levels contribute to the pathogenesis of these disorders, it is unknown whether dysregulated Id2 expression is sufficient to perturb normal brain development or function. Here, we show that mice with elevated Id2 expression during embryonic stages develop microcephaly, and that females in particular are prone to generalized tonic-clonic seizures. Analyses of Id2 transgenic brains indicate that Id2 activity is highly cell context specific: elevated Id2 expression in naive neural stem cells (NSCs) in early neuroepithelium induces apoptosis and loss of NSCs and intermediate progenitors. Activation of Id2 in maturing neuroepithelium results in less severe phenotypes and is accompanied by elevation of G1 cyclin expression and p53 target gene expression. In contrast, activation of Id2 in committed intermediate progenitors has no significant phenotype. Functional analysis with Id2-overexpressing and Id2-null NSCs shows that Id2 negatively regulates NSC self-renewal in vivo, in contrast to previous cell culture experiments. Deletion of p53 function from Id2-transgenic brains rescues apoptosis and results in increased incidence of brain tumors. Furthermore, Id2 overexpression normalizes the increased self-renewal of p53-null NSCs, suggesting that Id2 activates and modulates the p53 pathway in NSCs. Together, these data suggest that elevated Id2 expression in embryonic brains can cause deregulated NSC self-renewal, differentiation, and survival that manifest in multiple neurological outcomes in mature brains, including microcephaly, seizures, and brain tumors. STEM CELLS 2013;31:1010–1021
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1308" xmlns="http://purl.org/rss/1.0/"><title>Brief Report: Human Pluripotent Stem Cell Models of Fanconi Anemia Deficiency Reveal an Important Role for Fanconi Anemia Proteins in Cellular Reprogramming and Survival of Hematopoietic Progenitors</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1308</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Brief Report: Human Pluripotent Stem Cell Models of Fanconi Anemia Deficiency Reveal an Important Role for Fanconi Anemia Proteins in Cellular Reprogramming and Survival of Hematopoietic Progenitors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sun K. Yung, Katarzyna Tilgner, Maria H. Ledran, Saba Habibollah, Irina Neganova, Chatchawan Singhapol, Gabriele Saretzki, Miodrag Stojkovic, Lyle Armstrong, Stefan Przyborski, Majlinda Lako</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-24T09:40:31.640484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1308</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1308</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1308</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Embryonic Stem Cells/induced Pluripotent Stem Cells</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1022</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1029</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[
<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3>
<div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Fanconi anemia (FA) is a genomic instability disorder caused by mutations in genes involved in replication-dependant-repair and removal of DNA cross-links. Mouse models with targeted deletions of FA genes have been developed; however, none of these exhibit the human bone marrow aplasia. Human embryonic stem cell (hESC) differentiation recapitulates many steps of embryonic hematopoietic development and is a useful model system to investigate the early events of hematopoietic progenitor specification. It is now possible to derive patient-specific human-induced pluripotent stem cells (hiPSC); however, this approach has been rather difficult to achieve in FA cells due to a requirement for activation of FA pathway during reprogramming process which can be bypassed either by genetic complementation or reprogramming under hypoxic conditions. In this study, we report that FA-C patient-specific hiPSC lines can be derived under normoxic conditions, albeit at much reduced efficiency. These disease-specific hiPSC lines and hESC with stable knockdown of <em>FANCC</em> display all the in vitro hallmarks of pluripotency. Nevertheless, the disease-specific hiPSCs show a much higher frequency of chromosomal abnormalities compared to parent fibroblasts and are unable to generate teratoma composed of all three germ layers in vivo, likely due to increased genomic instability. Both FANCC-deficient hESC and hiPSC lines are capable of undergoing hematopoietic differentiation, but the hematopoietic progenitors display an increased apoptosis in culture and reduced clonogenic potential. Together these data highlight the critical requirement for FA proteins in survival of hematopoietic progenitors, cellular reprogramming, and maintenance of genomic stability. S<span class="smallCaps">TEM</span> C<span class="smallCaps">ELLS</span> 2013;31:1022–1029</p></div>
]]></content:encoded><description>

Fanconi anemia (FA) is a genomic instability disorder caused by mutations in genes involved in replication-dependant-repair and removal of DNA cross-links. Mouse models with targeted deletions of FA genes have been developed; however, none of these exhibit the human bone marrow aplasia. Human embryonic stem cell (hESC) differentiation recapitulates many steps of embryonic hematopoietic development and is a useful model system to investigate the early events of hematopoietic progenitor specification. It is now possible to derive patient-specific human-induced pluripotent stem cells (hiPSC); however, this approach has been rather difficult to achieve in FA cells due to a requirement for activation of FA pathway during reprogramming process which can be bypassed either by genetic complementation or reprogramming under hypoxic conditions. In this study, we report that FA-C patient-specific hiPSC lines can be derived under normoxic conditions, albeit at much reduced efficiency. These disease-specific hiPSC lines and hESC with stable knockdown of FANCC display all the in vitro hallmarks of pluripotency. Nevertheless, the disease-specific hiPSCs show a much higher frequency of chromosomal abnormalities compared to parent fibroblasts and are unable to generate teratoma composed of all three germ layers in vivo, likely due to increased genomic instability. Both FANCC-deficient hESC and hiPSC lines are capable of undergoing hematopoietic differentiation, but the hematopoietic progenitors display an increased apoptosis in culture and reduced clonogenic potential. Together these data highlight the critical requirement for FA proteins in survival of hematopoietic progenitors, cellular reprogramming, and maintenance of genomic stability. STEM CELLS 2013;31:1022–1029
</description></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1347" xmlns="http://purl.org/rss/1.0/"><title>Erratum</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1347</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Erratum</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T01:53:43.883914-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1347</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1347</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1347</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Erratum</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1030</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1030</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1346" xmlns="http://purl.org/rss/1.0/"><title>Erratum</title><link>http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1346</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Erratum</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2013-04-25T01:54:07.588031-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/stem.1346</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/stem.1346</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1002%2Fstem.1346</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Erratum</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1031</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1031</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item></rdf:RDF>